Johnson & Johnson (JNJ) 10-K 24 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 28, 2014	Feb. 17, 2015	Jun. 29, 2014
Document Information [Line Items]
Entity Registrant Name	JOHNSON & JOHNSON
Entity Central Index Key	200406
Current Fiscal Year End Date	-16
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	28-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		2,780,488,708
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$296,000,000,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 28, 2014		Dec. 29, 2013
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents (Notes 1 and 2)	$14,523		$20,927
Marketable securities (Notes 1 and 2)	18,566		8,279
Accounts receivable trade, less allowances for doubtful accounts $275 (2013, $333)	10,985		11,713
Inventories (Notes 1 and 3)	8,184		7,878
Deferred taxes on income (Note 8)	3,567		3,607
Prepaid expenses and other receivables	3,486		4,003
Total current assets	59,311		56,407
Property, plant and equipment, net (Notes 1 and 4)	16,126		16,710
Intangible assets, net (Notes 1 and 5)	27,222		27,947
Goodwill (Notes 1 and 5)	21,832		22,798
Deferred taxes on income (Note 8)	3,396		3,872
Other assets	3,232		4,949
Total assets	131,119	[1]	132,683	[1]
Current liabilities:
Loans and notes payable (Note 7)	3,638		4,852
Accounts payable	7,633		6,266
Accrued liabilities	6,553		7,685
Accrued rebates, returns and promotions	4,010		3,308
Accrued compensation and employee related obligations	2,751		2,794
Accrued taxes on income	500		770
Total current liabilities	25,085		25,675
Long-term debt (Note 7)	15,122		13,328
Deferred taxes on income (Note 8)	3,154		3,989
Employee related obligations (Notes 9 and 10)	9,972		7,784
Other liabilities	8,034		7,854
Total liabilities	61,367		58,630
Shareholders' equity:
Preferred stock — without par value (authorized and unissued 2,000,000 shares)	0		0
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120		3,120
Accumulated other comprehensive income (Note 13)	-10,722		-2,860
Retained earnings	97,245		89,493
Stockholders' Equity before Treasury Stock	89,643		89,753
Less: common stock held in treasury, at cost (Note 12) (336,620,000 shares and 299,215,000 shares)	19,891		15,700
Total shareholders’ equity	69,752		74,053
Total liabilities and shareholders’ equity	$131,119		$132,683
[1]	Long-lived assets include property, plant and equipment, net for 2014, 2013 and 2012 of $16,126, $16,710 and $16,097, respectively, and intangible assets and goodwill, net for 2014, 2013 and 2012 of $49,054, $50,745 and $51,176, respectively.

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, except Share data, unless otherwise specified
Current assets:
Allowances for doubtful accounts	$275	$333
Shareholders' equity:
Preferred Stock, Par or Stated Value Per Share	$0	$0
Preferred Stock, Shares Authorized	2,000,000	2,000,000
Preferred Stock, Shares Issued	0	0
Common stock, par value per share	$1	$1
Common stock, shares authorized	4,320,000,000	4,320,000,000
Common stock, shares issued	3,119,843,000	3,119,843,000
Treasury stock, shares	336,620,000	299,215,000

Consolidated_Statements_of_Ear

Consolidated Statements of Earnings (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012
Sales to customers	$74,331		$71,312		$67,224
Cost of products sold	22,746		22,342		21,658
Gross profit	51,585		48,970		45,566
Selling, marketing and administrative expenses	21,954		21,830		20,869
Research and development expense	8,494		8,183		7,665
In-process research and development	178		580		1,163
Interest income	-67		-74		-64
Interest expense, net of portion capitalized (Note 4)	533		482		532
Other (income) expense, net	-70		2,498		1,626
Earnings before provision for taxes on income	20,563	[1]	15,471	[2]	13,775	[3]
Provision for taxes on income (Note 8)	4,240		1,640		3,261
Net earnings	16,323		13,831		10,514
Add: Net loss attributable to noncontrolling interest	0		0		339
Net earnings attributable to Johnson & Johnson	$16,323		$13,831		$10,853
Net earnings per share attributable to Johnson & Johnson (Notes 1 and 15)
Basic	$5.80		$4.92		$3.94
Diluted	$5.70		$4.81		$3.86
Cash dividends per share	$2.76		$2.59		$2.40
Average shares outstanding (Notes 1 and 15)
Basic	2,815.20		2,809.20		2,753.30
Diluted	2,863.90		2,877		2,812.60
[1]	Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. Includes an additional year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.
[2]	Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
[3]	Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments, respectively. The Medical Devices segment also includes $110 million expense for the cost associated with the DePuy ASRâ„¢ Hip program.

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Net Earnings	$16,323	$13,831	$10,514
Other Comprehensive Income (Loss), net of tax
Foreign currency translation	-4,601	94	1,230
Securities
Unrealized holding gain (loss) arising during period	156	225	-248
Reclassifications to earnings	-5	-314	-5
Net change	151	-89	-253
Employee benefit plans
Prior service cost amortization during period	-18	9	2
Prior service credit (cost) - current year	211	-27	-8
Gain amortization during period	400	515	370
Gain (loss) - current year	-4,098	2,203	-1,643
Effect of exchange rates	197	8	-52
Net change	-3,308	2,708	-1,331
Derivatives & hedges
Unrealized gain (loss) arising during period	92	344	52
Reclassifications to earnings	-196	-107	124
Net change	-104	237	176
Other comprehensive income (loss)	-7,862	2,950	-178
Total comprehensive income	8,461	16,781	10,336
Comprehensive loss attributable to noncontrolling interest, net of tax	0	0	339
Comprehensive income attributable to Johnson & Johnson	$8,461	$16,781	$10,675

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Securities	$81	$48	$136
Employee Benefits	1,556	1,421	653
Derivatives & Hedges	$56	$128	$95

Consolidated_Statements_of_Equ

Consolidated Statements of Equity (USD $)		Total	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount	Synthes, Inc [Member]	Synthes, Inc [Member]	Synthes, Inc [Member]
In Millions								Retained Earnings	Treasury Stock Amount
Beginning Balance at Jan. 01, 2012		$57,080	$81,251	($5,632)	$3,120	($21,659)
Net earnings attributable to Johnson & Johnson		10,853	10,853
Cash dividends paid		-6,614	-6,614
Employee compensation and stock option plans		3,269	19			3,250
Issuance of common stock associated with the acquisition of Synthes, Inc.							13,335	483	12,852
Repurchase of common stock	[1]	-12,919				-12,919
Payments for Repurchase of Common Stock		12,919
Other comprehensive income (loss), net of tax		-178		-178
Ending Balance at Dec. 30, 2012		64,826	85,992	-5,810	3,120	-18,476
Net earnings attributable to Johnson & Johnson		13,831	13,831
Cash dividends paid		-7,286	-7,286
Employee compensation and stock option plans		3,285	-82			3,367
Issuance of common stock associated with the acquisition of Synthes, Inc.							0
Repurchase of common stock		-3,538	-2,947			-591
Payments for Repurchase of Common Stock		3,538
Other		-15	-15
Other comprehensive income (loss), net of tax		2,950		2,950
Ending Balance at Dec. 29, 2013		74,053	89,493	-2,860	3,120	-15,700
Net earnings attributable to Johnson & Johnson		16,323	16,323
Cash dividends paid		-7,768	-7,768
Employee compensation and stock option plans		2,164	-769			2,933
Issuance of common stock associated with the acquisition of Synthes, Inc.							0
Repurchase of common stock		-7,124				-7,124
Payments for Repurchase of Common Stock		7,124
Other		-34	-34
Other comprehensive income (loss), net of tax		-7,862		-7,862
Ending Balance at Dec. 28, 2014		$69,752	$97,245	($10,722)	$3,120	($19,891)
[1]	Includes repurchase of common stock associated with the acquisition of Synthes, Inc.

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
CASH FLOW FROM OPERATING ACTIVITIES
Net Earnings	$16,323	$13,831	$10,514
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	3,895	4,104	3,666
Stock based compensation	792	728	662
Noncontrolling interest	0	0	339
Venezuela adjustments	87	108	0
Asset write-downs	410	739	2,131
Net gain on sale of assets/businesses	-2,383	-113	-908
Net gain on equity investment transactions	0	-417	0
Deferred tax provision	441	-607	-39
Accounts receivable allowances	-28	-131	92
Changes in assets and liabilities, net of effects from acquisitions:
Increase in accounts receivable	-247	-632	-9
Increase in inventories	-1,120	-622	-1
Increase in accounts payable and accrued liabilities	955	1,821	2,768
Decrease/(Increase) in other current and non-current assets	442	-1,693	-1,264
(Decrease)/Increase in other current and non-current liabilities	-1,096	298	-2,555
Net cash flows from operating activities	18,471	17,414	15,396
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	-3,714	-3,595	-2,934
Proceeds from the disposal of assets/businesses, net	4,631	458	1,509
Acquisitions, net of cash acquired (Note 20)	-2,129	-835	-4,486
Purchases of investments	-34,913	-18,923	-13,434
Sales of investments	24,119	18,058	14,797
Other (primarily intangibles)	-299	-266	38
Net cash used by investing activities	-12,305	-5,103	-4,510
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	-7,768	-7,286	-6,614
Repurchase of common stock	-7,124	-3,538	-12,919
Proceeds from short-term debt	1,863	1,411	3,268
Retirement of short-term debt	-1,267	-1,397	-6,175
Proceeds from long-term debt	2,098	3,607	45
Retirement of long-term debt	-1,844	-1,593	-804
Proceeds from the exercise of stock options/excess tax benefits	1,782	2,649	2,720
Other	0	56	-83
Net cash used by financing activities	-12,260	-6,091	-20,562
Effect of exchange rate changes on cash and cash equivalents	-310	-204	45
(Decrease)/Increase in cash and cash equivalents	-6,404	6,016	-9,631
Cash and cash equivalents, beginning of year (Note 1)	20,927	14,911	24,542
Cash and cash equivalents, end of year (Note 1)	14,523	20,927	14,911
Supplemental Cash Flow Data
Interest	603	596	616
Interest, net of amount capitalized	488	491	501
Income taxes	3,536	3,155	2,507
Supplemental schedule of non-cash investing and financing activities
Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds	1,170	743	615
Conversion of debt	17	22	0
Acquisitions
Fair value of assets acquired	2,167	1,028	19,025
Fair value of liabilities assumed and non-controlling interests	-38	-193	-1,204
Net fair value of acquisitions	2,129	835	17,821
Net cash paid for aquisitions	2,129	835	4,486
Synthes, Inc [Member]
Supplemental schedule of non-cash investing and financing activities
Issuance of common stock associated with the acquisition of Synthes, Inc.	0	0	13,335
Acquisitions
Issuance of common stock associated with the acquisition of Synthes, Inc.	$0	$0	$13,335

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 28, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated.
	Description of the Company And Business Segments
	The Company has approximately 126,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.
	The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices (previously referred to as Medical Devices and Diagnostics). The Consumer segment includes a broad range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgical care, specialty surgery, cardiovascular care, diagnostics, diabetes care, and vision care markets, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, and clinics.
	New Accounting Pronouncements
	Recently Adopted Accounting Pronouncements
	During the fiscal first quarter of 2014, the Company adopted the Financial Accounting Standards Board (FASB) guidance clarifying the release of accumulated Foreign Currency Translation from other comprehensive income (OCI), into current year Net Earnings. The amendment requires that when the parent company ceases to have a controlling interest in a subsidiary or a business within a foreign entity the parent is to release accumulated Foreign Currency Translation from OCI. This update became effective for all annual periods and interim reporting periods beginning after December 15, 2013. The adoption of this standard did not have a material impact on the Company's results of operations, cash flows or financial position.
	During the fiscal first quarter of 2014, the Company adopted the FASB guidance on the presentation of unrecognized tax benefits when various qualifying tax credits exist. The amendment requires that unrecognized tax benefits be presented on the Consolidated Balance Sheet as a reduction to deferred tax assets created by net operating losses or other tax credits from prior periods that occur in the same taxing jurisdiction. To the extent that the unrecognized tax benefit exceeds these credits, it shall be presented as a liability. This update became effective for all annual periods and interim reporting periods beginning after December 15, 2013. The adoption of this standard did not have a material impact on the presentation of the Company's financial position.
	During the fiscal second quarter of 2014, the FASB issued amended guidance on the use and presentation of discontinued operations in an entity’s financial statements. The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity’s operations and financial results.  Examples of a strategic shift could include, but not be limited to, disposal of major geographic segments, a major line of business or other major business component of an entity. The new guidance also expands the required disclosures for entities that have assets held for sale but do not meet the new definition of discontinued operations. This amendment includes early adoption provisions allowing the Company to implement this update immediately for the first quarter of 2014. The Company elected to adopt this standard for the first quarter of 2014. The balances and updated disclosures required by the amended guidance are included in Note 20 in the Notes to the Consolidated Financial Statements.
	During the fiscal second quarter of 2014, the FASB issued Accounting Standards Update 2014-12: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This standard clarifies the current accounting guidance for entities that issue share-based payment awards that require a specific performance target be achieved for employees to become eligible to vest in the awards, which may occur subsequent to a required service period. Current accounting guidance does not explicitly address how to account for these types of awards. The new standard provides explicit guidance and clarifies that these types of performance targets should be treated as performance conditions. The accounting for share-based awards with performance conditions is already specified in current accounting guidance. This update is required to be adopted by all public companies for all annual periods and interim reporting periods beginning after December 15, 2015. Early adoption of this standard was permitted and the Company had elected to adopt this standard for the second quarter of 2014. The adoption of this standard did not have a material impact on the Company's results of operations, cash flows or financial position.
	Recently Issued Accounting Standards
	Not Adopted as of December 28, 2014
	During the fiscal second quarter of 2014, the FASB issued Accounting Standards Update 2014-09: Revenue from Contracts with Customers. This standard replaces substantially all current revenue recognition accounting guidance. This update is required to be adopted by all public companies for all annual periods and interim reporting periods beginning after December 15, 2016. Early adoption of this standard is not permitted.  The Company is currently assessing the impact of the future adoption of this standard on its financial statements.
	During the fiscal second quarter of 2014, the FASB issued amended guidance Accounting Standards Update No. 2014-10: Development Stage Entities: Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entity Guidance in Topic 810, Consolidation.  The change in the current guidance will require the Company to determine if it should consolidate one of these entities based on the change in the consolidation analysis.  This update to the consolidation analysis will become effective for all annual periods and interim reporting periods beginning after December 15, 2015.  The adoption of this standard is not expected to have a material impact on the presentation of the Company's results of operations, cash flows or financial position.
	During the fiscal third quarter of 2014, the FASB issued Accounting Standards Update No. 2014-15: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This standard requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016.  This standard is not expected to have any impact on current disclosures in the financial statements.
	Cash Equivalents
	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an "A" (or equivalent) credit rating. The Company invests its cash primarily in reverse repurchase agreements (RRAs), government securities and obligations, corporate debt securities and money market funds.
	RRAs are collateralized by deposits in the form of ‘Government Securities and Obligations’ for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.
	Investments
	Short-term marketable securities are carried at cost, which approximates fair value. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Long-term debt securities that the Company has the ability and intent to hold until maturity are carried at amortized cost. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company periodically reviews its investments in equity securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary. If losses on these securities are considered to be other than temporary, the loss is recognized in earnings.
	Property, Plant and Equipment and Depreciation
	Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:
	Building and building equipment	20 - 30 years
	Land and leasehold improvements	10 - 20 years
	Machinery and equipment	2 - 13 years
	The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years.
	The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.
	Revenue Recognition
	The Company recognizes revenue from product sales when the goods are shipped or delivered and title and risk of loss pass to the customer. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.
	Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates, which include Medicaid, are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.
	Sales returns are generally estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales returns accruals.
	Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual sales to customers during the fiscal reporting years 2014, 2013 and 2012.
	Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the year incurred. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. The Company also earns service revenue for co-promotion of certain products and includes it in sales to customers. These arrangements are evaluated to determine the appropriate amounts to be deferred.
	Shipping and Handling
	Shipping and handling costs incurred were $1,068 million, $1,128 million and $1,051 million in 2014, 2013 and 2012, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.
	Inventories
	Inventories are stated at the lower of cost or market determined by the first-in, first-out method.
	Intangible Assets and Goodwill
	The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed the annual impairment test for 2014 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.
	Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
	Financial Instruments
	As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
	The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
	Product Liability
	Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter. This is referred to as defense costs in connection with product liability litigation. In certain matters an indemnity amount is also recorded. This is referred to as product liability accrual.
	As a result of cost and availability factors, effective November 1, 2005, the Company ceased purchasing third-party product liability insurance. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. Based on the availability of prior coverage, receivables for insurance recoveries related to product liability claims are recorded on an undiscounted basis, when it is probable that a recovery will be realized. As appropriate, reserves against these receivables are recorded for estimated amounts that may not be collected from third-party insurers.
	Concentration of Credit Risk
	Global concentration of credit risk with respect to trade accounts receivables continues to be limited due to the large number of customers globally and adherence to internal credit policies and credit limits. Economic challenges in Italy, Spain, Greece and Portugal (the Southern European Region) have impacted certain payment patterns, which have historically been longer than those experienced in the U.S. and other international markets. The total net trade accounts receivable balance in the Southern European Region was approximately $1.8 billion as of December 28, 2014 and approximately $2.3 billion as of December 29, 2013. Approximately $1.1 billion as of December 28, 2014 and approximately $1.3 billion as of December 29, 2013 of the Southern European Region net trade accounts receivable balance related to the Company's Consumer, Vision Care and Diabetes Care businesses as well as certain Pharmaceutical and Medical Devices customers which are in line with historical collection patterns.
	The remaining balance of net trade accounts receivable in the Southern European Region has been negatively impacted by the timing of payments from certain government owned or supported health care customers as well as certain distributors of the Pharmaceutical and Medical Devices local affiliates. The total net trade accounts receivable balance for these customers were approximately $0.7 billion at December 28, 2014 and $1.0 billion at December 29, 2013. The Company continues to receive payments from these customers and in some cases late payment premiums. For customers where payment is expected over periods of time longer than one year, revenue and trade receivables have been discounted over the estimated period of time for collection. Allowances for doubtful accounts have been increased for these customers, but have been immaterial to date. The Company will continue to work closely with these customers on payment plans, monitor the economic situation and take appropriate actions as necessary.
	Research and Development
	Research and development expenses are expensed as incurred. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
	The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows:
	Nature/Type of Collaboration		Statement of Earnings Presentation
	Third-party sale of product		Sales to customers
	Royalties/milestones paid to collaborative partner (post-regulatory approval)*		Cost of products sold
	Royalties received from collaborative partner		Other income (expense), net
	Upfront payments & milestones paid to collaborative partner (pre-regulatory approval)		Research and development expense
	Research and development payments to collaborative partner		Research and development expense
	Research and development payments received from collaborative partner		Reduction of Research and development expense
	*	Milestones are capitalized as intangible assets and amortized to cost of goods sold over the useful life.
	For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.
	Advertising
Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.6 billion, $2.5 billion and $2.3 billion in 2014, 2013 and 2012, respectively.
Income Taxes
Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future.
The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.
At December 28, 2014 and December 29, 2013, the cumulative amounts of undistributed international earnings were approximately $53.4 billion and $50.9 billion, respectively. At December 28, 2014 and December 29, 2013, the Company's foreign subsidiaries held balances of cash and cash equivalents in the amounts of $14.3 billion and $18.6 billion, respectively. The Company has not provided deferred taxes on the undistributed earnings from certain international subsidiaries where the earnings are considered to be permanently reinvested. The Company intends to continue to reinvest these earnings in international operations. If the Company decided at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company does not determine the deferred tax liability associated with these undistributed earnings, as such determination is not practical.
See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.
Net Earnings Per Share
Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
Use of Estimates
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates.
The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.
Annual Closing Date
The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, as was the case in 2009, and is the case again in 2015.
Reclassification
Certain prior period amounts have been reclassified to conform to current year presentation.

Cash_Cash_Equivalents_and_Curr

Cash, Cash Equivalents and Current Marketable Securities	12 Months Ended
	Dec. 28, 2014
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Current Marketable Securities	Cash, Cash Equivalents and Current Marketable Securities
	At the end of 2014 and 2013, cash, cash equivalents and current marketable securities were comprised of:
	(Dollars in Millions)	2014		2013
	Cash	$	2,336	2,789
	Government securities and obligations	20,610		7,632
	Reverse repurchase agreements	6,735		15,006
	Corporate debt securities	1,343		1,467
	Money market funds	1,352		1,886
	Time deposits	713		426
	Total cash, cash equivalents and current marketable securities	$	33,089	29,206
	The estimated fair value approximated cost as of December 28, 2014 and December 29, 2013.
	As of December 28, 2014, current marketable securities consisted of $17,682 million, and $884 million of government securities and obligations and corporate debt securities, respectively, with no reverse repurchase agreements.
	As of December 29, 2013, current marketable securities consisted of $6,160 million, $1,100 million and $1,019 million of government securities and obligations, reverse repurchase agreements and corporate debt securities, respectively.
	Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.
	The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an "A" (or equivalent) credit rating.

Inventories

Inventories	12 Months Ended
	Dec. 28, 2014
Inventory Disclosure [Abstract]
INVENTORIES	Inventories
	At the end of 2014 and 2013, inventories were comprised of:
	(Dollars in Millions)	2014		2013
	Raw materials and supplies	$	1,214	1,224
	Goods in process	2,461		2,612
	Finished goods	4,509		4,042
	Total inventories	$	8,184	7,878

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 28, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment
	At the end of 2014 and 2013, property, plant and equipment at cost and accumulated depreciation were:
	(Dollars in Millions)	2014		2013
	Land and land improvements	$	833	885
	Buildings and building equipment	10,046		10,423
	Machinery and equipment	22,206		22,527
	Construction in progress	3,600		3,298
	Total property, plant and equipment, gross	$	36,685	37,133
	Less accumulated depreciation	20,559		20,423
	Total property, plant and equipment, net	$	16,126	16,710
	The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in 2014, 2013 and 2012 was $115 million, $105 million and $115 million, respectively.
	Depreciation expense, including the amortization of capitalized interest in 2014, 2013 and 2012, was $2.5 billion, $2.7 billion and $2.5 billion, respectively.
	Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	Intangible Assets and Goodwill
	At the end of 2014 and 2013, the gross and net amounts of intangible assets were:
	(Dollars in Millions)	2014			2013
	Intangible assets with definite lives:
	Patents and trademarks — gross	$	9,074		9,164
	Less accumulated amortization	4,700			4,146
	Patents and trademarks — net	$	4,374		5,018
	Customer relationships and other intangibles — gross	$	17,970		19,027
	Less accumulated amortization	5,227			4,872
	Customer relationships and other intangibles — net	$	12,743		14,155
	Intangible assets with indefinite lives:
	Trademarks	$	7,263		7,619
	Purchased in-process research and development	2,842			1,155
	Total intangible assets with indefinite lives	$	10,105		8,774
	Total intangible assets — net	$	27,222		27,947
	Goodwill as of December 28, 2014 and December 29, 2013, as allocated by segment of business, was as follows:
	(Dollars in Millions)	Consumer			Pharmaceutical		Med Devices		Total
	Goodwill at December 30, 2012	$	8,519		1,792		12,113		22,424
	Goodwill, related to acquisitions	83			246		9		338
	Goodwill, related to divestitures	(71		)	—		—		(71	)
	Currency translation/other	—			30		77		107
	Goodwill at December 29, 2013	$	8,531		2,068		12,199		22,798
	Goodwill, related to acquisitions	13			665		—		678
	Goodwill, related to divestitures	(138		)	—		(603	)	(741	)
	Currency translation/other	(731		)	(107	)	(65	)	(903	)
	Goodwill at December 28, 2014	$	7,675		2,626		11,531		21,832
	The weighted average amortization periods for patents and trademarks and customer relationships and other intangible assets are 17 years and 24 years, respectively. The amortization expense of amortizable assets included in cost of products sold was $1,398 million, $1,363 million and $1,146 million before tax, for the fiscal years ended December 28, 2014, December 29, 2013 and December 30, 2012, respectively. The estimated amortization expense for the five succeeding years approximates $1,300 million before tax, per year.
	See Note 20 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 28, 2014
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	Fair Value Measurements
	The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.
	Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are treated as fair value hedges. The Company may use forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.
	The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features or requirements to post collateral. On an ongoing basis, the Company monitors counterparty credit ratings. The Company considers credit non-performance risk to be low, because the Company enters into agreements with commercial institutions that have at least an "A" (or equivalent) credit rating. As of December 28, 2014, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $29.6 billion, $2.4 billion and $2.2 billion, respectively.
	All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
	The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account and are insignificant. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in Other (income) expense, net for forward foreign exchange contracts and cross currency interest rate swaps. For interest rate swaps designated as fair value hedges, hedge ineffectiveness, if any, is included in current period earnings within interest expense. For the current reporting period, hedge ineffectiveness associated with interest rate swaps are not material.
	As of December 28, 2014, the balance of deferred net gains on derivatives included in accumulated other comprehensive income was $141 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.
	The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal years ended December 28, 2014 and December 29, 2013:
	(Dollars in Millions)		Gain/(Loss)					Gain/(Loss) Reclassified From				Gain/(Loss) Recognized In
			Recognized In Accumulated OCI(1)					Accumulated OCI Into Income(1)				Other Income/Expense(2)
	Cash Flow Hedges by Income Statement Caption		2014			2013		2014		2013		2014		2013
	Sales to customers (3)		$	(106	)	45		(3	)	49		(5	)	2
	Cost of products sold (3)		58			271		204		69		2		23
	Research and development expense (3)		39			24		7		16		—		(4	)
	Interest (income)/Interest expense, net (4)		21			17		(15	)	(10	)	—		—
	Other (income) expense, net (3)		80			(13	)	3		(17	)	—		(4	)
	Total		$	92		344		196		107		(3	)	17
	All amounts shown in the table above are net of tax.
	(1)	Effective portion
	(2)	Ineffective portion
	(3)	Forward foreign exchange contracts
	(4)	Cross currency interest rate swaps
	For the fiscal years ended December 28, 2014 and December 29, 2013, a gain of $5 million and a gain of $32 million, respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments.
	Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest.
	The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 because they are traded in an active exchange market. The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value.
	The following three levels of inputs are used to measure fair value:
	Level 1 — Quoted prices in active markets for identical assets and liabilities.
	Level 2 — Significant other observable inputs.
	Level 3 — Significant unobservable inputs.
	The Company’s significant financial assets and liabilities measured at fair value as of December 28, 2014 and December 29, 2013 were as follows:
			2014									2013
	(Dollars in Millions)		Level 1			Level 2		Level 3		Total		Total (1)
	Derivatives designated as hedging instruments:
	Assets:
	Forward foreign exchange contracts		$	—		996		—		996		537
	Interest rate contracts (2)		—			31		—		31		169
	Total		—			1,027		—		1,027		706
	Liabilities:
	Forward foreign exchange contracts		—			751		—		751		133
	Interest rate contracts (3) (4)		—			8		—		8		26
	Total		—			759		—		759		159
	Derivatives not designated as hedging instruments:
	Assets:
	Forward foreign exchange contracts		—			29		—		29		25
	Liabilities:
	Forward foreign exchange contracts		—			51		—		51		29
	Other investments (5)		$	679		—		—		679		333
	(1)	2013 assets and liabilities are all classified as Level 2 with the exception of Other investments of $333 million, which are classified as Level 1.
	(2)	Includes $29 million and $169 million of non-current assets for the fiscal years ending December 28, 2014 and December 29, 2013, respectively.
	(3)	Includes $8 million and $19 million of non-current liabilities for the fiscal years ending December 28, 2014 and December 29, 2013, respectively.
	(4)	Includes cross currency interest rate swaps and interest rate swaps.
	(5)	Classified as non-current other assets.
	See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.

Borrowings

Borrowings	12 Months Ended
	Dec. 28, 2014
Borrowings [Abstract]
Borrowings	Borrowings
	The components of long-term debt are as follows:
	(Dollars in Millions)		2014				Effective Rate %			2013			Effective Rate %
	3 month LIBOR+0.09% FRN due 2014		$	—			—	%		750			0.33
	1.20% Notes due 2014		—				—			999			1.24
	2.15% Notes due 2016		898				2.22			898			2.22
	3 month LIBOR+0.07% FRN due 2016		800				0.31			800			0.31
	0.70% Notes due 2016		398				0.74			397			0.74
	5.55% Debentures due 2017		1,000				5.55			1,000			5.55
	1.125% Notes due 2017		697				1.15			—			—
	5.15% Debentures due 2018		898				5.15			898			5.15
	1.65% Notes due 2018		597				1.7			589			1.7
	4.75% Notes due 2019 (1B Euro 1.2199)(2)/ (1B Euro 1.3683)(3)		1,216			(2)	5.83			1,363		(3)	5.83
	1.875% Notes due 2019		497				1.93			—			—
	3% Zero Coupon Convertible Subordinated Debentures due 2020		158				3			179			3
	2.95% Debentures due 2020		543				3.15			542			3.15
	3.55% Notes due 2021		446				3.67			446			3.67
	2.45% Notes due 2021		349				2.48			—			—
	6.73% Debentures due 2023		250				6.73			250			6.73
	3.375% Notes due 2023		812			(5)	3.17			550			3.38
	5.50% Notes due 2024 (500MM GBP 1.5542)(2)/(500MM GBP 1.6414)(3)		772			(2)	6.75			816		(3)	6.75
	6.95% Notes due 2029		297				7.14			296			7.14
	4.95% Debentures due 2033		500				4.95			500			4.95
	4.375% Notes due 2033		865			(5)	4.23			646			4.42
	5.95% Notes due 2037		995				5.99			995			5.99
	5.85% Debentures due 2038		700				5.86			700			5.86
	4.50% Debentures due 2040		539				4.63			539			4.63
	4.85% Notes due 2041		298				4.89			298			4.89
	4.50% Notes due 2043		499				4.52			499			4.52
	Other		105				—			147			—
	Subtotal		15,129			(4)	4.08	%	(1)	15,097		(4)	4	(1	)
	Less current portion		7							1,769
	Total long-term debt		$	15,122						13,328
	(1)	Weighted average effective rate.
	(2)	Translation rate at December 28, 2014.
	(3)	Translation rate at December 29, 2013.
	(4)	The excess of the fair value over the carrying value of debt was $2.2 billion in 2014 and $1.4 billion in 2013.
	(5)	Includes the reopening of these issues.
	Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.
	The Company has access to substantial sources of funds at numerous banks worldwide. In September 2014, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September 17, 2015. Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or London Interbank Offered Rates (LIBOR), plus applicable margins. Commitment fees under the agreements are not material.
	Throughout 2014, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $3.6 billion at the end of 2014, of which $3.1 billion was borrowed under the Commercial Paper Program. The remainder principally represents local borrowing by international subsidiaries.
	The Company has a shelf registration with the U.S. Securities and Exchange Commission that enables the Company to issue debt securities and warrants to purchase debt securities on a timely basis. The Company issued bonds in November 2014 for a total of $2.0 billion for general corporate purposes. This included the reopening of the 2023 and 2033 bonds issues in December 2013.
	Aggregate maturities of long-term obligations commencing in 2015 are:
	(Dollars in Millions)
	2015		2016		2017		2018		2019		After 2019
	$7		2,152		1,722		1,496		1,713		8,039

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 28, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	Income Taxes
	The provision for taxes on income consists of:
	(Dollars in Millions)	2014				2013		2012
	Currently payable:
	U.S. taxes	$	2,625			594		2,023
	International taxes	1,174				1,653		1,277
	Total currently payable	3,799				2,247		3,300
	Deferred:
	U.S. taxes	(258		)		(251	)	(120	)
	International taxes	699				(356	)	81
	Total deferred	441				(607	)	(39	)
	Provision for taxes on income	$	4,240			1,640		3,261
	A comparison of income tax expense at the U.S. statutory rate of 35% in 2014, 2013 and 2012, to the Company’s effective tax rate is as follows:
	(Dollars in Millions)	2014				2013		2012
	U.S.	$	8,001			4,261		4,664
	International	12,562				11,210		9,111
	Earnings before taxes on income:	$	20,563			15,471		13,775
	Tax rates:
	U.S. statutory rate	35		%		35		35
	International operations excluding Ireland	(7.0		)		(10.6	)	(9.8	)
	Ireland and Puerto Rico operations	(6.9		)		(9.0	)	(3.9	)
	Research and orphan drug tax credits	(0.3		)		(0.8	)	—
	U.S. state and local	1				0.4		1.3
	U.S. manufacturing deduction	(0.6		)		(0.8	)	(0.9	)
	U.S. tax on international income	1.4				1.7		1.1
	U.S. tax benefit on asset/business disposals	(1.9		)		(5.1	)	—
	All other	(0.1		)		(0.2	)	0.9
	Effective tax rate	20.6		%		10.6		23.7
	The increase in the 2014 effective tax rate, as compared to 2013, was attributable to the following: the divestiture of the Ortho-Clinical Diagnostics business at an approximate 44% effective tax rate, litigation accruals at low tax rates, the mix of earnings into higher tax jurisdictions, primarily the U.S., the accrual of an additional year of the Branded Prescription Drug Fee, which is not tax deductible, and additional U.S. tax expense related to a planned increase in dividends from current year foreign earnings as compared to the prior year. These increases to the 2014 effective tax rate were partially offset by a tax benefit of $0.4 billion associated with the Conor Medsystems divestiture.
	The 2013 effective tax rate was reduced by a tax benefit associated with the write-off of assets for tax purposes associated with Scios, Inc., and the inclusion of both the 2013 and 2012 benefit from the Research and Development tax credit and the Controlled Foreign Corporation look-through provisions, because those provisions were enacted into law in January 2013 and were retroactive to January 1, 2012.
	The 2014 effective tax rate was also reduced as the Company adjusted its unrecognized tax benefits as a result of (i) the federal appeals court’s decision in OMJ Pharmaceuticals, Inc.’s litigation regarding credits under former Section 936 of the Internal Revenue Code (see Note 21 to the Consolidated Financial Statements for additional information), and (ii) a settlement of substantially all issues related to the Company’s U.S. Internal Revenue Service audit of tax years 2006 - 2009. The impact of the settlement is reflected in the U.S. tax on international income and the All other line items within the above reconciliation.
	The items noted above reflect the key drivers of the rate reconciliation.
	The Company has subsidiaries operating in Puerto Rico under various tax incentives.
	Temporary differences and carryforwards for 2014 and 2013 were as follows:
		2014 Deferred Tax						2013 Deferred Tax
	(Dollars in Millions)	Asset				Liability		Asset			Liability
	Employee related obligations	$	3,426					1,908
	Stock based compensation	799						1,121
	Depreciation					(564	)				(772	)
	Non-deductible intangibles					(6,671	)				(6,250	)
	International R&D capitalized for tax	1,433						1,656
	Reserves & liabilities	1,497						1,587
	Income reported for tax purposes	1,067						1,043
	Net operating loss carryforward international	949						1,090
	Miscellaneous international	1,128			(1)	(305	)	1,508		(1)	(361	)
	Miscellaneous U.S.	996						927
	Total deferred income taxes	$	11,295			(7,540	)	10,840			(7,383	)
	(1) The $1,128 million in 2014 was net of a valuation allowance related to Belgium of $172 million. The $1,508 million in 2013 was net of a valuation allowance related to Belgium of $187 million.
	The difference between the net deferred tax on income per the balance sheet and the net deferred tax above is included in taxes on income on the balance sheet. The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will realize future taxable income sufficient to utilize these deferred tax assets.
	The following table summarizes the activity related to unrecognized tax benefits:
	(Dollars in Millions)	2014				2013		2012
	Beginning of year	$	2,729			3,054		2,699
	Increases related to current year tax positions	281				643		538
	Increases related to prior period tax positions	295				80		57
	Decreases related to prior period tax positions	(288		)		(574	)	(41	)
	Settlements	(477		)		(418	)	(120	)
	Lapse of statute of limitations	(75		)		(56	)	(79	)
	End of year	$	2,465			2,729		3,054
	The unrecognized tax benefits of $2.5 billion at December 28, 2014, if recognized, would affect the Company’s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. The IRS has completed its audit for the tax years through 2009; however, there are a limited number of issues remaining open for prior tax years going back to 1999. In other major jurisdictions where the Company conducts business, the years remain open generally back to the year 2004. The Company believes it is possible that audits may be completed by tax authorities in some jurisdictions over the next twelve months.  However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.
	The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $12 million, $40 million and $41 million in 2014, 2013 and 2012, respectively. The total amount of accrued interest was $298 million and $412 million in 2014 and 2013, respectively.

Employee_Related_Obligations

Employee Related Obligations	12 Months Ended
	Dec. 28, 2014
Compensation Related Costs [Abstract]
Employee Related Obligations	Employee Related Obligations
	At the end of 2014 and 2013, employee related obligations recorded on the Consolidated Balance Sheets were:
	(Dollars in Millions)	2014		2013
	Pension benefits	$	4,547	2,950
	Postretirement benefits	3,161		2,655
	Postemployment benefits	2,062		1,872
	Deferred compensation	599		693
	Total employee obligations	10,369		8,170
	Less current benefits payable	397		386
	Employee related obligations — non-current	$	9,972	7,784
	Prepaid employee related obligations of $233 million and $2,363 million for 2014 and 2013, respectively, are included in other assets on the Consolidated Balance Sheets.

Pensions_and_Other_Benefit_Pla

Pensions and Other Benefit Plans	12 Months Ended
	Dec. 28, 2014
Compensation and Retirement Disclosure [Abstract]
Pensions and Other Benefit Plans	Pensions and Other Benefit Plans
	The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily health care, to all eligible U.S. retired employees and their dependents.
	Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.
	Retirement plan benefits for employees hired before January 1, 2015 are primarily based on the employee’s compensation during the last three to five years before retirement and the number of years of service. In 2014, the Company announced that the U.S. Defined Benefit plan was amended to adopt a new benefit formula, effective for employees hired on or after January 1, 2015. The benefits are calculated using a new formula based on employee compensation over total years of service.
	International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided.
	The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future.
	The Company uses the date of its consolidated financial statements (December 28, 2014 and December 29, 2013, respectively) as the measurement date for all U.S. and international retirement and other benefit plans.
	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2014, 2013 and 2012 include the following components:
			Retirement Plans										Other Benefit Plans
	(Dollars in Millions)		2014				2013			2012			2014			2013			2012
	Service cost		$	882			906			722			211			196			175
	Interest cost		1,018				908			878			197			151			165
	Expected return on plan assets		(1,607		)		(1,447	)		(1,236	)		(7	)		(6	)		(4	)
	Amortization of prior service cost (credit)		6				6			6			(34	)		(2	)		(3	)
	Amortization of net transition obligation		1				1			1			—			—			—
	Recognized actuarial losses		460				681			494			136			111			76
	Curtailments and settlements		(17		)		—			—			—			2			—
	Net periodic benefit cost		$	743			1,055			865			503			452			409
	Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company’s defined benefit retirement plans and other post-retirement plans:
	(Dollars in Millions)
	Amortization of net transition obligation	—
	Amortization of net actuarial losses	944
	Amortization of prior service credit	33
	Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the projected benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.
	Prior service costs/benefits for the U.S. pension plans are amortized over the remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.
	The weighted-average assumptions in the following table represent the rates used to develop the actuarial present value of projected benefit obligation for the year listed and also the net periodic benefit cost for the following year.
			Retirement Plans									Other Benefit Plans
			2014			2013			2012			2014			2013			2012
	Worldwide Benefit Plans
	Discount rate		3.78	%		4.78	%		4.25	%		4.31	%		5.25	%		4.55	%
	Expected long-term rate of return on plan assets		8.53	%		8.46	%		8.45	%
	Rate of increase in compensation levels		4.05	%		4.08	%		4.08	%		4.11	%		4.29	%		4.28	%
	The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities.
	The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market.
	For measurement of U.S. retirement benefit obligations, the mortality assumption was updated to a newly established 2014 mortality table resulting in an increase to the projected benefit obligation.
	The following table displays the assumed health care cost trend rates, for all individuals:
	Health Care Plans		2014			2013
	Health care cost trend rate assumed for next year		6	%		6.5	%
	Rate to which the cost trend rate is assumed to decline (ultimate trend)		4.5	%		4.5	%
	Year the rate reaches the ultimate trend rate		2032			2032
	A one-percentage-point change in assumed health care cost trend rates would have the following effect:
			One-Percentage-				One-Percentage-
	(Dollars in Millions)		Point Increase				Point Decrease
	Health Care Plans
	Total interest and service cost		$	45			$	(34	)
	Post-retirement benefit obligation		560				(444		)
	The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2014 and 2013 for the Company’s defined benefit retirement plans and other post-retirement plans:
			Retirement Plans							Other Benefit Plans
	(Dollars in Millions)		2014				2013			2014				2013
	Change in Benefit Obligation
	Projected benefit obligation — beginning of year		$	21,488			21,829			4,407				4,159
	Service cost		882				906			211				196
	Interest cost		1,018				908			197				151
	Plan participant contributions		59				54			—				—
	Amendments		(60		)		35			(254		)		7
	Actuarial (gains) losses		5,395				(1,432	)		1,030				296
	Divestitures & acquisitions		(121		)		8			—				—
	Curtailments, settlements & restructuring		(53		)		(15	)		—				(11	)
	Benefits paid from plan		(813		)		(751	)		(493		)		(373	)
	Effect of exchange rates		(906		)		(54	)		(17		)		(18	)
	Projected benefit obligation — end of year		$	26,889			21,488			5,081				4,407
	Change in Plan Assets
	Plan assets at fair value — beginning of year		$	20,901			17,536			87				122
	Actual return on plan assets		2,078				3,573			8				15
Company contributions		1,176				565			477				323
Plan participant contributions		59				54			—				—
Settlements		(40		)		(4	)		—				—
Divestitures & acquisitions		(109		)		9			—				—
Benefits paid from plan assets		(813		)		(751	)		(493		)		(373	)
Effect of exchange rates		(677		)		(81	)		—				—
Plan assets at fair value — end of year		$	22,575			20,901			79				87
Funded status — end of year		$	(4,314	)		(587	)		(5,002		)		(4,320	)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets		$	233			2,363			$	—			—
Current liabilities		(74		)		(71	)		(309		)		(302	)
Non-current liabilities		(4,473		)		(2,879	)		(4,693		)		(4,018	)
Total recognized in the consolidated balance sheet — end of year		$	(4,314	)		(587	)		$	(5,002	)		(4,320	)
Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:
Net actuarial loss		$	7,547			3,344			$	2,611			1,732
Prior service cost (credit)		(33		)		26			(225		)		(6	)
Unrecognized net transition obligation		1				2			—				—
Total before tax effects		$	7,515			3,372			$	2,386			1,726
Accumulated Benefit Obligations — end of year		$	23,816			19,203
		Retirement Plans							Other Benefit Plans
(Dollars in Millions)		2014				2013			2014				2013
Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income
Net periodic benefit cost		$	743			1,055			$	503			452
Net actuarial (gain) loss		4,942				(3,559	)		1,015				248
Amortization of net actuarial loss		(460		)		(681	)		(136		)		(111	)
Prior service cost (credit)		(60		)		34			(253		)		8
Amortization of prior service (cost) credit		(6		)		(13	)		34				—
Effect of exchange rates		(273		)		(6	)		—				(6	)
Total recognized in other comprehensive income, before tax		$	4,143			(4,225	)		$	660			139
Total recognized in net periodic benefit cost and other comprehensive income		$	4,886			(3,170	)		$	1,163			591
The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded.
In 2014, the Company contributed $561 million and $615 million to its U.S. and international pension plans, respectively.
The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 28, 2014 and December 29, 2013, respectively:
	U.S. Plans									International Plans
	Qualified Plans					Non-Qualified Plans				Funded Plans				Unfunded Plans
(Dollars in Millions)	2014			2013		2014		2013		2014		2013		2014		2013
Plan Assets	$	15,201		13,990		—		—		7,374		6,911		—		—
Projected Benefit Obligation	15,571			11,921		1,683		1,296		9,203		7,797		432		474
Accumulated Benefit Obligation	13,875			10,745		1,363		1,065		8,205		6,974		373		419
Over (Under) Funded Status
Projected Benefit Obligation	$	(370	)	2,069		(1,683	)	(1,296	)	(1,829	)	(886	)	(432	)	(474	)
Accumulated Benefit Obligation	1,326			3,245		(1,363	)	(1,065	)	(831	)	(63	)	(373	)	(419	)
Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $8.2 billion, $9.4 billion and $5.3 billion, respectively, at the end of 2014, and $5.4 billion, $5.8 billion and $3.3 billion, respectively, at the end of 2013.
The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans:
(Dollars in Millions)		2015				2016			2017			2018			2019			2020-2024
Projected future benefit payments
Retirement plans		$	793			813			868			907			963			5,858
Other benefit plans		$	316			309			306			303			300			1,475
The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.
(Dollars in Millions)		2015				2016			2017			2018			2019			2020-2024
Projected future contributions		$	74			75			78			84			89			531
Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.
The Company’s retirement plan asset allocation at the end of 2014 and 2013 and target allocations for 2015 are as follows:
		Percent of						Target
		Plan Assets						Allocation
		2014			2013			2015
Worldwide Retirement Plans
Equity securities		77	%		76	%		73	%
Debt securities		23			24			27
Total plan assets		100	%		100	%		100	%
Determination of Fair Value of Plan Assets
The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.
While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
Valuation Hierarchy
The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest.
A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Following is a description of the valuation methodologies used for the investments measured at fair value.
•	Short-term investments — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the Net Asset Value (NAV) provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in a market that is not active and classified as Level 2.
•	Government and agency securities — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2.
•	Debt instruments — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs.
•	Equity securities — Common stocks are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all common stock is classified within Level 1 of the valuation hierarchy.
•	Commingled funds — These investment vehicles are valued using the NAV provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Assets in the Level 2 category have a quoted market price in a market that is not active.
•	Insurance contracts — The instruments are issued by insurance companies. The fair value is based on negotiated value and the underlying investments held in separate account portfolios as well as considering the credit worthiness of the issuer. The underlying investments are government, asset-backed and fixed income securities. In general, insurance contracts are classified as Level 3 as there are no quoted prices nor other observable inputs for pricing.
•	Other assets — Other assets are represented primarily by limited partnerships and real estate investments, as well as commercial loans and commercial mortgages that are not classified as corporate debt. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2. Most limited partnerships represent investments in private equity and similar funds that are valued by the general partners. Certain of these limited partnerships, as well as any other assets valued using unobservable inputs, are classified as Level 3.
The following table sets forth the Retirement Plans' investments measured at fair value as of December 28, 2014 and December 29, 2013:
		Quoted Prices							Significant						Significant
		in Active							Other						Unobservable
		Markets for							Observable						Inputs
		Identical Assets							Inputs
		(Level 1)							(Level 2)						(Level 3)					Total Assets
(Dollars in Millions)		2014				2013			2014			2013			2014			2013		2014	2013
Short-term investment funds		$	168			304			551			561			—			—		719	865
Government and agency securities		—				—			1,934			1,965			—			—		1,934	1,965
Debt instruments		—				—			1,143			1,215			1			1		1,144	1,216
Equity securities		11,204				10,526			21			23			—			4		11,225	10,553
Commingled funds		—				—			7,205			5,846			46			44		7,251	5,890
Insurance contracts		—				—			—			2			24			23		24	25
Other assets		1				4			214			314			63			69		278	387
Investments at fair value		$	11,373			10,834			11,068			9,926			134			141		22,575	20,901
The Company's Other Benefit Plans are unfunded except for U.S. commingled funds (Level 2) of $79 million and $76 million at December 28, 2014 and December 29, 2013, respectively, and $0 million and $11 million of U.S. short-term-investment funds (Level 2) at December 28, 2014 and December 29, 2013, respectively.
The fair value of Johnson & Johnson Common Stock directly held in plan assets was $778 million (3.4% of total plan assets) at December 28, 2014 and $671 million (3.2% of total plan assets) at December 29, 2013.
Level 3 Gains and Losses
The table below sets forth a summary of changes in the fair value of the Plan’s Level 3 assets for the years ended December 28, 2014 and December 29, 2013:
(Dollars in Millions)		Debt Instruments				Equity Securities			Commingled Funds			Insurance Contracts			Other Assets			Total Level 3
Balance December 30, 2012		$	3			4			50			24			69			150
Realized gains (losses)		—				—			—			—			(5	)		(5	)
Unrealized gains (losses)		—				(1	)		—			(1	)		—			(2	)
Purchases, sales, issuances and settlements, net		(2		)		1			(6	)		—			5			(2	)
Balance December 29, 2013		1				4			44			23			69			141
Realized gains (losses)		—				—			—			—			(5	)		(5	)
Unrealized gains (losses)		—				—			2			—			—			2
Purchases, sales, issuances and settlements, net		—				—			(2	)		3			(1	)		—
Transfers in/out and exchange rate changes		—				(4	)		2			(2	)		—			(4	)
Balance December 28, 2014		$	1			—			46			24			63			134

Savings_Plan

Savings Plan	12 Months Ended
	Dec. 28, 2014
Savings Plan [Abstract]
Savings Plan	Savings Plan
	The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $172 million, $164 million and $160 million in 2014, 2013 and 2012, respectively.

Capital_and_Treasury_Stock

Capital and Treasury Stock	12 Months Ended
	Dec. 28, 2014
Equity [Abstract]
Capital and Treasury Stock	Capital and Treasury Stock
	Changes in treasury stock were:
		Treasury Stock
	(Amounts in Millions Except Treasury Stock Shares in Thousands)	Shares		Amount
	Balance at January 1, 2012	395,480		$	21,659
	Employee compensation and stock option plans	(55,170	)	(3,250		)
	Issuance of common stock associated with the acquisition of Synthes, Inc.	(203,740	)	(12,852		)
	Repurchase of common stock (1)	204,784		12,919
	Balance at December 30, 2012	341,354		18,476
	Employee compensation and stock option plans	(48,555	)	(3,367		)
	Repurchase of common stock	6,416		591
	Balance at December 29, 2013	299,215		15,700
	Employee compensation and stock option plans	(32,302	)	(2,933		)
	Repurchase of common stock	69,707		7,124
	Balance at December 28, 2014	336,620		$	19,891
	(1) Includes repurchase of common stock associated with the acquisition of Synthes, Inc.
	Aggregate shares of common stock issued were approximately 3,119,843,000 shares at the end of 2014, 2013 and 2012.
	Cash dividends paid were $2.76 per share in 2014, compared with dividends of $2.59 per share in 2013, and $2.40 per share in 2012.
	On July 21, 2014, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. As of December 28, 2014, $3.5 billion has been repurchased under the program. Share repurchases will take place on the open market from time to time based on market conditions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes. The Company intends to finance the share repurchase program through available cash.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 28, 2014
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	Accumulated Other Comprehensive Income
	Components of other comprehensive income (loss) consist of the following:
	(Dollars in Millions)	Foreign			Gain/(Loss) On Securities		Employee Benefit Plans		Gain/		Total
		Currency Translation							(Loss) On		Accumulated
									Derivatives & Hedges		Other
											Comprehensive Income (Loss)
	January 1, 2012	$	(1,526	)	448		(4,386	)	(168	)	(5,632	)
	Net 2012 changes	1,230			(253	)	(1,331	)	176		(178	)
	December 30, 2012	(296		)	195		(5,717	)	8		(5,810	)
	Net 2013 changes	94			(89	)	2,708		237		2,950
	29-Dec-13	(202		)	106		(3,009	)	245		(2,860	)
	Net 2014 changes	(4,601		)	151		(3,308	)	(104	)	(7,862	)
	28-Dec-14	$	(4,803	)	257		(6,317	)	141		(10,722	)
	Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.
	Details on reclassifications out of Accumulated Other Comprehensive Income:
	Gain/(Loss) on Securities - reclassifications released to Other (income) expense, net.
	Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.
	Gain/(Loss) on Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.

International_Currency_Transla

International Currency Translation	12 Months Ended
	Dec. 28, 2014
Foreign Currency Translation [Abstract]
International Currency Transalation	International Currency Translation
	For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency.
	In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.
	A rollforward of the changes during 2014, 2013 and 2012 for foreign currency translation adjustments is included in Note 13.
	Net currency transaction gains and losses included in Other (income) expense were losses of $156 million, $186 million and $58 million in 2014, 2013 and 2012, respectively.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 28, 2014
Earnings Per Share [Abstract]
EARNINGS PER SHARE	Earnings Per Share
	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 28, 2014, December 29, 2013 and December 30, 2012:
	(In Millions Except Per Share Amounts)	2014			2013		2012
	Basic net earnings per share attributable to Johnson & Johnson	$	5.8		4.92		3.94
	Average shares outstanding — basic	2,815.20			2,809.20		2,753.30
	Potential shares exercisable under stock option plans	142.6			148.5		164.6
	Less: shares repurchased under treasury stock method	(96.5		)	(103.3	)	(128.2	)
	Convertible debt shares	2.6			3		3.6
	Accelerated share repurchase program	—			19.6		19.3
	Adjusted average shares outstanding — diluted	2,863.90			2,877.00		2,812.60
	Diluted net earnings per share attributable to Johnson & Johnson	$	5.7		4.81		3.86
	The diluted net earnings per share calculation included the dilutive effect of convertible debt that is offset by the related reduction in interest expense of $3 million after-tax for 2014 and $4 million for years 2013 and 2012.
	The diluted earnings per share calculation for 2014 and 2013 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock. Diluted net earnings per share for 2012 excluded 0.2 million shares related to stock options, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share.
	The diluted earnings per share calculation for the fiscal years ended December 29, 2013 and December 30, 2012 included the dilutive effect of 19.6 million shares and 19.3 million shares, respectively, related to the accelerated share repurchase program, associated with the acquisition of Synthes, Inc. See Note 20 to the Consolidated Financial Statements for additional details.

Rental_Expense_and_Lease_Commi

Rental Expense and Lease Commitments	12 Months Ended
	Dec. 28, 2014
Leases, Operating [Abstract]
Rental Expense and Lease Commitments	Rental Expense and Lease Commitments
	Rentals of space, vehicles, manufacturing equipment and office and data processing equipment under operating leases were approximately $341 million, $363 million and $375 million in 2014, 2013 and 2012, respectively.
	The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at December 28, 2014 are:
	(Dollars in Millions)
	2015	2016	2017	2018	2019	After 2019	Total
	$200	157	111	80	66	77	691
	Commitments under capital leases are not significant.

Common_Stock_Stock_Option_Plan

Common Stock, Stock Option Plans and Stock Compensation Agreements	12 Months Ended
	Dec. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock, Stock Option Plans and Stock Compensation Agreements	Common Stock, Stock Option Plans and Stock Compensation Agreements
	At December 28, 2014, the Company had 3 stock-based compensation plans. The shares outstanding are for contracts under the Company's 2000 Stock Option Plan, the 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012. Shares available for future grants under the 2012 Long-Term Incentive Plan were 530 million at the end of 2014.
	The compensation cost that has been charged against income for these plans was $792 million, $728 million and $662 million for 2014, 2013 and 2012, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $259 million, $243 million and $220 million for 2014, 2013 and 2012, respectively. The total unrecognized compensation cost was $722 million, $636 million and $565 million for 2014, 2013 and 2012, respectively. The weighted average period for this cost to be recognized was 1.18 years, 1.26 years and 1.02 years for 2014, 2013, and 2012, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.
	The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished throughout the year for the number of shares used to settle employee benefit equity issuances.
	Stock Options
	Stock options expire 10 years from the date of grant and vest over service periods that range from 6 months to 4 years. All options are granted at the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange on the date of grant.
	The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. Expected volatility represents a blended rate of 4-year daily historical average volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. Historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant.
	The average fair value of options granted was $8.42, $4.88 and $6.39, in 2014, 2013 and 2012, respectively. The fair value was estimated based on the weighted average assumptions of:
		2014			2013			2012
	Risk-free rate	1.87	%		1.01	%		1.06	%
	Expected volatility	14.6	%		14.04	%		18.38	%
	Expected life (in years)	6			6			6
	Dividend yield	3.1	%		3.4	%		3.6	%
	A summary of option activity under the Plan as of December 28, 2014, December 29, 2013 and December 30, 2012, and changes during the years ending on those dates is presented below:
	(Shares in Thousands)		Outstanding Shares			Weighted				Aggregate
						Average Exercise Price				Intrinsic
										Value
										(Dollars in Millions)
	Shares at January 1, 2012		179,459			$	60.1			$	1,004
	Options granted		8,661			65.36
	Options exercised		(49,388	)		56.73
	Options canceled/forfeited		(4,381	)		62.97
	Shares at December 30, 2012		134,351			61.58				1,061
	Options granted		29,010			72.54
	Options exercised		(41,357	)		59.99
	Options canceled/forfeited		(2,448	)		65.89
	Shares at December 29, 2013		119,556			64.7				3,306
	Options granted		24,356			90.44
	Options exercised		(25,319	)		62.31
	Options canceled/forfeited		(2,881	)		75.48
	Shares at December 28, 2014		115,712			$	70.37			$	4,014
	The total intrinsic value of options exercised was $954 million, $941 million and $547 million in 2014, 2013 and 2012, respectively.
	The following table summarizes stock options outstanding and exercisable at December 28, 2014:
	(Shares in Thousands)		Outstanding							Exercisable
	Exercise Price Range		Options			Average Life(1)		Average Exercise Price		Options		Average Exercise Price
	$52.13-$58.33		10,182			4.1		$58.32		10,182		$58.32
	$58.34-$62.20		24,179			3.1		$60.68		23,653		$60.64
	$62.62-$65.62		25,630			4.4		$64.60		18,346		$64.30
	$65.80-$72.54		32,252			6.6		$71.43		5,661		$66.20
	$90.44-$100.48		23,469			9.1		$90.44		4		$90.44
			115,712			5.7		$70.37		57,846		$61.94
	(1) Average contractual life remaining in years.
	Stock options outstanding at December 29, 2013 and December 30, 2012 were 119,556 and an average life of 5.1 years and 134,351 and an average life of 4.3 years, respectively. Stock options exercisable at December 29, 2013 and December 30, 2012 were 75,210 at an average price of $62.01 and 104,860 at an average price of $61.15, respectively.
	Restricted Share Units and Performance Share Units
	The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson & Johnson Common Stock after the end of a three-year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three-year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: sales, adjusted operational earnings per share, and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted.
	A summary of the restricted share units and performance share units activity under the Plans as of December 28, 2014 is presented below:
	(Shares in Thousands)		Outstanding Restricted Share Units			Outstanding Performance Share Units
	Shares at January 1, 2012		31,026
	Granted		12,197			327
	Issued		(9,278	)		—
	Canceled/forfeited		(2,111	)		(42	)
	Shares at December 30, 2012		31,834			285
	Granted		10,582			1,290
	Issued		(10,078	)		—
	Canceled/forfeited		(1,721	)		(40	)
	Shares at December 29, 2013		30,617			1,535
	Granted		8,487			1,113
	Issued		(9,685	)		(19	)
	Canceled/forfeited		(1,726	)		(98	)
	Shares at December 28, 2014		27,693			2,531
	The average fair value of the restricted share units granted was $83.01, $65.90 and $58.93 in 2014, 2013 and 2012, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $541.0 million, $569.2 million and $483.2 million in 2014, 2013 and 2012, respectively.
	The weighted average fair value of the performance share units granted was $85.94, $73.42 and $55.01 in 2014, 2013 and 2012, calculated using the weighted average fair market value for each of the three component goals at the date of grant.
	The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.  The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. The fair value of performance share units issued in 2014 was $1.4 million due to accelerated vesting in accordance with the plan document. No performance share units vested in 2013 and 2012.

Segments_of_Business_and_Geogr

Segments of Business and Geographic Areas	12 Months Ended
	Dec. 28, 2014
Segment Reporting [Abstract]
SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS	Segments of Business and Geographic Areas
			Sales to Customers
	(Dollars in Millions)		2014		2013	2012
	Consumer —
	United States		$	5,096	5,162	5,046
	International		9,400		9,535	9,401
	Total		14,496		14,697	14,447
	Pharmaceutical —
	United States		17,432		13,948	12,421
	International		14,881		14,177	12,930
	Total		32,313		28,125	25,351
	Medical Devices —
	United States		12,254		12,800	12,363
	International		15,268		15,690	15,063
	Total		27,522		28,490	27,426
	Worldwide total		$	74,331	71,312	67,224
			Pre-Tax Profit				Identifiable Assets
	(Dollars in Millions)		2014 (3)		2013 (4)	2012 (5)	2014		2013	2012
	Consumer		$	1,941	1,973	1,693	$	21,813	23,711	24,131
	Pharmaceutical		11,696		9,178	6,075	25,803		23,783	23,219
	Medical Devices		7,953		5,261	7,187	41,445		44,585	42,926
	Total		21,590		16,412	14,955	89,061		92,079	90,276
	Less: Expense not allocated to segments (1)		1,027		941	1,180
	General corporate (2)						42,058		40,604	31,071
	Worldwide total		$	20,563	15,471	13,775	$	131,119	132,683	121,347
			Additions to Property,				Depreciation and
			Plant & Equipment				Amortization
	(Dollars in Millions)		2014		2013	2012	2014		2013	2012
	Consumer		$	581	533	468	$	577	539	575
	Pharmaceutical		977		856	737	1,053		1,075	1,010
	Medical Devices		1,807		1,724	1,230	1,974		2,224	1,857
	Segments total		3,365		3,113	2,435	3,604		3,838	3,442
	General corporate		349		482	499	291		266	224
	Worldwide total		$	3,714	3,595	2,934	$	3,895	4,104	3,666
			Sales to Customers				Long-Lived Assets (6)
	(Dollars in Millions)		2014		2013	2012	2014		2013	2012
	United States		$	34,782	31,910	29,830	$	36,835	35,880	35,115
	Europe		18,947		18,599	16,945	21,559		24,868	25,261
	Western Hemisphere excluding U.S.		7,160		7,421	7,207	3,210		3,281	3,636
	Asia-Pacific, Africa		13,442		13,382	13,242	2,438		2,434	2,362
	Segments total		74,331		71,312	67,224	64,042		66,463	66,374
	General corporate						1,138		992	899
	Other non long-lived assets						65,939		65,228	54,074
	Worldwide total		$	74,331	71,312	67,224	$	131,119	132,683	121,347
	­
	See Note 1 for a description of the segments in which the Company operates.
	Export sales are not significant. In 2014, the Company had one wholesaler distributing products for all three segments that represented approximately 11.0% of the total consolidated revenues. In 2013 and 2012, the Company did not have a customer that represented 10.0% of total revenues.
	(1)	Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes currency related expense of $0.2 billion associated with the acquisition of Synthes, Inc. in 2012.
	(2)	General corporate includes cash, cash equivalents and marketable securities.
	(3)	Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. Includes an additional year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.
	(4)	Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
	(5)	Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments, respectively. The Medical Devices segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.
	(6)	Long-lived assets include property, plant and equipment, net for 2014, 2013 and 2012 of $16,126, $16,710 and $16,097, respectively, and intangible assets and goodwill, net for 2014, 2013 and 2012 of $49,054, $50,745 and $51,176, respectively.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 28, 2014
Selected Quarterly Financial Information [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited)
	Selected unaudited quarterly financial data for the years 2014 and 2013 are summarized below:
			2014					2013
	(Dollars in Millions Except Per Share Data)		First Quarter (1)		Second Quarter (2)	Third Quarter (3)	Fourth Quarter (4)	First Quarter (5)	Second Quarter (6)	Third Quarter (7)	Fourth Quarter (8)
	Segment sales to customers
	Consumer		$	3,557	3,744	3,589	3,606	3,675	3,658	3,611	3,753
	Pharmaceutical		7,498		8,509	8,307	7,999	6,768	7,025	7,036	7,296
	Medical Devices		7,060		7,242	6,571	6,649	7,062	7,194	6,928	7,306
	Total sales		18,115		19,495	18,467	18,254	17,505	17,877	17,575	18,355
	Gross profit		12,660		13,456	13,068	12,401	11,951	12,388	12,231	12,400
	Earnings before provision for taxes on income		5,424		5,626	6,810	2,703	4,261	4,793	3,667	2,750
	Net earnings attributable to Johnson & Johnson		4,727		4,326	4,749	2,521	3,497	3,833	2,982	3,519
	Basic net earnings per share attributable to Johnson & Johnson		$	1.67	1.53	1.69	0.9	1.25	1.36	1.06	1.25
	Diluted net earnings per share attributable to Johnson & Johnson		$	1.64	1.51	1.66	0.89	1.22	1.33	1.04	1.23
	-1	The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.
	(2)	The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
	(3)	The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
	(4)	The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
	(5)	The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).
	(6)	The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).
	(7)	The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.
	(8)	The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASR™ Hip program and a $707 million tax benefit associated with Scios Inc.

Business_Combinations_and_Dive

Business Combinations and Divestitures	12 Months Ended
	Dec. 28, 2014
Business Combinations [Abstract]
BUSINESS COMBINATIONS AND DIVESTITURES	Business Combinations and Divestitures
	Certain businesses were acquired for $2,129 million in cash and $38 million of liabilities assumed during 2014. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.
	The 2014 acquisitions included: Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform; Alios BioPharma, Inc., a privately-held, clinical stage biopharmaceutical company focused on developing therapies for viral diseases; and the ORSLTM electrolyte ready-to-drink brand from Jagdale Industries Ltd. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $2,069 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Of this amount, approximately $1,913 million has been identified as the value of IPR&D associated with the acquisitions of Covagen AG and Alios BioPharma, Inc. The value of the IPR&D was calculated using cash flow projections discounted for the inherent risk in the projects.
	The IPR&D related to the acquisition of Alios BioPharma, Inc. (Alios) of $1,688 million is associated with Alios’ lead compound AL-8176, an orally administered antiviral therapy for treatment of infants with respiratory syncytial virus (RSV). A probability of success factor of 60.0% was used to reflect inherent clinical and regulatory risk. The discount rate applied was 11.4%. The IPR&D related to the acquisition of Covagen AG of $225 million is associated with Covagen’s lead compound COVA-322, currently in Phase 1b study for psoriasis and holding potential as a treatment for a broad range of inflammatory diseases including rheumatoid arthritis. A probability of success factor of 26% was used to reflect inherent clinical and regulatory risk. The discount rate applied was 12.5%.
	Certain businesses were acquired for $835 million in cash and $193 million of liabilities assumed during 2013. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.
	The assumed liabilities primarily represent the fair value of the contingent consideration which may be payable related to the acquisition of Aragon Pharmaceuticals, Inc. As per terms of the agreement, additional payments of up to $350 million may be paid in the future based on reaching predetermined milestones.
	The 2013 acquisitions included: Flexible Stenting Solutions, Inc., a leading developer of innovative flexible peripheral arterial, venous and biliary stents; Shanghai Elsker Mother & Baby Co., Ltd, a baby care company in China and Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.
	The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $941 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Of this amount, approximately $831 million has been identified as the value of IPR&D associated with the acquisitions of Aragon Pharmaceuticals, Inc. and Flexible Stenting Solutions, Inc.
	The IPR&D related to the acquisition of Aragon Pharmaceuticals, Inc. of $810 million is associated with Aragon’s androgen receptor antagonist program for treatment of hormonally-driven cancers. The value of the IPR&D was calculated using cash flow projections discounted for the inherent risk in such projects. Probability of success factors ranging from 37% - 52.0% were used to reflect inherent clinical and regulatory risk. The discount rate applied was 15.5%. The IPR&D related to the acquisition of Flexible Stenting Solutions, Inc. of $21 million is associated with the approval for peripheral vascular indications, including the superficial femoral artery indication. A probability of success factor of 100% was used and a discount rate ranging between 16.5% - 17.5% was applied.
	Certain businesses were acquired for $17,821 million in cash and stock and $1,204 million of liabilities assumed during 2012. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.
	The 2012 acquisitions included: Synthes, Inc., a global developer and manufacturer of orthopaedics devices; Guangzhou Bioseal Biotech Co., Ltd., a developer of biologic combinations addressing moderate to severe hemostasis; Angiotech Pharmaceuticals, Inc., intellectual property and know how related to the QuillTM Knotless Tissue-Closure Device; CorImmun GmbH, a developer of a phase II treatment for CHF; Calibra Medical, Inc., a developer of a unique, wearable three-day insulin patch for convenient and discreet mealtime dosing for people with diabetes who take multiple daily injections of insulin; Spectrum Vision LLC, a full service distributor of contact lenses serving Russia with facilities in the Ukraine and Kazakhstan; and marketing authorizations, trademarks, and patents extending ZYRTEC® related market rights in Australia and Canada.
	The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $15,785 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Of this amount, approximately $208 million has been identified as the value of IPR&D associated with the acquisitions of CorImmun GmbH and Synthes, Inc.
	The IPR&D related to the acquisition of Synthes, Inc. of $63 million is associated with orthopaedic devices, and the IPR&D associated with CorImmun of $145 million is related to a CHF treatment. These IPR&D values were calculated using the cash flow projections discounted for the risk inherent in such projects. Synthes, Inc. had a probability of success factor of 100%, discounted using a 14% rate. CorImmun had a probability of success factor of 38%, discounted using a 25% rate. During 2013, the Company recorded a charge of $0.2 billion for the impairment of the in-process research and development associated with CorImmun.
	During the fiscal second quarter of 2012, the Company completed the acquisition of Synthes, Inc., a global developer and manufacturer of orthopaedics devices, for a purchase price of $20.2 billion in cash and stock. The net acquisition cost of the transaction was $17.5 billion based on cash on hand at closing of $2.7 billion.
	Under the terms of the agreement, each share of Synthes, Inc. common stock was exchanged for CHF 55.65 in cash and 1.717 shares of Johnson & Johnson common stock, based on the calculated exchange ratio. The exchange ratio was calculated on June 12, 2012 and based on the relevant exchange rate and closing price of Johnson & Johnson common stock on that date, the total fair value of consideration transferred was $19.7 billion. When the acquisition was completed on June 14, 2012, based on the relevant exchange rate and closing price of Johnson & Johnson common stock on that date, the total fair value of the consideration transferred was $20.2 billion. Janssen Pharmaceutical, a company organized under the laws of Ireland and a wholly-owned subsidiary of Johnson & Johnson, used cash on hand to satisfy the cash portion of the merger consideration.
	The stock portion of the merger consideration consisted of shares of Johnson & Johnson common stock purchased by Janssen Pharmaceutical from two banks, pursuant to two accelerated share repurchase (ASR) agreements dated June 12, 2012. On June 13, 2012, Janssen Pharmaceutical purchased an aggregate of approximately 203.7 million shares of Johnson & Johnson common stock at an initial purchase price of $12.9 billion under the ASR agreements, with all of the shares delivered to Janssen Pharmaceutical on June 13, 2012.  During the fiscal third quarter of 2013, the Company settled the remaining liabilities under the ASR agreements for $2.9 billion in cash which was recorded as a reduction to equity.
	In addition, while the Company believes that the transactions under each ASR agreement and a series of related internal transactions were consummated in a tax efficient manner in accordance with applicable law, it is possible that the Internal Revenue Service could assert one or more contrary positions to challenge the transactions from a tax perspective. If challenged, an amount up to the total purchase price for the Synthes shares could be treated as subject to applicable U.S. tax at approximately the statutory rate to the Company, plus interest.
	The following table summarizes the consideration transferred to acquire Synthes, Inc. valued on the acquisition date of June 14, 2012:
	(Dollars in Millions)
	Cash (multiply 55.65CHF by shares of Synthes common stock outstanding by the exchange rate)(A)		$	6,902
	Common Stock (multiply 1.717 by shares of Synthes common stock outstanding by J&J stock price)(B)		$	13,335
	Total fair value of consideration transferred		$	20,237
	(A) Synthes common stock outstanding of 118.7 million shares as of the acquisition date and CHF/USD exchange rate of .95674
	(B) Johnson & Johnson closing stock price on the New York Stock Exchange as of acquisition date of $65.45 per share.
	The Company continues to execute the integration plans to combine businesses, sales organizations, systems and locations as a result of which the Company has and will continue to incur integration costs.
	The operating results of Synthes were reported in the Company's financial statements beginning on June 14, 2012. Total sales and net earnings for Synthes for the fiscal year ended December 30, 2012 were $2,159 million and $324 million, respectively.
	The following table provides pro forma results of operations for the fiscal year ended December 30, 2012, as if Synthes, Inc. had been acquired as of the beginning of the period presented. The pro forma results include the effect of divestitures and certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the integration of Synthes, Inc. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future.
		Unaudited Pro forma consolidated results
	(Dollars in Millions Except Per Share Amounts)	2012
	Net Sales	$	68,894
	Net Earnings attributable to Johnson & Johnson	$	11,564
	Diluted Net Earnings per share attributable to Johnson & Johnson	$	4.11
	The Company recorded acquisition related costs before tax of $754 million, $683 million and $1,028 million in 2014, 2013 and 2012, respectively, which were recorded in Other (income) expense and Cost of products sold.
	In connection with the Synthes acquisition, DePuy Orthopaedics, Inc. agreed to divest certain rights and assets related to its trauma business to Biomet, Inc. and completed the initial closing for this transaction in the fiscal second quarter of 2012, including those countries that represented the majority of sales. As of December 30, 2012, the transaction had closed worldwide.
	With the exception of the Synthes, Inc. acquisition, supplemental pro forma information for 2014, 2013 and 2012 in accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations, cash flows or financial position.
	During 2014, the Company divestitures included: The Ortho-Clinical Diagnostics business to The Carlyle Group; the K-Y® brand to Reckitt Benckiser Group PLC in the U.S. and certain other markets; and the BENECOL® brand to Raisio plc. In 2014, the gains on the divestitures of businesses were approximately $2.4 billion. The Company completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4.0 billion and the Company recorded a pre-tax net gain of approximately $1.9 billion. Ortho-Clinical Diagnostics' results are included in the Company's Medical Devices segment pre-tax profit. As of December 28, 2014, the assets classified as held for sale relating to the Ortho-Clinical Diagnostics companies in countries that have not completely closed due to local regulatory requirements were $41 million of inventory, classified as prepaid expenses and other on the Consolidated Balance Sheet and $117 million of property, plant and equipment, classified as other assets on the Consolidated Balance Sheet.
	During 2013, the Company divestitures included: women's sanitary protection products in the U.S., Canada and the Caribbean to Energizer Holdings, Inc.; Rolaids® to Chattem, Inc.; DORIBAX® rights to Shionogi; and the sale of certain consumer brands and certain pharmaceutical products. In 2013, the gains on the divestitures of businesses were $0.1 billion. During 2012, the Company divestitures included: BYSTOLIC® (nebivolol) IP rights to Forest Laboratories, Inc.; the trauma business of Depuy Orthopaedics, Inc. to Biomet, Inc.; the Therakos business to an affiliate of Gores Capital Partners III, L.P.; the sale of certain consumer brands; and the RhoGAM® business. In 2012, the gains on the divestitures of businesses were $0.9 billion.
	In January 2015, a definitive agreement was announced to divest the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution for approximately $1.05 billion. The transaction is expected to close in the fiscal second quarter of 2015, subject to customary closing conditions and completion of financing.

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 28, 2014
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	Legal Proceedings
	Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.
	The Company records accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of December 28, 2014, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to determine an estimate of the possible loss or range of loss beyond the amounts already accrued. These matters can be affected by various factors, including whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; or there are numerous parties involved. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions.
	In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution in any reporting period of one or more of these matters, either alone or in the aggregate, may have a material adverse effect on the Company's results of operations and cash flows for that period.
	PRODUCT LIABILITY
	Certain subsidiaries of Johnson & Johnson are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While these subsidiaries believe they have substantial defenses, it is not feasible to predict the ultimate outcome of litigation. The Company has established product liability accruals in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. In addition, product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.
	The most significant of these cases include the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, the PINNACLE® Acetabular Cup System, pelvic meshes and RISPERDAL®. As of December 28, 2014, in the U.S. there were approximately 11,200 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, 7,300 with respect to the PINNACLE® Acetabular Cup System, 36,600 with respect to pelvic meshes, and 1,200 with respect to RISPERDAL®.
	In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in Federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada and Australia. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR™ Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. This settlement covered approximately 8,000 patients. In February 2015, DePuy reached an additional agreement, subject to final documentation, which would effectively extend the existing settlement program to ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 1, 2015. This second agreement is estimated to cover approximately 1,400 additional patients. The estimated cost of these agreements is covered by existing accruals. This settlement program is expected to bring to a close significant ASR Hip litigation activity in the U.S. However, many lawsuits in the U.S. will remain, and the settlement program does not address litigation outside of the U.S. The Company continues to receive information with respect to potential costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the DePuy ASR™ Hip program and related product liability litigation. Updates to these accruals may be required in the future as additional information becomes available.
	Claims for personal injury have also been made against DePuy and Johnson & Johnson relating to DePuy's PINNACLE® Acetabular Cup System used in hip replacement surgery. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in Federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom. The Company has established an accrual to cover defense costs in connection with product liability litigation associated with DePuy's PINNACLE® Acetabular Cup System. Changes to this accrual may be required in the future as additional information becomes available.
	Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in Federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Southern District of West Virginia. In addition, class actions and individual personal injury cases or claims have been commenced in Australia, Belgium, Canada, England, Israel, Italy, the Netherlands, Scotland and Venezuela, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. The Company has established an accrual with respect to product liability litigation associated with Ethicon's pelvic mesh products. Changes to this accrual may be required in the future as additional information becomes available.
	Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL®, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established an accrual to cover defense costs in connection with product liability litigation associated with RISPERDAL®. Changes to this accrual may be required in the future as additional information becomes available.
	INTELLECTUAL PROPERTY
	Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products. Although these subsidiaries believe that they have substantial defenses to these challenges with respect to all material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could potentially adversely affect the ability of these subsidiaries to sell their products, or require the payment of past damages and future royalties. The most significant of these matters are described below.
	Medical Devices
	In January 2010, Tyco Healthcare Group, LP (Tyco) and U.S. Surgical Corporation (now Covidien plc) filed a lawsuit against Ethicon Endo-Surgery, Inc. (EES) in the United States District Court for the District of Connecticut alleging that EES's HARMONIC® shears infringed three Tyco patents. The case was tried in July 2012, and in March 2013, the Court ruled that some of EES's HARMONIC® shears infringed Tyco's patents and ordered EES to pay damages of approximately $176 million, but declined to order injunctive relief. EES appealed and in December 2014, the United States Court of Appeals for the Federal Circuit reversed the District Court's ruling and found all the asserted claims invalid. In January 2015, Tyco filed a motion for rehearing. In July 2014, Covidien filed another patent infringement lawsuit against EES in the United States District Court for the District of Connecticut seeking damages and a preliminary injunction, alleging that EES's newest version of its harmonic scalpels, the HARMONIC ACE®+ 7 Shears and the HARMONIC ACE®+ Shears, infringed the three Tyco patents asserted in the previous case. Covidien brought a motion for a preliminary injunction against the HARMONIC ACE®+ 7 Shears, and in October 2014, the District Court granted Covidien's motion for a preliminary injunction. EES appealed and the Court of Appeals for the Federal Circuit granted EES an interim stay of the injunction. The claims asserted by Covidien in this case are the same claims that were declared invalid in December 2014 by the Court of Appeals in the Tyco case discussed above.
	In November 2007, Roche Diagnostics Operations, Inc., et al. (Roche) filed a patent infringement lawsuit against LifeScan, Inc. (LifeScan) in the United States District Court for the District of Delaware, alleging LifeScan's OneTouch® Line of Blood Glucose Monitoring Systems infringe two patents related to the use of microelectrode sensors. Roche is seeking monetary damages and injunctive relief. In September 2009, LifeScan obtained a favorable ruling on claim construction that precluded a finding of infringement. The Court entered judgment against Roche in July 2010 and Roche appealed. The Court of Appeals reversed the District Court's ruling on claim construction and remanded the case to the District Court for new findings on the issue. In December 2014, the District Court ruled in LifeScan's favor and reinstated the original claim construction. In February 2015, Roche appealed the ruling.
	In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVC) in the United States District Court for the Eastern District of Texas alleging that JJVC's manufacture and sale of its ACUVUE®ADVANCE® and ACUVUE® OASYS® Hydrogel Contact Lenses infringe their U.S. Patent No. 5,712,327 (the Chang patent). Rembrandt is seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida. In May 2012, the jury returned a verdict holding that neither of the accused lenses infringes the '327 patent. Rembrandt appealed, and in August 2013, the United States Court of Appeals for the Federal Circuit affirmed the District Court's judgment. Rembrandt asked the District Court to grant it a new trial based on alleged new evidence, and in July 2014, the District Court denied Rembrandt’s motion. Rembrandt has appealed the District Court's denial of its motion for a new trial.
	In December 2009, the State of Israel filed a lawsuit in the District Court in Tel Aviv Jaffa against Omrix Biopharmaceuticals, Inc. and various affiliates (Omrix). In the lawsuit, the State claims that an employee of a government-owned hospital was the inventor on several patents related to fibrin glue technology that the employee developed while he was a government employee. The State claims that he had no right to transfer any intellectual property to Omrix because it belongs to the State. The State is seeking damages plus royalties on QUIXIL™ and EVICEL® products, or alternatively, transfer of the patents to the State. The case remains active, but no trial date has been set.
	In September 2011, LifeScan, Inc. (LifeScan) filed a lawsuit against Shasta Technologies, Instacare Corp and Conductive Technologies (collectively, Shasta) in the United States District Court for the Northern District of California for patent infringement for the making and marketing of a strip for use in LifeScan's OneTouch® Blood Glucose Meters. Shasta has alleged that the three LifeScan patents-in-suit are invalid. Shasta also challenged the validity of the asserted patents in the United States Patent and Trademark Office (USPTO) and the patent infringement case has been stayed pending the outcome of the USPTO proceedings. The validity of two of the patents was confirmed by the USPTO and in August 2014, the USPTO determined that the third patent, U.S. Patent No. 7,250,105 (the '105 patent), is invalid. LifeScan is appealing that decision. The patent case has resumed on the two other patents. In April 2013, Shasta brought counterclaims for alleged antitrust violations and false advertising and those claims have been stayed pending resolution of the patent infringement case. In May 2014, LifeScan filed a patent infringement lawsuit against UniStrip Technologies, LLC (UniStrip) in the United States District Court for the District of North Carolina alleging that the making and marketing of Unistrip’s strips infringe the same patents asserted against Shasta above. That case has been stayed pending the outcome of the appeal of the USPTO's decision on the validity of the '105 patent. In July 2014, UniStrip brought a lawsuit against LifeScan in the United States District Court for the Eastern District of Pennsylvania, alleging antitrust violations relating to marketing practices for LifeScan's strips.
	In November 2011, Howmedica Osteonics Corp. (Howmedica) and Stryker Ireland Ltd. (Stryker) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. (DePuy) in the United States District Court for the District of New Jersey alleging infringement by DePuy's PINNACLE® Acetabular Cup System and DURALOC® Acetabular Cup System of a patent relating to a dual-locking mechanism feature in an acetabular cup system. Howmedica and Stryker sought monetary damages and injunctive relief. DePuy filed a counterclaim in February 2012 asserting that Stryker's Trident Acetabular Hip System infringes DePuy's U.S. Patent No. 6,610,097. DePuy sought damages and injunctive relief. In June 2014, the case was settled and dismissed.
	In May 2012, Medtronic MiniMed, Inc., Medtronic Puerto Rico Operations Co. and MiniMed Distribution Corp. (collectively, Medtronic MiniMed) filed a patent infringement lawsuit against Animas Corporation (Animas) in the United States District Court for the Central District of California alleging that Animas's OneTouch® Ping® Glucose Management System and the IR 1250, IR 2020 and IR 2000 insulin pumps infringe nine of their patents. Medtronic MiniMed since withdrew two of the patents from the lawsuit and is seeking monetary damages and injunctive relief with respect to the remaining patents. In July 2014, Animas entered into a settlement of this lawsuit.
	In September 2012, Bonutti Skeletal Innovations LLC (Bonutti), a non-practicing entity, filed a patent infringement lawsuit against DePuy Mitek, LLC, The DePuy Institute, LLC (now DePuy Synthes Institute, LLC), DePuy, Inc. (now DePuy Synthes, Inc.) and DePuy Orthopaedics, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts, alleging that DePuy’s manufacture, sale and/or method of using the SIGMA® Family of Partial and Total Knee Systems and the LCS® COMPLETE™ Knee System willfully infringe three of Bonutti’s patents. Bonutti also alleges that the method of using certain of DePuy’s suture anchors willfully infringe four of Bonutti’s other patents. In August 2014, the parties entered into a settlement of the portion of the lawsuit relating to suture anchors.
	In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that all of Cordis's sales of the CYPHER® and CYPHER SELECT™ Stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents.  Medinol is seeking damages and attorney's fees. After trial in January 2014, the District Court dismissed the case, finding Medinol unreasonably delayed bringing its claims, and Medinol did not appeal the decision. In September 2014, the District Court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol is appealing this decision.
	In January 2014, Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare S.A. (collectively, Baxter) filed a lawsuit against Johnson & Johnson, Ethicon, Inc. (Ethicon), Ferrosan Medical Devices A/S and Packaging Coordinators Inc. in the United States District Court for the Northern District of Illinois, alleging that the manufacture, importation, sale and/or use of Ethicon’s SURGIFLO® Hemostatic Matrix family of products infringes six of Baxter’s patents. Baxter is seeking monetary damages and injunctive relief. In February 2014, Baxter also filed a complaint before the United States International Trade Commission (ITC) against the same defendants alleging that the importation into the United States of Ethicon’s SURGIFLO® Hemostatic Matrix Family of Products violates Section 337 of the Tariff Act of 1930 due to the alleged infringement of four of its products, and is seeking an exclusion order to enjoin the importation into the United States of such products. The District Court case has been stayed pending the outcome of the ITC case. All the patents expire in August 2016. The ITC case was tried in January 2015 and the parties are awaiting a decision.
	In June 2014, My Health, Inc. (My Health) filed a patent infringement lawsuit against LifeScan, Inc. (LifeScan) in the United States District Court for the Eastern District of Texas, alleging LifeScan's OneTouch® Verio®IQ Blood Glucose Monitoring System infringes My Health's patent related to a method for monitoring and treating patients. My Health is seeking monetary damages and injunctive relief. In August 2014, LifeScan filed a motion to dismiss the lawsuit. In October 2014, Lifescan filed an Inter Partes review proceeding in the United States Patent and Trademark Office seeking to invalidate My Health’s patent. In December 2014, LifeScan moved to stay the lawsuit pending a decision in the Inter Partes review proceeding.
	In December 2014, Bonutti Skeletal Innovations LLC (Bonutti) sued DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. in the United States District Court for the District of Massachusetts, alleging that DePuy Synthes's product line of spine implants infringes six patents owned by Bonutti, generally covering wedge implants and their methods of implantation.
	Pharmaceutical
	In May 2009, Abbott Biotechnology Ltd. (Abbott) filed a patent infringement lawsuit against Centocor, Inc. (Centocor) (now Janssen Biotech, Inc. (JBI)) in the United States District Court for the District of Massachusetts alleging that SIMPONI® infringes Abbott's U.S. Patent Nos. 7,223,394 and 7,541,031 (the Salfeld patents). Abbott was seeking monetary damages and injunctive relief. The parties have settled the case.
	In August 2009, Abbott GmbH & Co. (Abbott GmbH) and Abbott Bioresearch Center (collectively now referred to as, AbbVie) filed a patent infringement lawsuit against Centocor (now JBI) in the United States District Court for the District of Massachusetts alleging that STELARA® infringes two United States patents assigned to Abbott GmbH. Trial was held in September 2012 and a jury returned a verdict in favor of JBI, invalidating AbbVie's patent claims. AbbVie appealed, and in July 2014, the Court of Appeals for the Federal Circuit affirmed the lower court's ruling. Also in August 2009, Abbott GmbH and Abbott Laboratories Limited (collectively now referred to as, AbbVie) brought a patent infringement lawsuit in The Federal Court of Canada alleging that STELARA® infringes Abbott GmbH's Canadian patent. A trial was held in December 2013 in the Canadian case and the Court ruled in favor of AbbVie, finding that the asserted claims were valid and infringed by STELARA®. JBI appealed that decision. In May 2014, AbbVie's motion for an injunction was granted in part, and JBI also appealed that decision. In October 2014, the appellate court overturned the finding of liability, remanded the case to the trial court for re-trial, and lifted the injunction. In addition to the U.S. and Canadian litigations, in August 2012, AbbVie filed patent infringement lawsuits related to STELARA® in the Netherlands, Switzerland and Germany. The parties have settled all of the cases discussed above related to STELARA®.
	In 2012 and 2013, Noramco, Inc. (Noramco), a subsidiary of Johnson & Johnson, moved to intervene in several patent infringement lawsuits filed in the United States District Court for the Southern District of New York by Purdue Pharma L.P. and others (Purdue) against Noramco oxycodone customers, Impax Laboratories, Inc. (Impax), Teva Pharmaceuticals USA, Inc. (Teva) and Amneal Pharmaceuticals, LLC (Amneal), Watson Laboratories, Inc.- Florida (Watson) and Andrx Labs, LLC (Andrx). The lawsuits are in response to the defendants' respective Abbreviated New Drug Applications seeking approval to market generic extended release oxycodone products before the expiration of certain Purdue patents. Three of the asserted patents relate to oxycodone and processes for making oxycodone, and Noramco has agreed to defend the lawsuits on behalf of Impax, Teva, Amneal, Watson, and Andrx. In April 2013, Watson and Andrx entered into a settlement with Purdue. The trial against Impax and Teva (as well as two parties not defended by Noramco) took place in September 2013, and Noramco defended Teva and Impax. In November 2013, Impax entered into a settlement with Purdue. In January 2014, the Court issued a decision invalidating the relevant Purdue patents and subsequently dismissed the lawsuit against Amneal (and other parties not defended by Noramco). Purdue has appealed the Court's decision. In December 2014, Teva entered into a confidential settlement with Purdue, and Teva subsequently moved to have the appeal dismissed as moot in view of the settlement. Purdue has opposed Teva's motion.
	In August 2012, Dr. James M. Swanson filed a lawsuit against ALZA Corporation (ALZA) in the Northern District of California seeking to be added as an inventor on three ALZA-owned patents relating to CONCERTA®. Alternatively, Dr. Swanson has alleged that the patents-in-suit are invalid as a result of ALZA's alleged omission of Dr. Swanson as a named inventor. The lawsuit also includes claims of fraud, breach of fiduciary duty and unfair competition. Dr. Swanson is seeking damages and an award of unjust enrichment. ALZA filed a motion to dismiss Dr. Swanson's claims, as well as counterclaims for breach of contract and negligent misrepresentation. The Court granted the motion in part, and denied it in part. ALZA filed a motion for summary judgment on the issue of inventorship and a hearing was held in February 2015. The parties are awaiting a decision.
	Johnson & Johnson acquired the prostate cancer business of Aragon Pharmaceuticals, Inc. (Aragon), including ARN-509, a compound being tested for treatment of prostate cancer, in September 2013. Prior to the acquisition, in May 2011, Medivation, Inc. (Medivation) had sued Aragon and the University of California seeking rights to ARN-509. In December 2012, the State Court granted summary judgment to Aragon on Medivation's claims, awarding the rights of the ARN-509 compound to Aragon, and in January 2013, the Court dismissed the case against Aragon. Medivation has appealed.
	REMICADE® Related Cases
	In March 2013, Hospira Healthcare Corporation (Hospira) filed an impeachment proceeding against The Kennedy Institute of Rheumatology (Kennedy) challenging the validity of a Canadian patent related to REMICADE® (a Feldman patent), which is exclusively licensed to Janssen Biotech, Inc. (JBI). In October 2013, Kennedy, along with JBI, Janssen Inc. and Cilag GmbH International (both affiliates of JBI), filed a counterclaim for infringement against Celltrion Healthcare Co., Ltd., Celltrion Inc. (together, Celltrion) and Hospira. The counterclaim alleges that the products described in Celltrion’s and Hospira’s marketing applications to Health Canada for their subsequent entry biologics (SEB) to REMICADE® would infringe the Feldman patents owned by Kennedy. Discovery in the patent action is ongoing. Trial has been scheduled for September 2016.
	In January 2014, Health Canada approved Celltrion’s SEB to REMICADE®, allowing Celltrion to market its biosimilar version of REMICADE® in Canada, regardless of the pending patent action. In June 2014, Hospira received approval for its SEB to REMICADE®. In July 2014, Janssen Inc. (Janssen) filed a lawsuit to compel the Canadian Minister of Health to withdraw the Notice of Compliance for Hospira’s SEB because Hospira did not serve a Notice of Allegation on Janssen to address the patent listed by Janssen on the Patent Register. If the Notice of Compliance is withdrawn, Hospira would have to serve a Notice of Allegation and Janssen could commence an application to prohibit issuance of the Notice of Compliance until expiry of the relevant patent. A hearing has been scheduled for March 2015.
	In September 2013, JBI and NYU Langone Medical Center (NYU Medical Center) received an Office Action from the United States Patent and Trademark Office (USPTO) rejecting the claims in U.S. Patent No. 6,284,471 relating to REMICADE® (the '471 patent) in a reexamination proceeding instituted by a third party.  The '471 patent is co-owned by JBI and NYU Medical Center, and NYU Medical Center granted JBI an exclusive license to NYU Medical Center's rights under the patent. Currently, the '471 patent in the United States expires in September 2018. JBI responded to that rejection in December 2013 and in August 2014, JBI and NYU Medical Center received a further rejection. JBI responded to the rejection by filing a further amendment and in November 2014, JBI's petition to enter the amendment was granted. The application was returned to the examiner for issuance of a new Office Action, which occurred in February 2015 further rejecting the patent. JBI has sixty days to respond to the rejection. JBI believes the '471 patent is valid, will respond to the latest Office Action to defend the patent and, if necessary, JBI will pursue all available appeals.
	In March 2014, Celltrion filed a declaratory judgment lawsuit against JBI in the United States District Court for the District of Massachusetts seeking to invalidate the '471 patent and two other U.S. patents that relate to REMICADE® and are co-owned by JBI and NYU Medical Center, and exclusively licensed to JBI (collectively, the Le patents). JBI moved to dismiss the case for lack of jurisdiction and Celltrion voluntarily dismissed its lawsuit. Also in March 2014, Celltrion filed a lawsuit in the United States District Court for the Southern District of New York against Kennedy seeking to invalidate three patents owned by Kennedy (the Feldman patents). The Feldman patents are licensed to JBI and also relate to REMICADE®. Kennedy moved to dismiss the case for lack of jurisdiction, including failure to comply with the procedural requirements of the Biologics Price Competition and Innovation Act (the BPCIA). In December 2014, the Court granted the motion.
	In August 2014, Hospira, Inc. (Hospira) filed a lawsuit in the United States District Court for the Southern District of New York against JBI, New York University (NYU), NYU Medical Center and Kennedy seeking to invalidate the Feldman patents. Hospira alleges that it has exclusive rights to market Celltrion's biosimilar version of REMICADE® in the United States if it is approved by the FDA. In October 2014, JBI, NYU and NYU Medical Center moved to dismiss this case for lack of jurisdiction, including failure to comply with the procedural requirements of the BPCIA. In December 2014, the Court granted the motion.
	In August 2014, Celltrion filed for FDA approval to make and sell its own biosimilar version of REMICADE®. In February 2015, JBI received a Notice of Commercial Marketing from Celltrion in accordance with the BPCIA notifying JBI that Celltrion and/or Hospira intend to begin commercial marketing of a biosimilar product as early as 180 days from the date of the notice. The parties are proceeding with the patent resolution procedures set forth in the BPCIA. JBI believes the patents are valid and will enforce the relevant patents.
	If any of the Le or Feldman patents is found to be invalid, any such patent could not be relied upon to prevent the introduction of biosimilar versions of REMICADE®. The timing of the possible introduction of a biosimilar version of REMICADE® in the United States would be subject to approval by the FDA. Loss of exclusivity will likely result in a reduction in sales as biosimilar versions of REMICADE® are introduced to the market.
	Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)
	The following summarizes lawsuits pending against generic companies that have filed Abbreviated New Drug Applications (ANDAs) with the FDA, or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson & Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of the applicable patents. In the event the subsidiaries are not successful in these actions, or the statutory 30-month stays of the ANDAs expire before the United States District Court rulings are obtained, the third-party companies involved will have the ability, upon approval of the FDA, to introduce generic versions of the products at issue to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset.
	PREZISTA®
	A number of generic companies have filed ANDAs seeking approval to market generic versions of PREZISTA®. In November 2010, Tibotec, Inc. (now Tibotec, LLC) and Tibotec Pharmaceuticals (now Janssen R&D Ireland) (collectively, Tibotec) filed a patent infringement lawsuit against Lupin, Ltd., Lupin Pharmaceuticals, Inc. (collectively, Lupin), Mylan, Inc. and Mylan Pharmaceuticals, Inc. (collectively, Mylan) in the United States District Court for the District of New Jersey in response to Lupin's and Mylan's respective ANDAs seeking approval to market generic versions of Tibotec's PREZISTA® product before the expiration of Tibotec's patent relating to PREZISTA®. Lupin and Mylan each filed counterclaims alleging non-infringement and invalidity. In July 2011, Tibotec filed another patent infringement lawsuit against Lupin in the United States District Court for the District of New Jersey in response to Lupin's supplement to its ANDA to add new dosage strengths for its proposed product. In August 2011, Tibotec and G.D. Searle & Company (G.D. Searle) filed a patent infringement lawsuit against Lupin and Mylan in response to their notice letters advising that their ANDAs are seeking approval to market generic versions of Tibotec's PREZISTA® product before the expiration of two additional patents relating to PREZISTA® that Tibotec exclusively licenses from G.D. Searle. In September 2011, the Court consolidated the above lawsuits (referred to here as the First Consolidated Action).
	The approved New Drug Application for PREZISTA® was transferred from Tibotec, Inc. to Janssen Products, LP in December 2011. In 2012 and 2013, Janssen Products, LP and Janssen R&D Ireland (collectively, Janssen) added several patents that they own or exclusively license from G.D. Searle to the First Consolidated Action against Mylan and Lupin. In June 2013, Janssen and G.D. Searle dismissed their claims relating to the patents owned by G.D. Searle against Lupin and Mylan, based on those parties’ agreement not to seek FDA approval of their respective ANDAs until the November 2017 expiration of the G.D. Searle patents. After a trial regarding the remaining patents in the First Consolidated Action, the Court issued a decision in August 2014 in favor of Janssen, holding that the asserted patents are valid and would be infringed by Lupin's and Mylan's marketing of their proposed products. Lupin filed an appeal.
	In May 2013, Lupin notified Janssen that it filed an ANDA seeking approval to market a new dosage strength of its generic version of PREZISTA®.  In response, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey, alleging that Lupin's new dosage strength would infringe the same patents that Janssen is asserting against Lupin in the original action. In March 2014, Janssen filed a patent infringement lawsuit against Lupin in the United States District Court for the District of New Jersey, alleging infringement of United States Patent No 8,518,987. In January 2015, the Court consolidated these lawsuits (referred to here as the Second Consolidated Action), and stayed them pending Lupin's appeal of the Court's decision in the First Consolidated Action.
	Janssen filed a patent infringement lawsuit against Hetero Drugs, Ltd. Unit III and Hetero USA Inc. in March 2013 in the United States District Court for the District of New Jersey, alleging infringement of United States Patent Nos. 7,126,015 and 7,595,408. Discovery in this case is ongoing and a trial date is set for October 2015.
	Janssen and G.D. Searle also filed patent infringement lawsuits against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Ltd. (collectively, Teva) in the United States District Court for the District of New Jersey in response to Teva's ANDA seeking approval to market a generic version of PREZISTA® before the expiration of certain patents relating to PREZISTA® that Janssen either owns or exclusively licenses from G.D. Searle. In March 2014, the parties entered into a settlement agreement and the lawsuits against Teva were dismissed.
	In July 2014, Janssen filed a patent infringement lawsuit against Mylan in the United States District Court for the District of New Jersey, alleging infringement of United States Patent No. 8,153,829. Discovery in the case in ongoing.
	In August 2014, Janssen filed patent infringement lawsuits against Cipla Ltd. and Cipla USA, Inc. (collectively, Cipla) in the United States District Courts for the Districts of New Jersey and Delaware in response to Cipla’s ANDA seeking approval to market a generic version of Janssen’s PREZISTA® product before the expiration of certain of Janssen’s patents relating to PREZISTA®. Cipla filed counterclaims seeking declarations of noninfringement and invalidity of the patents-in-suit. Discovery is ongoing.
	In response to its Notice of Allegation seeking approval to market a generic version of PREZISTA® in Canada before the expiration of Canadian Patent No. 2,485,834, Janssen Inc. and Janssen R&D Ireland filed a Notice of Application against Mylan Pharmaceuticals ULC in July 2014. In December 2014, Janssen R&D Ireland transferred its PREZISTA® patents to Janssen Sciences Ireland UC, and Janssen Sciences Ireland UC was substituted for Janssen R&D Ireland as plaintiff in the above-referenced actions. In January 2015, Janssen Inc. and Janssen Sciences Ireland UC filed a Notice of Application against Teva Canada Limited in response to its Notice of Allegation seeking approval to market a generic version of PREZISTA® before the expiration of Canadian Patent No. 2,485,834.
	In each of the above lawsuits, Janssen sought or is seeking an Order enjoining the defendants from marketing their generic versions of PREZISTA® before the expiration of the relevant patents.
	CONCERTA®
	In June 2013, ALZA Corporation (ALZA) and Janssen Pharmaceuticals, Inc. (JPI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against Par Pharmaceuticals, Inc. (Par), Osmotica Kereskedelmies Szolgaltato Kft (Osmotica), and Norwich Pharmaceuticals, Inc. (Norwich) in response to those parties' ANDAs seeking approval to market a generic version of CONCERTA® before the expiration of United States Patent No. 8,163,798 (the '798 patent). In addition, in September 2013, Par and Osmotica filed counterclaims against ALZA and JPI seeking declarations of invalidity and noninfringement of the patent-in-suit, and Norwich filed a motion to dismiss. Norwich was dismissed from the case in October 2013 based on its agreement to be bound by the outcome of the case with Osmotica. In March 2014, ALZA and JPI amended its complaint against Par and Osmotica to assert infringement of newly issued United States Patent No. 8,629,179 (the ‘179 patent). In June 2014, ALZA, JPI and Osmotica entered into a settlement of the action, and in September 2014, ALZA, JPI and Par entered into a settlement.
	In May 2014, ALZA and JPI filed a patent infringement lawsuit in the United States District Court for the District of West Virginia against Mylan, Inc. and Mylan Pharmaceuticals, Inc. (Mylan) in response to its ANDA seeking approval to market a generic version of CONCERTA® before the expiration of the ‘798 patent. Mylan filed counterclaims seeking declarations of invalidity and noninfringement of the patents-in-suit.
	In June 2014, ALZA and JPI filed a patent infringement lawsuit in the District of Delaware against Sandoz, Inc. in response to its ANDA seeking approval to market a generic version of CONCERTA® before the expiration of the ‘798 and ‘179 patents. Sandoz filed counterclaims seeking declarations of invalidity, unenforceability, and noninfringement of the patents-in-suit. In December 2014, the parties entered into a settlement agreement and the lawsuit was dismissed.
	In December 2014, Janssen Inc. and ALZA filed a Notice of Application against Actavis Pharma Company (Actavis) in response to its Notice of Allegation seeking approval to market a generic version of CONCERTA® before the expiration of Canadian Patent No. 2,264,852.
	In each of the above lawsuits, ALZA and/or JPI are seeking an Order enjoining the defendants from marketing their generic versions of CONCERTA® before the expiration of the ‘798 and/or ‘179 patents.
	NUCYNTA® AND NUCYNTA® ER
	In July 2013, Janssen Pharmaceuticals, Inc. (JPI) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against Actavis Elizabeth LLC, Actavis Inc. and Actavis LLC (collectively, Actavis), as well as Alkem Laboratories Limited and Ascend Laboratories, LLC (collectively, Alkem).  The patent infringement claims against Actavis and Alkem relate to their respective ANDAs seeking approval to market a generic version of NUCYNTA® ER before the expiration of United States Reissue Patent No. 39,593 (the ‘593 patent), United States Patent No. 7,994,364 (the ‘364 patent) and, as to Actavis only, United States Patent No. 8,309,060 (the ‘060 patent).  The lawsuit also includes a patent infringement claim against Alkem in response to its ANDA seeking approval to market a generic version of NUCYNTA® before the expiration of the ‘593 and ‘364 patents. In December 2013, JPI filed an additional complaint in the District Court of New Jersey against Alkem asserting United States Patent No. 8,536,130 related to its ANDA seeking approval to market a generic version of NUCYNTA® ER. In August 2014, JPI amended the complaint against Alkem to add additional dosage strengths.
	In October 2013, JPI received a Paragraph IV Notice from Sandoz, Inc. (Sandoz) with respect to NUCYNTA® related to the ‘364 patent, and a Paragraph IV Notice from Roxane Laboratories, Inc. (Roxane) with respect to NUCYNTA® related to the ‘364 and ‘593 patents.  In response to those notices, JPI filed an additional complaint in the United States District Court for the District of New Jersey against Roxane and Sandoz asserting the '364 patent against Sandoz and the ‘364 and ‘593 patents against Roxane. In April 2014, JPI and Sandoz entered into a joint stipulation of dismissal of the case against Sandoz, based on Sandoz’s agreement not to enter the market prior to the expiration of the asserted patents. In June 2014, in response to a Paragraph IV Notice from Roxane with respect to NUCYNTA® ER, JPI filed a complaint asserting the ‘364 and ‘593 patents against Roxane.
	In July 2014, in response to a Paragraph IV Notice from Watson Laboratories, Inc. (Watson) with respect to the NUCYNTA® oral solution product and the '364 and '593 patents, JPI filed a lawsuit in the United States District Court for the District of New Jersey asserting the '364 and '593 patents against Watson.
	In each of the above lawsuits, JPI is seeking an Order enjoining the defendants from marketing their generic versions of NUCYNTA® ER and NUCYNTA® before the expiration of the asserted patents.
	GOVERNMENT PROCEEDINGS
Like other companies in the pharmaceutical and medical devices industries, Johnson & Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. As a result, interaction with government agencies is ongoing. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.
Average Wholesale Price (AWP) Litigation
Johnson & Johnson and several of its pharmaceutical subsidiaries (the J&J AWP Defendants), along with numerous other pharmaceutical companies, are defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a Multi-District Litigation (MDL) in the United States District Court for the District of Massachusetts.
The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. In June 2007, after a trial on the merits, the MDL Court dismissed the claims of two of the plaintiff classes against the J&J AWP Defendants. In March 2011, the Court dismissed the claims of the third class against the J&J AWP Defendants without prejudice.
AWP cases brought by various Attorneys General have proceeded to trial against other manufacturers. Several state cases against certain subsidiaries of Johnson & Johnson have been settled, including the case in Alaska, which settled in April 2014, and cases are still pending in Illinois, New Jersey, Wisconsin, Utah and Pennsylvania. The cases in Illinois, New Jersey and Wisconsin have not yet proceeded to trial. In Utah, the claims brought by the Attorney General were dismissed by the Court in 2013, but the State may appeal the dismissal after the conclusion of similar pending matters against other defendants. The AWP case against the J&J AWP Defendants brought by the Attorney General of the Commonwealth of Pennsylvania was tried in Commonwealth Court in 2010. The Court found in the Commonwealth's favor with regard to certain of its claims under the Pennsylvania Unfair Trade Practices and Consumer Protection Law (“UTPL”), entered an injunction, and awarded $45 million in restitution and $6.5 million in civil penalties. The Court found in the J&J AWP Defendants' favor on the Commonwealth's claims of unjust enrichment, misrepresentation/fraud, civil conspiracy, and on certain of the Commonwealth's claims under the UTPL. The J&J AWP Defendants appealed the Commonwealth Court's UTPL ruling, and in June 2014, the Pennsylvania Supreme Court vacated the judgment entered by the Commonwealth Court and remanded the case for further proceedings. On remand, in January 2015, the Commonwealth Court dismissed the monetary awards against the J&J AWP Defendants, which may be appealed.
RISPERDAL®
In November 2013, Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc. (JPI), finalized previously disclosed settlement agreements with the United States Department of Justice and forty-five states resolving federal investigations and state Medicaid claims related to past promotional practices of RISPERDAL® from 1999 through 2005, and other matters. JPI had also settled alleged consumer fraud claims in connection with the sale and marketing of RISPERDAL® with thirty-six states and the District of Columbia in September 2012. In addition to these actions, the Attorneys General of several states brought actions against JPI, related to the sale and marketing of RISPERDAL®, seeking one or more of the following remedies: reimbursement of Medicaid or other public funds for RISPERDAL® prescriptions written for off-label use, compensation for treating their citizens for alleged adverse reactions to RISPERDAL®, civil fines or penalties for violations of state false claims acts or consumer fraud statutes, punitive damages, or other relief relating to alleged unfair business practices. Certain of these actions also sought injunctive relief relating to the promotion of RISPERDAL®. Many of the actions and claims brought by the state Attorneys General have been settled, either individually or as part of the settlements described above.
Four states have remaining claims in litigation related to RISPERDAL®: one claim is on remand in Arkansas; the case in South Carolina is on appeal; in Kentucky, a trial has been set for April 2016; and in Mississippi, the case has not progressed to trial. The Company has not accrued an amount equal to the judgment obtained in South Carolina. To the extent any state has an outstanding Medicaid-related claim not resolved by the settlements referenced above, the Company has accrued an amount approximately equal to what that state would have received if it had participated in the relevant federal settlement. State cases that went to judgment after trial are discussed below.
In 2004, the Attorney General of West Virginia commenced a lawsuit against Janssen Pharmaceutica, Inc. (now JPI) based on claims of alleged consumer fraud as to DURAGESIC®, as well as RISPERDAL®. JPI was found liable and damages were assessed at $4.5 million. JPI filed an appeal, and in November 2010, the West Virginia Supreme Court of Appeals reversed the trial court's decision. In December 2010, the Attorney General of West Virginia dismissed the case as it related to RISPERDAL® without any payment. Thereafter, JPI settled the case insofar as it related to DURAGESIC®.
In 2004, the Attorney General of Louisiana filed a multi-count Complaint against Janssen Pharmaceutica, Inc. (now JPI). Johnson & Johnson was later added as a defendant. The case was tried in October 2010. The issue tried to the jury was whether Johnson & Johnson or JPI had violated the State's Medical Assistance Program Integrity Law (the Act) through misrepresentations allegedly made in the mailing of a November 2003 Dear Health Care Professional letter regarding RISPERDAL®. The jury returned a verdict that JPI and Johnson & Johnson had violated the Act and awarded $257.7 million in damages. The trial judge subsequently awarded the Attorney General counsel fees and expenses in the amount of $73 million. In January 2014, the Louisiana Supreme Court reversed the District Court’s judgment in favor of the Attorney General, and rendered judgment in favor of Johnson & Johnson and JPI. In April 2014, the Louisiana Supreme Court denied the Attorney General's petition seeking a rehearing of the appellate arguments, resulting in final dismissal of the case.
In 2007, the Office of General Counsel of the Commonwealth of Pennsylvania filed a lawsuit against Janssen Pharmaceutica, Inc. (now JPI) on a multi-Count Complaint related to Janssen Pharmaceutica's sale of RISPERDAL® to the Commonwealth's Medicaid program. The trial occurred in June 2010. The trial judge dismissed the case after the close of the plaintiff's evidence. The Commonwealth filed an appeal and in July 2012, the Pennsylvania Appeals Court upheld the dismissal of the Commonwealth's case.
In 2007, the Attorney General of South Carolina filed a lawsuit against Johnson & Johnson and Janssen Pharmaceutica, Inc. (now JPI) on several counts. In March 2011, the matter was tried to a jury on liability only, at which time the lawsuit was limited to claims of violation of the South Carolina Unfair Trade Practices Act, including, among others, questions of whether Johnson & Johnson or JPI engaged in unfair or deceptive acts or practices in the conduct of any trade or commerce by distributing the November 2003 Dear Health Care Professional letter regarding RISPERDAL® or in their use of the product's FDA-approved label. The jury found in favor of Johnson & Johnson and against JPI. In June 2011, the Court awarded civil penalties of approximately $327.1 million against JPI. JPI has appealed this judgment and the Company believes it has strong arguments supporting the appeal. Oral argument on the appeal took place before the South Carolina Supreme Court in March 2013, and the parties are awaiting a decision.
In April 2012, in the lawsuit brought by the Attorney General of Arkansas, the jury found against both JPI and Johnson & Johnson, and the Court imposed penalties in the amount of approximately $1.2 billion. In January 2013, the trial court awarded attorney fees of approximately $181 million. JPI and Johnson & Johnson appealed both awards to the Arkansas Supreme Court, and in March 2014, the Arkansas Supreme Court dismissed the State’s claim under the Arkansas Medicaid Fraud False Claims Act, as well as the approximately $1.2 billion in penalties, and reversed and remanded a claim under the Arkansas Deceptive Trade Practices Act. In April 2014, the Arkansas Supreme Court rejected a petition by the State for rehearing on the case. Trial on the remand of the case is scheduled for June 2015.
McNeil Consumer Healthcare
Starting in June 2010, McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. (McNeil Consumer Healthcare) and certain affiliates, including Johnson & Johnson (the Companies), received grand jury subpoenas from the United States Attorney's Office for the Eastern District of Pennsylvania requesting documents broadly relating to recalls of various products of McNeil Consumer Healthcare, and the FDA inspections of the Fort Washington, Pennsylvania and Lancaster, Pennsylvania manufacturing facilities, as well as certain documents relating to recalls of a small number of products of other subsidiaries. In addition, in February 2011, the government served McNEIL-PPC, Inc. (McNEIL-PPC) with a Civil Investigative Demand seeking records relevant to its investigation to determine if there was a violation of the Federal False Claims Act. The grand jury and False Claims investigations are continuing. The Companies are cooperating with the United States Attorney's Office in responding to these investigations.
The Companies have also received Civil Investigative Demands from multiple State Attorneys General Offices broadly relating to the McNeil recall issues. The Companies continue to cooperate with these inquiries, which are being coordinated through a multi-state coalition. If a resolution cannot be reached with this multi-state coalition, it is possible that individual State Attorneys General Offices may file civil monetary claims against the Companies. In January 2011, the Oregon Attorney General filed a civil complaint against Johnson & Johnson, McNEIL-PPC and McNeil Healthcare LLC in state court alleging civil violations of the Oregon Unlawful Trade Practices Act relating to an earlier recall of a McNeil OTC product. In November 2012, the state court granted a motion by the Companies to dismiss Oregon's complaint in its entirety, with prejudice.  In December 2012, Oregon filed a Notice of Appeal in the Court of Appeals of the State of Oregon. Oral argument took place in July 2014 and the parties are awaiting a decision.
Opioids Litigation
Along with other pharmaceutical companies, Janssen Pharmaceuticals, Inc. (JPI) has been named in a number of lawsuits alleging claims related to opioid marketing practices.  In May 2014, Santa Clara and Orange Counties in California (the Counties) filed a complaint in state court in Orange County, California against numerous pharmaceutical manufacturers, including JPI, alleging claims related to opioid marketing practices, including false advertising, unfair competition, and public nuisance. In June 2014, the City of Chicago filed a complaint in Cook County Circuit Court against several pharmaceutical manufacturers, including JPI, alleging a number of claims related to opioid marketing practices, including consumer fraud violations and false claims. The case was later removed to the United States District Court for the Northern District of Illinois, and in December 2014, defendants filed a motion to dismiss the City of Chicago's First Amended Complaint for failure to state a claim. In September 2014, the Tennessee Attorney General Division of Consumer Affairs issued a Request for Information to JPI related to opioids marketing practices.
Other
In September 2011, Synthes, Inc. (Synthes) received a Civil Investigative Demand issued pursuant to the False Claims Act from the United States Attorney's Office for the Eastern District of Pennsylvania. The Demand sought information regarding allegations that fellowships had been offered to hospitals in exchange for agreements to purchase products. Synthes has produced documents and information in response to the Demand and is cooperating with the inquiry.
In May 2012, Acclarent, Inc. (Acclarent) received a subpoena from the United States Attorney's Office for the District of Massachusetts requesting documents broadly relating to the sales, marketing and alleged off-label promotion by Acclarent of RELIEVA STRATUS® MicroFlow Spacer products. The investigation is continuing and Acclarent is cooperating with the United States Attorney's Office in responding to the subpoena.
In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now DePuy Synthes, Inc.), and Johnson & Johnson Services, Inc. (the Companies) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the ASR™ XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a qui tam case filed pursuant to the False Claims Act against the Companies. The District Court issued an order in August 2014 that publicly unsealed the United States' declination notice; however, the complaint in the matter remains under seal. In addition, in October 2013, a group of state Attorneys General issued Civil Investigative Demands relating to the development, sales and marketing of several of DePuy Orthopaedics, Inc.’s hip products. In July 2014, the Oregon Department of Justice, which was investigating these matters independently of the other states, announced a settlement of its ASR™ XL Hip device investigation for a total payment of $4 million to the State of Oregon.
In October 2012, Johnson & Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson & Johnson's subsidiary, Ethicon, Inc. (Ethicon). Johnson & Johnson and Ethicon have since entered into a series of tolling agreements with the 45 states and the District of Columbia participating in the multi-state investigation and have responded to Civil Investigative Demands served by certain of the participating states.
In December 2012, Therakos, Inc. (Therakos), formerly a subsidiary of Johnson & Johnson and part of the Ortho-Clinical Diagnostics, Inc. (OCD) franchise, received a letter from the civil division of the United States Attorney's Office for the Eastern District of Pennsylvania informing Therakos that the United States Attorney's Office was investigating the sales and marketing of Uvadex® (methoxsalen) and the Uvar Xts® System during the period 2000 to the present. The United States Attorney's Office requested that OCD and Johnson & Johnson preserve documents that could relate to the investigation. Therakos was subsequently acquired by an affiliate of Gores Capital Partners III, L.P. in January 2013. OCD and Johnson & Johnson retain certain liabilities that may result from the investigation for activity that occurred prior to the sale of Therakos. In March 2014, the United States Attorney’s Office requested that Johnson & Johnson produce certain documents, and Johnson & Johnson is cooperating with the request. Following the divestiture of OCD, Johnson & Johnson retains OCD’s portion of any liability that may result from the investigation for activity that occurred prior to the sale of Therakos.
In May 2013, Janssen Pharmaceuticals, Inc. (JPI) received a subpoena from the Atlanta Regional Office of the Department of Health and Human Services, Office of Inspector General, seeking production of documents and information regarding: (1) the sales, marketing and promotional practices, including the remuneration of healthcare providers, related to NUCYNTA® IR and NUCYNTA® ER; and (2) any studies, reports and/or complaints regarding the safety and/or actual or potential side effects of NUCYNTA® IR and NUCYNTA® ER. In October 2014, the United States Department of Justice (DOJ) informed JPI that the government's investigation stemmed from the filing of a qui tam complaint, that the DOJ had formally declined to intervene in the qui tam action, and that the DOJ was closing its investigation related to NUCYNTA® IR and NUCYNTA® ER. The plaintiff in the qui tam complaint filed a notice of dismissal and the Court dismissed the qui tam action in December 2014.
In recent years, Johnson & Johnson has received numerous requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson & Johnson to cooperate with these inquiries by producing the requested information.
GENERAL LITIGATION
In September 2006, Johnson & Johnson filed a lawsuit against Guidant Corporation (Guidant) in the United States District Court for the Southern District of New York, alleging that Guidant breached provisions of a merger agreement between Johnson & Johnson and Guidant. In June 2011, Guidant filed a motion for summary judgment and in July 2014, the judge denied Guidant’s motion. The trial concluded in January 2015 and in February 2015, before a decision was issued by the Court, Johnson & Johnson and Guidant entered into a settlement agreement, pursuant to which Guidant agreed to pay Johnson & Johnson $600 million and agreed that it will not sue Johnson & Johnson or its affiliates for patent infringement regarding certain stent products. Johnson & Johnson will dismiss its action against Guidant with prejudice. The Company will record this transaction in fiscal year 2015.
In June 2009, following the public announcement that Ortho-Clinical Diagnostics, Inc. (OCD)  had received a grand jury subpoena from the United States Department of Justice, Antitrust Division, in connection with an investigation that has since been closed, multiple class action complaints were filed against OCD by direct purchasers seeking damages for alleged price fixing. These cases were consolidated for pre-trial purposes in the United States District Court for the Eastern District of Pennsylvania as In re Blood Reagent Antitrust Litigation. In August 2012, the District Court granted a motion filed by Plaintiffs for class certification. In October 2012, the United States Court of Appeals for the Third Circuit granted OCD's petition for interlocutory review of the class certification ruling. Oral argument on the appeal was held in February 2014 and the parties are awaiting a decision. Following the divestiture of OCD, Johnson & Johnson retains any liability that may result from these cases.
In September 2010, a shareholder, Ronald Monk, filed a lawsuit in the United States District Court for the District of New Jersey seeking class certification and alleging that Johnson & Johnson and certain individuals, including executive officers and employees of Johnson & Johnson, failed to disclose that a number of manufacturing facilities failed to maintain current good manufacturing practices, and that as a result, the price of the Company's stock declined significantly. Plaintiff sought to pursue remedies under the Securities Exchange Act of 1934 to recover his alleged economic losses. In December 2011, a motion by Johnson & Johnson to dismiss was granted in part and denied in part. In September 2012, Plaintiff filed a Second Amended Complaint and Johnson & Johnson and the individual defendants moved to dismiss Plaintiff's Second Amended Complaint in part. Following mediation, the parties reached an agreement in principle to settle the case, and in July 2013, filed for preliminary approval of the proposed settlement. In November 2013, the Court approved the settlement. Three parties that had objected to the settlement appealed the Court’s approval orders. Prior to the mediation for the appeal, the parties agreed to dismiss the appeal with prejudice and without costs against any party. The United States Court of Appeals for the Third Circuit dismissed the case in April 2014.
In April 2011, OMJ Pharmaceuticals, Inc. (OMJ PR) filed a lawsuit against the United States in United States District Court for the District of Puerto Rico alleging overpayment of federal income taxes for the tax years ended November 30, 1999 and November 30, 2000. OMJ PR alleged that the Internal Revenue Service erroneously calculated OMJ PR's tax credits under Section 936 of the Tax Code. OMJ PR filed a motion for summary judgment, and the United States filed a cross motion for summary judgment. In October 2012, the Court granted a motion by the United States for summary judgment and denied a motion by OMJ PR for summary judgment. OMJ PR appealed this decision. In June 2014, the appellate court reversed the trial court’s decision and instructed the trial court to enter summary judgment in favor of OMJ PR.
In September 2011, Johnson & Johnson, Johnson & Johnson Inc. and McNeil Consumer Healthcare Division of Johnson & Johnson Inc. received a Notice of Civil Claim filed by Nick Field in the Supreme Court of British Columbia, Canada (the BC Civil Claim). The BC Civil Claim is a putative class action brought on behalf of persons who reside in British Columbia and who purchased during the period between September 20, 2001 and in or about December 2010 one or more various McNeil infants' or children's over-the-counter medicines that were manufactured at the Fort Washington facility. The BC Civil Claim alleges that the defendants violated the BC Business Practices and Consumer Protection Act, and other Canadian statutes and common laws, by selling medicines that were allegedly not safe and/or effective or did not comply with Canadian Good Manufacturing Practices. The class certification hearing is scheduled for October 2015.
In August 2014, United States Customs and Border Protection issued a Penalty Notice against Janssen Ortho LLC (Janssen Ortho), assessing penalties for the alleged improper classification of darunavir ethanolate (PREZISTA®) in connection with its importation into the United States. In October 2014, Janssen Ortho submitted a Petition for Relief in response to the Penalty Notice.
Johnson & Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.
Shareholder Derivative Action
In September 2011, two shareholder derivative lawsuits were filed in the United States District Court for the District of New Jersey by Donovan Spamer and The George Leon Family Trust naming current and former directors of Johnson & Johnson as defendants and Johnson & Johnson as the nominal defendant. These lawsuits allege that the defendants breached their fiduciary duties in their decisions with respect to the compensation of the Chief Executive Officer during the period from 2008 through 2011, and that the defendants made misleading statements in the Company's annual proxy statements. Both of these lawsuits were voluntarily dismissed without prejudice, but a similar lawsuit, The George Leon Family Trust v. Coleman, was refiled in July 2012. That lawsuit sought a variety of relief, including monetary damages, injunctive relief, and corporate governance reforms. In June 2013, the Board of Directors of Johnson & Johnson (the Board) received a report prepared by special, independent counsel to the Board, which investigated the allegations contained in the derivative actions filed by Donovan Spamer and by The George Leon Family Trust, and in several shareholder demand letters that the Board received in 2011 and 2012 raising similar issues. The report recommended that Johnson & Johnson reject the shareholder demands and take whatever steps are necessary or appropriate to secure dismissal of the derivative litigation. The Board unanimously adopted the report's recommendations.
In September 2013, Johnson & Johnson moved to dismiss or, in the alternative, for summary judgment in The George Leon Family Trust v. Coleman, based upon the Board’s determination. In October 2013, the plaintiff in the Leon litigation filed an amended complaint and Johnson & Johnson moved to dismiss the amended complaint or, in the alternative, for summary judgment, based upon the Board’s determination. In June 2014, the Court granted summary judgment in favor of Johnson & Johnson.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 28, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated.
Description of the Company And Business Segments	Description of the Company And Business Segments
	The Company has approximately 126,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.
	The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices (previously referred to as Medical Devices and Diagnostics). The Consumer segment includes a broad range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgical care, specialty surgery, cardiovascular care, diagnostics, diabetes care, and vision care markets, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, and clinics.
New Accounting Pronouncements	New Accounting Pronouncements
	Recently Adopted Accounting Pronouncements
	During the fiscal first quarter of 2014, the Company adopted the Financial Accounting Standards Board (FASB) guidance clarifying the release of accumulated Foreign Currency Translation from other comprehensive income (OCI), into current year Net Earnings. The amendment requires that when the parent company ceases to have a controlling interest in a subsidiary or a business within a foreign entity the parent is to release accumulated Foreign Currency Translation from OCI. This update became effective for all annual periods and interim reporting periods beginning after December 15, 2013. The adoption of this standard did not have a material impact on the Company's results of operations, cash flows or financial position.
	During the fiscal first quarter of 2014, the Company adopted the FASB guidance on the presentation of unrecognized tax benefits when various qualifying tax credits exist. The amendment requires that unrecognized tax benefits be presented on the Consolidated Balance Sheet as a reduction to deferred tax assets created by net operating losses or other tax credits from prior periods that occur in the same taxing jurisdiction. To the extent that the unrecognized tax benefit exceeds these credits, it shall be presented as a liability. This update became effective for all annual periods and interim reporting periods beginning after December 15, 2013. The adoption of this standard did not have a material impact on the presentation of the Company's financial position.
	During the fiscal second quarter of 2014, the FASB issued amended guidance on the use and presentation of discontinued operations in an entity’s financial statements. The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity’s operations and financial results.  Examples of a strategic shift could include, but not be limited to, disposal of major geographic segments, a major line of business or other major business component of an entity. The new guidance also expands the required disclosures for entities that have assets held for sale but do not meet the new definition of discontinued operations. This amendment includes early adoption provisions allowing the Company to implement this update immediately for the first quarter of 2014. The Company elected to adopt this standard for the first quarter of 2014. The balances and updated disclosures required by the amended guidance are included in Note 20 in the Notes to the Consolidated Financial Statements.
	During the fiscal second quarter of 2014, the FASB issued Accounting Standards Update 2014-12: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This standard clarifies the current accounting guidance for entities that issue share-based payment awards that require a specific performance target be achieved for employees to become eligible to vest in the awards, which may occur subsequent to a required service period. Current accounting guidance does not explicitly address how to account for these types of awards. The new standard provides explicit guidance and clarifies that these types of performance targets should be treated as performance conditions. The accounting for share-based awards with performance conditions is already specified in current accounting guidance. This update is required to be adopted by all public companies for all annual periods and interim reporting periods beginning after December 15, 2015. Early adoption of this standard was permitted and the Company had elected to adopt this standard for the second quarter of 2014. The adoption of this standard did not have a material impact on the Company's results of operations, cash flows or financial position.
	Recently Issued Accounting Standards
	Not Adopted as of December 28, 2014
	During the fiscal second quarter of 2014, the FASB issued Accounting Standards Update 2014-09: Revenue from Contracts with Customers. This standard replaces substantially all current revenue recognition accounting guidance. This update is required to be adopted by all public companies for all annual periods and interim reporting periods beginning after December 15, 2016. Early adoption of this standard is not permitted.  The Company is currently assessing the impact of the future adoption of this standard on its financial statements.
	During the fiscal second quarter of 2014, the FASB issued amended guidance Accounting Standards Update No. 2014-10: Development Stage Entities: Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entity Guidance in Topic 810, Consolidation.  The change in the current guidance will require the Company to determine if it should consolidate one of these entities based on the change in the consolidation analysis.  This update to the consolidation analysis will become effective for all annual periods and interim reporting periods beginning after December 15, 2015.  The adoption of this standard is not expected to have a material impact on the presentation of the Company's results of operations, cash flows or financial position.
	During the fiscal third quarter of 2014, the FASB issued Accounting Standards Update No. 2014-15: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This standard requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016.  This standard is not expected to have any impact on current disclosures in the financial statements.
Cash Equivalents	Cash Equivalents
	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an "A" (or equivalent) credit rating. The Company invests its cash primarily in reverse repurchase agreements (RRAs), government securities and obligations, corporate debt securities and money market funds.
	RRAs are collateralized by deposits in the form of ‘Government Securities and Obligations’ for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.
Investments	Investments
	Short-term marketable securities are carried at cost, which approximates fair value. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Long-term debt securities that the Company has the ability and intent to hold until maturity are carried at amortized cost. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company periodically reviews its investments in equity securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary. If losses on these securities are considered to be other than temporary, the loss is recognized in earnings.
Property, Plant and Equipment and Depreciation	Property, Plant and Equipment and Depreciation
	Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:
	Building and building equipment	20 - 30 years
	Land and leasehold improvements	10 - 20 years
	Machinery and equipment	2 - 13 years
	The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years.
	The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.
Revenue Recognition	Revenue Recognition
	The Company recognizes revenue from product sales when the goods are shipped or delivered and title and risk of loss pass to the customer. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.
	Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates, which include Medicaid, are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.
	Sales returns are generally estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales returns accruals.
	Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual sales to customers during the fiscal reporting years 2014, 2013 and 2012.
	Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the year incurred. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. The Company also earns service revenue for co-promotion of certain products and includes it in sales to customers. These arrangements are evaluated to determine the appropriate amounts to be deferred.
Shipping and Handling	Shipping and Handling
	Shipping and handling costs incurred were $1,068 million, $1,128 million and $1,051 million in 2014, 2013 and 2012, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.
Inventories	Inventories
	Inventories are stated at the lower of cost or market determined by the first-in, first-out method.
Intangible Assets and Goodwill	Intangible Assets and Goodwill
	The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed the annual impairment test for 2014 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired.
	Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
Financial Instruments	Financial Instruments
	As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
	The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
Product Liability	Product Liability
	Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter. This is referred to as defense costs in connection with product liability litigation. In certain matters an indemnity amount is also recorded. This is referred to as product liability accrual.
	As a result of cost and availability factors, effective November 1, 2005, the Company ceased purchasing third-party product liability insurance. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. Based on the availability of prior coverage, receivables for insurance recoveries related to product liability claims are recorded on an undiscounted basis, when it is probable that a recovery will be realized. As appropriate, reserves against these receivables are recorded for estimated amounts that may not be collected from third-party insurers.
Concentration of Credit Risk	Concentration of Credit Risk
	Global concentration of credit risk with respect to trade accounts receivables continues to be limited due to the large number of customers globally and adherence to internal credit policies and credit limits. Economic challenges in Italy, Spain, Greece and Portugal (the Southern European Region) have impacted certain payment patterns, which have historically been longer than those experienced in the U.S. and other international markets. The total net trade accounts receivable balance in the Southern European Region was approximately $1.8 billion as of December 28, 2014 and approximately $2.3 billion as of December 29, 2013. Approximately $1.1 billion as of December 28, 2014 and approximately $1.3 billion as of December 29, 2013 of the Southern European Region net trade accounts receivable balance related to the Company's Consumer, Vision Care and Diabetes Care businesses as well as certain Pharmaceutical and Medical Devices customers which are in line with historical collection patterns.
	The remaining balance of net trade accounts receivable in the Southern European Region has been negatively impacted by the timing of payments from certain government owned or supported health care customers as well as certain distributors of the Pharmaceutical and Medical Devices local affiliates. The total net trade accounts receivable balance for these customers were approximately $0.7 billion at December 28, 2014 and $1.0 billion at December 29, 2013. The Company continues to receive payments from these customers and in some cases late payment premiums. For customers where payment is expected over periods of time longer than one year, revenue and trade receivables have been discounted over the estimated period of time for collection. Allowances for doubtful accounts have been increased for these customers, but have been immaterial to date. The Company will continue to work closely with these customers on payment plans, monitor the economic situation and take appropriate actions as necessary.
Research and Development	Research and Development
	Research and development expenses are expensed as incurred. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
	The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows:
	Nature/Type of Collaboration		Statement of Earnings Presentation
	Third-party sale of product		Sales to customers
	Royalties/milestones paid to collaborative partner (post-regulatory approval)*		Cost of products sold
	Royalties received from collaborative partner		Other income (expense), net
	Upfront payments & milestones paid to collaborative partner (pre-regulatory approval)		Research and development expense
	Research and development payments to collaborative partner		Research and development expense
	Research and development payments received from collaborative partner		Reduction of Research and development expense
	*	Milestones are capitalized as intangible assets and amortized to cost of goods sold over the useful life.
	For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.
Advertising	Advertising
	Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses.
Income Taxes	Income Taxes
	Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future.
	The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.
	At December 28, 2014 and December 29, 2013, the cumulative amounts of undistributed international earnings were approximately $53.4 billion and $50.9 billion, respectively. At December 28, 2014 and December 29, 2013, the Company's foreign subsidiaries held balances of cash and cash equivalents in the amounts of $14.3 billion and $18.6 billion, respectively. The Company has not provided deferred taxes on the undistributed earnings from certain international subsidiaries where the earnings are considered to be permanently reinvested. The Company intends to continue to reinvest these earnings in international operations. If the Company decided at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company does not determine the deferred tax liability associated with these undistributed earnings, as such determination is not practical.
Net Earnings Per Share	Net Earnings Per Share
	Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
Use of Estimates	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates.
	The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.
Annual Closing Date	Annual Closing Date
	The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, as was the case in 2009, and is the case again in 2015.
Reclassification	Reclassification
	Certain prior period amounts have been reclassified to conform to current year presentation.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 28, 2014
Accounting Policies [Abstract]
Estimated useful lives of assets	Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:
	Building and building equipment	20 - 30 years
	Land and leasehold improvements	10 - 20 years
	Machinery and equipment	2 - 13 years

Cash_Cash_Equivalents_and_Curr1

Cash, Cash Equivalents and Current Marketable Securities (Tables)	12 Months Ended
	Dec. 28, 2014
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Current Marketable Securities	At the end of 2014 and 2013, cash, cash equivalents and current marketable securities were comprised of:
	(Dollars in Millions)	2014		2013
	Cash	$	2,336	2,789
	Government securities and obligations	20,610		7,632
	Reverse repurchase agreements	6,735		15,006
	Corporate debt securities	1,343		1,467
	Money market funds	1,352		1,886
	Time deposits	713		426
	Total cash, cash equivalents and current marketable securities	$	33,089	29,206

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 28, 2014
Inventory Disclosure [Abstract]
Summary of Inventories	At the end of 2014 and 2013, inventories were comprised of:
	(Dollars in Millions)	2014		2013
	Raw materials and supplies	$	1,214	1,224
	Goods in process	2,461		2,612
	Finished goods	4,509		4,042
	Total inventories	$	8,184	7,878

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 28, 2014
Property, Plant and Equipment [Abstract]
Property, plant and equipment at cost and accumulated depreciation	At the end of 2014 and 2013, property, plant and equipment at cost and accumulated depreciation were:
	(Dollars in Millions)	2014		2013
	Land and land improvements	$	833	885
	Buildings and building equipment	10,046		10,423
	Machinery and equipment	22,206		22,527
	Construction in progress	3,600		3,298
	Total property, plant and equipment, gross	$	36,685	37,133
	Less accumulated depreciation	20,559		20,423
	Total property, plant and equipment, net	$	16,126	16,710

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets and Goodwill	At the end of 2014 and 2013, the gross and net amounts of intangible assets were:
	(Dollars in Millions)	2014			2013
	Intangible assets with definite lives:
	Patents and trademarks — gross	$	9,074		9,164
	Less accumulated amortization	4,700			4,146
	Patents and trademarks — net	$	4,374		5,018
	Customer relationships and other intangibles — gross	$	17,970		19,027
	Less accumulated amortization	5,227			4,872
	Customer relationships and other intangibles — net	$	12,743		14,155
	Intangible assets with indefinite lives:
	Trademarks	$	7,263		7,619
	Purchased in-process research and development	2,842			1,155
	Total intangible assets with indefinite lives	$	10,105		8,774
	Total intangible assets — net	$	27,222		27,947
Goodwill	Goodwill as of December 28, 2014 and December 29, 2013, as allocated by segment of business, was as follows:
	(Dollars in Millions)	Consumer			Pharmaceutical		Med Devices		Total
	Goodwill at December 30, 2012	$	8,519		1,792		12,113		22,424
	Goodwill, related to acquisitions	83			246		9		338
	Goodwill, related to divestitures	(71		)	—		—		(71	)
	Currency translation/other	—			30		77		107
	Goodwill at December 29, 2013	$	8,531		2,068		12,199		22,798
	Goodwill, related to acquisitions	13			665		—		678
	Goodwill, related to divestitures	(138		)	—		(603	)	(741	)
	Currency translation/other	(731		)	(107	)	(65	)	(903	)
	Goodwill at December 28, 2014	$	7,675		2,626		11,531		21,832

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 28, 2014
Fair Value Disclosures [Abstract]
Summary of designated derivatives	The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal years ended December 28, 2014 and December 29, 2013:
	(Dollars in Millions)		Gain/(Loss)					Gain/(Loss) Reclassified From				Gain/(Loss) Recognized In
			Recognized In Accumulated OCI(1)					Accumulated OCI Into Income(1)				Other Income/Expense(2)
	Cash Flow Hedges by Income Statement Caption		2014			2013		2014		2013		2014		2013
	Sales to customers (3)		$	(106	)	45		(3	)	49		(5	)	2
	Cost of products sold (3)		58			271		204		69		2		23
	Research and development expense (3)		39			24		7		16		—		(4	)
	Interest (income)/Interest expense, net (4)		21			17		(15	)	(10	)	—		—
	Other (income) expense, net (3)		80			(13	)	3		(17	)	—		(4	)
	Total		$	92		344		196		107		(3	)	17
	All amounts shown in the table above are net of tax.
	(1)	Effective portion
	(2)	Ineffective portion
	(3)	Forward foreign exchange contracts
	(4)	Cross currency interest rate swaps
Financial assets and liabilities at fair value	The Company’s significant financial assets and liabilities measured at fair value as of December 28, 2014 and December 29, 2013 were as follows:
			2014									2013
	(Dollars in Millions)		Level 1			Level 2		Level 3		Total		Total (1)
	Derivatives designated as hedging instruments:
	Assets:
	Forward foreign exchange contracts		$	—		996		—		996		537
	Interest rate contracts (2)		—			31		—		31		169
	Total		—			1,027		—		1,027		706
	Liabilities:
	Forward foreign exchange contracts		—			751		—		751		133
	Interest rate contracts (3) (4)		—			8		—		8		26
	Total		—			759		—		759		159
	Derivatives not designated as hedging instruments:
	Assets:
	Forward foreign exchange contracts		—			29		—		29		25
	Liabilities:
	Forward foreign exchange contracts		—			51		—		51		29
	Other investments (5)		$	679		—		—		679		333
	(1)	2013 assets and liabilities are all classified as Level 2 with the exception of Other investments of $333 million, which are classified as Level 1.
	(2)	Includes $29 million and $169 million of non-current assets for the fiscal years ending December 28, 2014 and December 29, 2013, respectively.
	(3)	Includes $8 million and $19 million of non-current liabilities for the fiscal years ending December 28, 2014 and December 29, 2013, respectively.
	(4)	Includes cross currency interest rate swaps and interest rate swaps.
	(5)	Classified as non-current other assets.

Borrowings_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 28, 2014
Income Tax Disclosure [Abstract]
Provision for income taxes	The provision for taxes on income consists of:
	(Dollars in Millions)	2014				2013		2012
	Currently payable:
	U.S. taxes	$	2,625			594		2,023
	International taxes	1,174				1,653		1,277
	Total currently payable	3,799				2,247		3,300
	Deferred:
	U.S. taxes	(258		)		(251	)	(120	)
	International taxes	699				(356	)	81
	Total deferred	441				(607	)	(39	)
	Provision for taxes on income	$	4,240			1,640		3,261
Comparison of income taxes at Statutory rate and Company's effective tax rate	A comparison of income tax expense at the U.S. statutory rate of 35% in 2014, 2013 and 2012, to the Company’s effective tax rate is as follows:
	(Dollars in Millions)	2014				2013		2012
	U.S.	$	8,001			4,261		4,664
	International	12,562				11,210		9,111
	Earnings before taxes on income:	$	20,563			15,471		13,775
	Tax rates:
	U.S. statutory rate	35		%		35		35
	International operations excluding Ireland	(7.0		)		(10.6	)	(9.8	)
	Ireland and Puerto Rico operations	(6.9		)		(9.0	)	(3.9	)
	Research and orphan drug tax credits	(0.3		)		(0.8	)	—
	U.S. state and local	1				0.4		1.3
	U.S. manufacturing deduction	(0.6		)		(0.8	)	(0.9	)
	U.S. tax on international income	1.4				1.7		1.1
	U.S. tax benefit on asset/business disposals	(1.9		)		(5.1	)	—
	All other	(0.1		)		(0.2	)	0.9
	Effective tax rate	20.6		%		10.6		23.7
Deferred income tax assets and liabilities	Temporary differences and carryforwards for 2014 and 2013 were as follows:
		2014 Deferred Tax						2013 Deferred Tax
	(Dollars in Millions)	Asset				Liability		Asset			Liability
	Employee related obligations	$	3,426					1,908
	Stock based compensation	799						1,121
	Depreciation					(564	)				(772	)
	Non-deductible intangibles					(6,671	)				(6,250	)
	International R&D capitalized for tax	1,433						1,656
	Reserves & liabilities	1,497						1,587
	Income reported for tax purposes	1,067						1,043
	Net operating loss carryforward international	949						1,090
	Miscellaneous international	1,128			(1)	(305	)	1,508		(1)	(361	)
	Miscellaneous U.S.	996						927
	Total deferred income taxes	$	11,295			(7,540	)	10,840			(7,383	)
	(1) The $1,128 million in 2014 was net of a valuation allowance related to Belgium of $172 million. The $1,508 million in 2013 was net of a valuation allowance related to Belgium of $187 million.
Changes in/activity related to unrecognized tax benefits	The following table summarizes the activity related to unrecognized tax benefits:
	(Dollars in Millions)	2014				2013		2012
	Beginning of year	$	2,729			3,054		2,699
	Increases related to current year tax positions	281				643		538
	Increases related to prior period tax positions	295				80		57
	Decreases related to prior period tax positions	(288		)		(574	)	(41	)
	Settlements	(477		)		(418	)	(120	)
	Lapse of statute of limitations	(75		)		(56	)	(79	)
	End of year	$	2,465			2,729		3,054

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 28, 2014
Income Tax Disclosure [Abstract]
Provision for income taxes	The provision for taxes on income consists of:
	(Dollars in Millions)	2014				2013		2012
	Currently payable:
	U.S. taxes	$	2,625			594		2,023
	International taxes	1,174				1,653		1,277
	Total currently payable	3,799				2,247		3,300
	Deferred:
	U.S. taxes	(258		)		(251	)	(120	)
	International taxes	699				(356	)	81
	Total deferred	441				(607	)	(39	)
	Provision for taxes on income	$	4,240			1,640		3,261
Comparison of income taxes at Statutory rate and Company's effective tax rate	A comparison of income tax expense at the U.S. statutory rate of 35% in 2014, 2013 and 2012, to the Company’s effective tax rate is as follows:
	(Dollars in Millions)	2014				2013		2012
	U.S.	$	8,001			4,261		4,664
	International	12,562				11,210		9,111
	Earnings before taxes on income:	$	20,563			15,471		13,775
	Tax rates:
	U.S. statutory rate	35		%		35		35
	International operations excluding Ireland	(7.0		)		(10.6	)	(9.8	)
	Ireland and Puerto Rico operations	(6.9		)		(9.0	)	(3.9	)
	Research and orphan drug tax credits	(0.3		)		(0.8	)	—
	U.S. state and local	1				0.4		1.3
	U.S. manufacturing deduction	(0.6		)		(0.8	)	(0.9	)
	U.S. tax on international income	1.4				1.7		1.1
	U.S. tax benefit on asset/business disposals	(1.9		)		(5.1	)	—
	All other	(0.1		)		(0.2	)	0.9
	Effective tax rate	20.6		%		10.6		23.7
Deferred income tax assets and liabilities	Temporary differences and carryforwards for 2014 and 2013 were as follows:
		2014 Deferred Tax						2013 Deferred Tax
	(Dollars in Millions)	Asset				Liability		Asset			Liability
	Employee related obligations	$	3,426					1,908
	Stock based compensation	799						1,121
	Depreciation					(564	)				(772	)
	Non-deductible intangibles					(6,671	)				(6,250	)
	International R&D capitalized for tax	1,433						1,656
	Reserves & liabilities	1,497						1,587
	Income reported for tax purposes	1,067						1,043
	Net operating loss carryforward international	949						1,090
	Miscellaneous international	1,128			(1)	(305	)	1,508		(1)	(361	)
	Miscellaneous U.S.	996						927
	Total deferred income taxes	$	11,295			(7,540	)	10,840			(7,383	)
	(1) The $1,128 million in 2014 was net of a valuation allowance related to Belgium of $172 million. The $1,508 million in 2013 was net of a valuation allowance related to Belgium of $187 million.
Changes in/activity related to unrecognized tax benefits	The following table summarizes the activity related to unrecognized tax benefits:
	(Dollars in Millions)	2014				2013		2012
	Beginning of year	$	2,729			3,054		2,699
	Increases related to current year tax positions	281				643		538
	Increases related to prior period tax positions	295				80		57
	Decreases related to prior period tax positions	(288		)		(574	)	(41	)
	Settlements	(477		)		(418	)	(120	)
	Lapse of statute of limitations	(75		)		(56	)	(79	)
	End of year	$	2,465			2,729		3,054

Employee_Related_Obligations_T

Employee Related Obligations (Tables)	12 Months Ended
	Dec. 28, 2014
Compensation Related Costs [Abstract]
Employee related obligations	At the end of 2014 and 2013, employee related obligations recorded on the Consolidated Balance Sheets were:
	(Dollars in Millions)	2014		2013
	Pension benefits	$	4,547	2,950
	Postretirement benefits	3,161		2,655
	Postemployment benefits	2,062		1,872
	Deferred compensation	599		693
	Total employee obligations	10,369		8,170
	Less current benefits payable	397		386
	Employee related obligations — non-current	$	9,972	7,784

Pensions_and_Other_Postretirem

Pensions and Other Postretirement Benefits (Tables)	12 Months Ended
	Dec. 28, 2014
Compensation and Retirement Disclosure [Abstract]
Components of net periodic benefit cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2014, 2013 and 2012 include the following components:
			Retirement Plans										Other Benefit Plans
	(Dollars in Millions)		2014				2013			2012			2014			2013			2012
	Service cost		$	882			906			722			211			196			175
	Interest cost		1,018				908			878			197			151			165
	Expected return on plan assets		(1,607		)		(1,447	)		(1,236	)		(7	)		(6	)		(4	)
	Amortization of prior service cost (credit)		6				6			6			(34	)		(2	)		(3	)
	Amortization of net transition obligation		1				1			1			—			—			—
	Recognized actuarial losses		460				681			494			136			111			76
	Curtailments and settlements		(17		)		—			—			—			2			—
	Net periodic benefit cost		$	743			1,055			865			503			452			409
Amounts expected to be recognized in net periodic benefit cost	Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company’s defined benefit retirement plans and other post-retirement plans:
	(Dollars in Millions)
	Amortization of net transition obligation	—
	Amortization of net actuarial losses	944
	Amortization of prior service credit	33
Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation	The weighted-average assumptions in the following table represent the rates used to develop the actuarial present value of projected benefit obligation for the year listed and also the net periodic benefit cost for the following year.
			Retirement Plans									Other Benefit Plans
			2014			2013			2012			2014			2013			2012
	Worldwide Benefit Plans
	Discount rate		3.78	%		4.78	%		4.25	%		4.31	%		5.25	%		4.55	%
	Expected long-term rate of return on plan assets		8.53	%		8.46	%		8.45	%
	Rate of increase in compensation levels		4.05	%		4.08	%		4.08	%		4.11	%		4.29	%		4.28	%
Assumed health care cost trend rates	The following table displays the assumed health care cost trend rates, for all individuals:
	Health Care Plans		2014			2013
	Health care cost trend rate assumed for next year		6	%		6.5	%
	Rate to which the cost trend rate is assumed to decline (ultimate trend)		4.5	%		4.5	%
	Year the rate reaches the ultimate trend rate		2032			2032
Effect of one percentage point change in assumed health care cost trend rates	A one-percentage-point change in assumed health care cost trend rates would have the following effect:
			One-Percentage-				One-Percentage-
	(Dollars in Millions)		Point Increase				Point Decrease
	Health Care Plans
	Total interest and service cost		$	45			$	(34	)
	Post-retirement benefit obligation		560				(444		)
Schedule of Net Funded Status	The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2014 and 2013 for the Company’s defined benefit retirement plans and other post-retirement plans:
			Retirement Plans							Other Benefit Plans
	(Dollars in Millions)		2014				2013			2014				2013
	Change in Benefit Obligation
	Projected benefit obligation — beginning of year		$	21,488			21,829			4,407				4,159
	Service cost		882				906			211				196
	Interest cost		1,018				908			197				151
	Plan participant contributions		59				54			—				—
	Amendments		(60		)		35			(254		)		7
	Actuarial (gains) losses		5,395				(1,432	)		1,030				296
	Divestitures & acquisitions		(121		)		8			—				—
	Curtailments, settlements & restructuring		(53		)		(15	)		—				(11	)
	Benefits paid from plan		(813		)		(751	)		(493		)		(373	)
	Effect of exchange rates		(906		)		(54	)		(17		)		(18	)
	Projected benefit obligation — end of year		$	26,889			21,488			5,081				4,407
	Change in Plan Assets
	Plan assets at fair value — beginning of year		$	20,901			17,536			87				122
	Actual return on plan assets		2,078				3,573			8				15
	Company contributions		1,176				565			477				323
	Plan participant contributions		59				54			—				—
	Settlements		(40		)		(4	)		—				—
	Divestitures & acquisitions		(109		)		9			—				—
	Benefits paid from plan assets		(813		)		(751	)		(493		)		(373	)
	Effect of exchange rates		(677		)		(81	)		—				—
	Plan assets at fair value — end of year		$	22,575			20,901			79				87
	Funded status — end of year		$	(4,314	)		(587	)		(5,002		)		(4,320	)
	Amounts Recognized in the Company’s Balance Sheet consist of the following:
	Non-current assets		$	233			2,363			$	—			—
	Current liabilities		(74		)		(71	)		(309		)		(302	)
	Non-current liabilities		(4,473		)		(2,879	)		(4,693		)		(4,018	)
	Total recognized in the consolidated balance sheet — end of year		$	(4,314	)		(587	)		$	(5,002	)		(4,320	)
	Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:
	Net actuarial loss		$	7,547			3,344			$	2,611			1,732
	Prior service cost (credit)		(33		)		26			(225		)		(6	)
	Unrecognized net transition obligation		1				2			—				—
	Total before tax effects		$	7,515			3,372			$	2,386			1,726
	Accumulated Benefit Obligations — end of year		$	23,816			19,203
			Retirement Plans							Other Benefit Plans
	(Dollars in Millions)		2014				2013			2014				2013
	Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income
	Net periodic benefit cost		$	743			1,055			$	503			452
	Net actuarial (gain) loss		4,942				(3,559	)		1,015				248
	Amortization of net actuarial loss		(460		)		(681	)		(136		)		(111	)
	Prior service cost (credit)		(60		)		34			(253		)		8
	Amortization of prior service (cost) credit		(6		)		(13	)		34				—
	Effect of exchange rates		(273		)		(6	)		—				(6	)
	Total recognized in other comprehensive income, before tax		$	4,143			(4,225	)		$	660			139
	Total recognized in net periodic benefit cost and other comprehensive income		$	4,886			(3,170	)		$	1,163			591
Information related to the benefit obligation and the fair value of plan assets	The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 28, 2014 and December 29, 2013, respectively:
		U.S. Plans									International Plans
		Qualified Plans					Non-Qualified Plans				Funded Plans				Unfunded Plans
	(Dollars in Millions)	2014			2013		2014		2013		2014		2013		2014		2013
	Plan Assets	$	15,201		13,990		—		—		7,374		6,911		—		—
	Projected Benefit Obligation	15,571			11,921		1,683		1,296		9,203		7,797		432		474
	Accumulated Benefit Obligation	13,875			10,745		1,363		1,065		8,205		6,974		373		419
	Over (Under) Funded Status
	Projected Benefit Obligation	$	(370	)	2,069		(1,683	)	(1,296	)	(1,829	)	(886	)	(432	)	(474	)
	Accumulated Benefit Obligation	1,326			3,245		(1,363	)	(1,065	)	(831	)	(63	)	(373	)	(419	)
Projected future benefit payments from company's retirement and other benefit plans	The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans:
	(Dollars in Millions)		2015				2016			2017			2018			2019			2020-2024
	Projected future benefit payments
	Retirement plans		$	793			813			868			907			963			5,858
	Other benefit plans		$	316			309			306			303			300			1,475
Projected future minimum contributions to the Company's U.S. and international unfunded retirement plans	The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.
	(Dollars in Millions)		2015				2016			2017			2018			2019			2020-2024
	Projected future contributions		$	74			75			78			84			89			531
Company' retirement plan asset allocation and target allocations	The Company’s retirement plan asset allocation at the end of 2014 and 2013 and target allocations for 2015 are as follows:
			Percent of						Target
			Plan Assets						Allocation
			2014			2013			2015
	Worldwide Retirement Plans
	Equity securities		77	%		76	%		73	%
	Debt securities		23			24			27
	Total plan assets		100	%		100	%		100	%
Schedule of Defined Benefit Plans Disclosures	The following table sets forth the Retirement Plans' investments measured at fair value as of December 28, 2014 and December 29, 2013:
			Quoted Prices							Significant						Significant
			in Active							Other						Unobservable
			Markets for							Observable						Inputs
			Identical Assets							Inputs
			(Level 1)							(Level 2)						(Level 3)					Total Assets
	(Dollars in Millions)		2014				2013			2014			2013			2014			2013		2014	2013
	Short-term investment funds		$	168			304			551			561			—			—		719	865
	Government and agency securities		—				—			1,934			1,965			—			—		1,934	1,965
	Debt instruments		—				—			1,143			1,215			1			1		1,144	1,216
	Equity securities		11,204				10,526			21			23			—			4		11,225	10,553
	Commingled funds		—				—			7,205			5,846			46			44		7,251	5,890
	Insurance contracts		—				—			—			2			24			23		24	25
	Other assets		1				4			214			314			63			69		278	387
	Investments at fair value		$	11,373			10,834			11,068			9,926			134			141		22,575	20,901
Summary of changes in the fair value of the Plan's Level 3 assets	The table below sets forth a summary of changes in the fair value of the Plan’s Level 3 assets for the years ended December 28, 2014 and December 29, 2013:
	(Dollars in Millions)		Debt Instruments				Equity Securities			Commingled Funds			Insurance Contracts			Other Assets			Total Level 3
	Balance December 30, 2012		$	3			4			50			24			69			150
	Realized gains (losses)		—				—			—			—			(5	)		(5	)
	Unrealized gains (losses)		—				(1	)		—			(1	)		—			(2	)
	Purchases, sales, issuances and settlements, net		(2		)		1			(6	)		—			5			(2	)
	Balance December 29, 2013		1				4			44			23			69			141
	Realized gains (losses)		—				—			—			—			(5	)		(5	)
	Unrealized gains (losses)		—				—			2			—			—			2
	Purchases, sales, issuances and settlements, net		—				—			(2	)		3			(1	)		—
	Transfers in/out and exchange rate changes		—				(4	)		2			(2	)		—			(4	)
	Balance December 28, 2014		$	1			—			46			24			63			134

Capital_and_Treasury_Stock_Tab

Capital and Treasury Stock (Tables)	12 Months Ended
	Dec. 28, 2014
Equity [Abstract]
Changes in treasury stock	Changes in treasury stock were:
		Treasury Stock
	(Amounts in Millions Except Treasury Stock Shares in Thousands)	Shares		Amount
	Balance at January 1, 2012	395,480		$	21,659
	Employee compensation and stock option plans	(55,170	)	(3,250		)
	Issuance of common stock associated with the acquisition of Synthes, Inc.	(203,740	)	(12,852		)
	Repurchase of common stock (1)	204,784		12,919
	Balance at December 30, 2012	341,354		18,476
	Employee compensation and stock option plans	(48,555	)	(3,367		)
	Repurchase of common stock	6,416		591
	Balance at December 29, 2013	299,215		15,700
	Employee compensation and stock option plans	(32,302	)	(2,933		)
	Repurchase of common stock	69,707		7,124
	Balance at December 28, 2014	336,620		$	19,891
	(1) Includes repurchase of common stock associated with the acquisition of Synthes, Inc.

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 28, 2014
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following:
	(Dollars in Millions)	Foreign			Gain/(Loss) On Securities		Employee Benefit Plans		Gain/		Total
		Currency Translation							(Loss) On		Accumulated
									Derivatives & Hedges		Other
											Comprehensive Income (Loss)
	January 1, 2012	$	(1,526	)	448		(4,386	)	(168	)	(5,632	)
	Net 2012 changes	1,230			(253	)	(1,331	)	176		(178	)
	December 30, 2012	(296		)	195		(5,717	)	8		(5,810	)
	Net 2013 changes	94			(89	)	2,708		237		2,950
	29-Dec-13	(202		)	106		(3,009	)	245		(2,860	)
	Net 2014 changes	(4,601		)	151		(3,308	)	(104	)	(7,862	)
	28-Dec-14	$	(4,803	)	257		(6,317	)	141		(10,722	)

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 28, 2014
Earnings Per Share [Abstract]
Reconciliation of basic net earnings per share to diluted net earnings per share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 28, 2014, December 29, 2013 and December 30, 2012:
	(In Millions Except Per Share Amounts)	2014			2013		2012
	Basic net earnings per share attributable to Johnson & Johnson	$	5.8		4.92		3.94
	Average shares outstanding — basic	2,815.20			2,809.20		2,753.30
	Potential shares exercisable under stock option plans	142.6			148.5		164.6
	Less: shares repurchased under treasury stock method	(96.5		)	(103.3	)	(128.2	)
	Convertible debt shares	2.6			3		3.6
	Accelerated share repurchase program	—			19.6		19.3
	Adjusted average shares outstanding — diluted	2,863.90			2,877.00		2,812.60
	Diluted net earnings per share attributable to Johnson & Johnson	$	5.7		4.81		3.86

Rental_Expense_and_Lease_Commi1

Rental Expense and Lease Commitments (Tables)	12 Months Ended
	Dec. 28, 2014
Leases, Operating [Abstract]
Schedule of minimum rental payments under operating leases	The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at December 28, 2014 are:
	(Dollars in Millions)
	2015	2016	2017	2018	2019	After 2019	Total
	$200	157	111	80	66	77	691

Common_Stock_Stock_Option_Plan1

Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)	12 Months Ended
	Dec. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The average fair value of options granted was $8.42, $4.88 and $6.39, in 2014, 2013 and 2012, respectively. The fair value was estimated based on the weighted average assumptions of:
		2014			2013			2012
	Risk-free rate	1.87	%		1.01	%		1.06	%
	Expected volatility	14.6	%		14.04	%		18.38	%
	Expected life (in years)	6			6			6
	Dividend yield	3.1	%		3.4	%		3.6	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of option activity under the Plan as of December 28, 2014, December 29, 2013 and December 30, 2012, and changes during the years ending on those dates is presented below:
	(Shares in Thousands)		Outstanding Shares			Weighted				Aggregate
						Average Exercise Price				Intrinsic
										Value
										(Dollars in Millions)
	Shares at January 1, 2012		179,459			$	60.1			$	1,004
	Options granted		8,661			65.36
	Options exercised		(49,388	)		56.73
	Options canceled/forfeited		(4,381	)		62.97
	Shares at December 30, 2012		134,351			61.58				1,061
	Options granted		29,010			72.54
	Options exercised		(41,357	)		59.99
	Options canceled/forfeited		(2,448	)		65.89
	Shares at December 29, 2013		119,556			64.7				3,306
	Options granted		24,356			90.44
	Options exercised		(25,319	)		62.31
	Options canceled/forfeited		(2,881	)		75.48
	Shares at December 28, 2014		115,712			$	70.37			$	4,014
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes stock options outstanding and exercisable at December 28, 2014:
	(Shares in Thousands)		Outstanding							Exercisable
	Exercise Price Range		Options			Average Life(1)		Average Exercise Price		Options		Average Exercise Price
	$52.13-$58.33		10,182			4.1		$58.32		10,182		$58.32
	$58.34-$62.20		24,179			3.1		$60.68		23,653		$60.64
	$62.62-$65.62		25,630			4.4		$64.60		18,346		$64.30
	$65.80-$72.54		32,252			6.6		$71.43		5,661		$66.20
	$90.44-$100.48		23,469			9.1		$90.44		4		$90.44
			115,712			5.7		$70.37		57,846		$61.94
	(1) Average contractual life remaining in years.
Schedule Of Share Based Compensation Other Than Stock Options Activity [Table Text Block]	A summary of the restricted share units and performance share units activity under the Plans as of December 28, 2014 is presented below:
	(Shares in Thousands)		Outstanding Restricted Share Units			Outstanding Performance Share Units
	Shares at January 1, 2012		31,026
	Granted		12,197			327
	Issued		(9,278	)		—
	Canceled/forfeited		(2,111	)		(42	)
	Shares at December 30, 2012		31,834			285
	Granted		10,582			1,290
	Issued		(10,078	)		—
	Canceled/forfeited		(1,721	)		(40	)
	Shares at December 29, 2013		30,617			1,535
	Granted		8,487			1,113
	Issued		(9,685	)		(19	)
	Canceled/forfeited		(1,726	)		(98	)
	Shares at December 28, 2014		27,693			2,531

Segments_of_Business_and_Geogr1

Segments of Business and Geographic Areas (Tables)	12 Months Ended
	Dec. 28, 2014
Segment Reporting [Abstract]
Operating profit by segment of business
			Sales to Customers
	(Dollars in Millions)		2014		2013	2012
	Consumer —
	United States		$	5,096	5,162	5,046
	International		9,400		9,535	9,401
	Total		14,496		14,697	14,447
	Pharmaceutical —
	United States		17,432		13,948	12,421
	International		14,881		14,177	12,930
	Total		32,313		28,125	25,351
	Medical Devices —
	United States		12,254		12,800	12,363
	International		15,268		15,690	15,063
	Total		27,522		28,490	27,426
	Worldwide total		$	74,331	71,312	67,224
			Pre-Tax Profit				Identifiable Assets
	(Dollars in Millions)		2014 (3)		2013 (4)	2012 (5)	2014		2013	2012
	Consumer		$	1,941	1,973	1,693	$	21,813	23,711	24,131
	Pharmaceutical		11,696		9,178	6,075	25,803		23,783	23,219
	Medical Devices		7,953		5,261	7,187	41,445		44,585	42,926
	Total		21,590		16,412	14,955	89,061		92,079	90,276
	Less: Expense not allocated to segments (1)		1,027		941	1,180
	General corporate (2)						42,058		40,604	31,071
	Worldwide total		$	20,563	15,471	13,775	$	131,119	132,683	121,347
			Additions to Property,				Depreciation and
			Plant & Equipment				Amortization
	(Dollars in Millions)		2014		2013	2012	2014		2013	2012
	Consumer		$	581	533	468	$	577	539	575
	Pharmaceutical		977		856	737	1,053		1,075	1,010
	Medical Devices		1,807		1,724	1,230	1,974		2,224	1,857
	Segments total		3,365		3,113	2,435	3,604		3,838	3,442
	General corporate		349		482	499	291		266	224
	Worldwide total		$	3,714	3,595	2,934	$	3,895	4,104	3,666
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
			Sales to Customers				Long-Lived Assets (6)
	(Dollars in Millions)		2014		2013	2012	2014		2013	2012
	United States		$	34,782	31,910	29,830	$	36,835	35,880	35,115
	Europe		18,947		18,599	16,945	21,559		24,868	25,261
	Western Hemisphere excluding U.S.		7,160		7,421	7,207	3,210		3,281	3,636
	Asia-Pacific, Africa		13,442		13,382	13,242	2,438		2,434	2,362
	Segments total		74,331		71,312	67,224	64,042		66,463	66,374
	General corporate						1,138		992	899
	Other non long-lived assets						65,939		65,228	54,074
	Worldwide total		$	74,331	71,312	67,224	$	131,119	132,683	121,347
	­
	See Note 1 for a description of the segments in which the Company operates.
	Export sales are not significant. In 2014, the Company had one wholesaler distributing products for all three segments that represented approximately 11.0% of the total consolidated revenues. In 2013 and 2012, the Company did not have a customer that represented 10.0% of total revenues.
	(1)	Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes currency related expense of $0.2 billion associated with the acquisition of Synthes, Inc. in 2012.
	(2)	General corporate includes cash, cash equivalents and marketable securities.
	(3)	Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. Includes an additional year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.
	(4)	Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
	(5)	Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments, respectively. The Medical Devices segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.
	(6)	Long-lived assets include property, plant and equipment, net for 2014, 2013 and 2012 of $16,126, $16,710 and $16,097, respectively, and intangible assets and goodwill, net for 2014, 2013 and 2012 of $49,054, $50,745 and $51,176, respectively.

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 28, 2014
Selected Quarterly Financial Information [Abstract]
Summary of Selected Quarterly Financial Data (unaudited)	Selected unaudited quarterly financial data for the years 2014 and 2013 are summarized below:
			2014					2013
	(Dollars in Millions Except Per Share Data)		First Quarter (1)		Second Quarter (2)	Third Quarter (3)	Fourth Quarter (4)	First Quarter (5)	Second Quarter (6)	Third Quarter (7)	Fourth Quarter (8)
	Segment sales to customers
	Consumer		$	3,557	3,744	3,589	3,606	3,675	3,658	3,611	3,753
	Pharmaceutical		7,498		8,509	8,307	7,999	6,768	7,025	7,036	7,296
	Medical Devices		7,060		7,242	6,571	6,649	7,062	7,194	6,928	7,306
	Total sales		18,115		19,495	18,467	18,254	17,505	17,877	17,575	18,355
	Gross profit		12,660		13,456	13,068	12,401	11,951	12,388	12,231	12,400
	Earnings before provision for taxes on income		5,424		5,626	6,810	2,703	4,261	4,793	3,667	2,750
	Net earnings attributable to Johnson & Johnson		4,727		4,326	4,749	2,521	3,497	3,833	2,982	3,519
	Basic net earnings per share attributable to Johnson & Johnson		$	1.67	1.53	1.69	0.9	1.25	1.36	1.06	1.25
	Diluted net earnings per share attributable to Johnson & Johnson		$	1.64	1.51	1.66	0.89	1.22	1.33	1.04	1.23
	-1	The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.
	(2)	The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
	(3)	The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
	(4)	The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
	(5)	The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).
	(6)	The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).
	(7)	The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.
	(8)	The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASR™ Hip program and a $707 million tax benefit associated with Scios Inc.

Business_Combinations_and_Dive1

Business Combinations and Divestitures (Tables)	12 Months Ended
	Dec. 28, 2014
Business Combinations [Abstract]
Business Acquisition, Schedule of Consideration Transferred [Table Text Block]	The following table summarizes the consideration transferred to acquire Synthes, Inc. valued on the acquisition date of June 14, 2012:
	(Dollars in Millions)
	Cash (multiply 55.65CHF by shares of Synthes common stock outstanding by the exchange rate)(A)		$	6,902
	Common Stock (multiply 1.717 by shares of Synthes common stock outstanding by J&J stock price)(B)		$	13,335
	Total fair value of consideration transferred		$	20,237
	(A) Synthes common stock outstanding of 118.7 million shares as of the acquisition date and CHF/USD exchange rate of .95674
	(B) Johnson & Johnson closing stock price on the New York Stock Exchange as of acquisition date of $65.45 per share.
Business Acquisition, Pro Forma Information [Table Text Block]	The following table provides pro forma results of operations for the fiscal year ended December 30, 2012, as if Synthes, Inc. had been acquired as of the beginning of the period presented. The pro forma results include the effect of divestitures and certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the integration of Synthes, Inc. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future.
		Unaudited Pro forma consolidated results
	(Dollars in Millions Except Per Share Amounts)	2012
	Net Sales	$	68,894
	Net Earnings attributable to Johnson & Johnson	$	11,564
	Diluted Net Earnings per share attributable to Johnson & Johnson	$	4.11

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 28, 2014
Minimum [Member] | Building and building equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Minimum [Member] | Land And Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	10 years
Minimum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	2 years
Maximum [Member] | Building and building equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	30 years
Maximum [Member] | Land And Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	13 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textuals) (USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
	Employee
	Segment
Concentration of Credit Risk [Line Items]
Number Of Employees Engaged In Company Activities Worldwide	126,500
Number Of Business Segments	3
Sales Return Reserve as a Percent to Sales	1.00%	1.00%
Shipping, Handling and Transportation Costs	$1,068,000,000	$1,128,000,000	$1,051,000,000
Revenue From Shipping And Handling As Percentage Of Sales	less than 0.5%
Advertising Expense	2,600,000,000	2,500,000,000	2,300,000,000
Cumulative Amount Of Undistributed International Earnings	53,400,000,000	50,900,000,000
Cash and Cash Equivalents, at Carrying Value	14,523,000,000	20,927,000,000	14,911,000,000	24,542,000,000
Fiscal Year	52 weeks, but every five or six years the fiscal year consists of 53 weeks
Southern European Region [Member]
Concentration of Credit Risk [Line Items]
Accounts Receivable, Net	1,800,000,000	2,300,000,000
Consumer Vision Care Diabetes Care And Certain Pharmaceutical And Medical Devices And Diagnostic Customers [Member] | Southern European Region [Member]
Concentration of Credit Risk [Line Items]
Accounts Receivable, Net	1,100,000,000	1,300,000,000
Certain Distributors Of Pharmaceutical And Medical Devices And Diagnostic [Member] | Southern European Region [Member]
Concentration of Credit Risk [Line Items]
Accounts Receivable, Net	700,000,000	1,000,000,000
International [Member]
Concentration of Credit Risk [Line Items]
Cash and Cash Equivalents, at Carrying Value	$14,300,000,000	$18,600,000,000
Minimum [Member] | Software Development [Member]
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets	3 years
Maximum [Member] | Software Development [Member]
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets	8 years

Cash_Cash_Equivalents_and_Curr2

Cash, Cash Equivalents and Current Marketable Securities (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash	$2,336	$2,789
Government securities and obligations	20,610	7,632
Reverse repurchase agreements	6,735	15,006
Corporate debt securities	1,343	1,467
Money market funds	1,352	1,886
Time deposits	713	426
Total cash, cash equivalents and current marketable securities	$33,089	$29,206

Cash_Cash_Equivalents_and_Curr3

Cash, Cash Equivalents and Current Marketable Securities (Details Textual) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Cash Cash Equivalents and Current Marketable Securities [Line Items]
Available-for-sale Securities, Current	$18,566	$8,279
Debt Securities [Member]
Cash Cash Equivalents and Current Marketable Securities [Line Items]
Available-for-sale Securities, Current	17,682	6,160
Repurchase Agreements [Member]
Cash Cash Equivalents and Current Marketable Securities [Line Items]
Available-for-sale Securities, Current		1,100
Corporate Debt Securities [Member]
Cash Cash Equivalents and Current Marketable Securities [Line Items]
Available-for-sale Securities, Current	$884	$1,019

Inventories_Details

Inventories (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Summary of Inventories
Raw materials and supplies	$1,214	$1,224
Goods in process	2,461	2,612
Finished goods	4,509	4,042
Total inventories	$8,184	$7,878

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Property, Plant and Equipment, Net [Abstract]
Land and land improvements	$833	$885
Buildings and building equipment	10,046	10,423
Machinery and equipment	22,206	22,527
Construction in progress	3,600	3,298
Total property, plant and equipment, gross	36,685	37,133
Less accumulated depreciation	20,559	20,423
Total property, plant and equipment, net	$16,126	$16,710

Property_Plant_and_Equipment_D1

Property, Plant and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Property Plant And Equipment (Textual) [Abstract]
Interest expense capitalized	$115,000,000	$105,000,000	$115,000,000
Depreciation expense, including the amortization of capitalized interest	$2,500,000,000	$2,700,000,000	$2,500,000,000

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$10,105	$8,774
Total intangible assets - net	27,222	27,947
Trademarks [Member]
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	7,263	7,619
Purchased In-Process Research And Development [Member]
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	2,842	1,155
Patents And Trademarks [Member]
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	9,074	9,164
Less accumulated amortization	4,700	4,146
Finite-Lived Intangible Assets, Net	4,374	5,018
Customer relationships and other intangible assets [Member]
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	17,970	19,027
Less accumulated amortization	5,227	4,872
Finite-Lived Intangible Assets, Net	$12,743	$14,155

Intangible_Assets_and_Goodwill3

Intangible Assets and Goodwill Goodwill By Segment (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013
Goodwill [Roll Forward]
Goodwill Beginning of Period	$22,798	$22,424
Goodwill, related to acquisitions	678	338
Goodwill, Written off Related to Sale of Business Unit	-741	-71
Currency translation/Other	-903	107
Goodwill End of Period	21,832	22,798
Consumer [Member]
Goodwill [Roll Forward]
Goodwill Beginning of Period	8,531	8,519
Goodwill, related to acquisitions	13	83
Goodwill, Written off Related to Sale of Business Unit	-138	-71
Currency translation/Other	-731	0
Goodwill End of Period	7,675	8,531
Pharmaceutical [Member]
Goodwill [Roll Forward]
Goodwill Beginning of Period	2,068	1,792
Goodwill, related to acquisitions	665	246
Goodwill, Written off Related to Sale of Business Unit	0	0
Currency translation/Other	-107	30
Goodwill End of Period	2,626	2,068
Medical Devices [Member]
Goodwill [Roll Forward]
Goodwill Beginning of Period	12,199	12,113
Goodwill, related to acquisitions	0	9
Goodwill, Written off Related to Sale of Business Unit	-603	0
Currency translation/Other	-65	77
Goodwill End of Period	$11,531	$12,199

Intangible_Assets_and_Goodwill4

Intangible Assets and Goodwill (Details Textuals) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	$1,398	$1,363	$1,146
Estimated amortization expense per year	$1,300
Patents And Trademarks [Member]
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	17 years
Customer relationships and other intangible assets [Member]
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	24 years

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Designated as Hedging Instrument [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014		Dec. 29, 2013
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	$92	[1]	$344	[1]
Gain/ (Loss) reclassified from Accumulated OCI into income	196	[1]	107	[1]
Gain/ (Loss) recognized in Other income/expense	-3	[2]	17	[2]
Foreign exchange contracts [Member] | Sales to customers [Member]
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	-106	[1],[3]	45	[1],[3]
Gain/ (Loss) reclassified from Accumulated OCI into income	-3	[1],[3]	49	[1],[3]
Gain/ (Loss) recognized in Other income/expense	-5	[2],[3]	2	[2],[3]
Foreign exchange contracts [Member] | Cost of products sold [Member]
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	58	[1],[3]	271	[1],[3]
Gain/ (Loss) reclassified from Accumulated OCI into income	204	[1],[3]	69	[1],[3]
Gain/ (Loss) recognized in Other income/expense	2	[2],[3]	23	[2],[3]
Foreign exchange contracts [Member] | Research and development expense [Member]
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	39	[1],[3]	24	[1],[3]
Gain/ (Loss) reclassified from Accumulated OCI into income	7	[1],[3]	16	[1],[3]
Gain/ (Loss) recognized in Other income/expense	0	[2],[3]	-4	[2],[3]
Foreign exchange contracts [Member] | Other Income Expense Net [Member]
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	80	[1],[3]	-13	[1],[3]
Gain/ (Loss) reclassified from Accumulated OCI into income	3	[1],[3]	-17	[1],[3]
Gain/ (Loss) recognized in Other income/expense	0	[2],[3]	-4	[2],[3]
Cross currency interest rate swaps [Member] | Interest (income)/Interest expense, net [Member]
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	21	[1],[4]	17	[1],[4]
Gain/ (Loss) reclassified from Accumulated OCI into income	-15	[1],[4]	-10	[1],[4]
Gain/ (Loss) recognized in Other income/expense	$0	[2],[4]	$0	[2],[4]
[1]	Effective portion
[2]	Ineffective portion
[3]	Forward foreign exchange contracts
[4]	Cross currency interest rate swaps

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	Dec. 28, 2014		Dec. 29, 2013
In Millions, unless otherwise specified
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$1,027
Derivatives designated as hedging instruments : Liabilities	759
Equity method investments, fair market disclosure	679	[1]
Quoted prices in active markets for identical assets and liabilities Level 1 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Equity method investments, fair market disclosure	679	[1]	333	[1],[2]
Significant other observable inputs Level 2 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,027		706	[2]
Derivatives designated as hedging instruments : Liabilities	759		159	[2]
Equity method investments, fair market disclosure	0
Significant unobservable inputs Level 3 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Equity method investments, fair market disclosure	0
Interest Rate Contract [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	31	[3]
Derivatives designated as hedging instruments : Liabilities	8	[4],[5]
Derivative Assets, Noncurrent	29		169
Derivative Liabilities, Noncurrent	8		19
Interest Rate Contract [Member] | Quoted prices in active markets for identical assets and liabilities Level 1 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract [Member] | Significant other observable inputs Level 2 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	31	[3]	169	[2],[3]
Derivatives designated as hedging instruments : Liabilities	8	[4],[5]	26	[2],[4],[5]
Interest Rate Contract [Member] | Significant unobservable inputs Level 3 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Foreign exchange contracts [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	996
Derivatives designated as hedging instruments : Liabilities	751
Derivatives not designated as hedging instruments : Assets	29
Derivatives not designated as hedging instruments : Liabilities	51
Foreign exchange contracts [Member] | Quoted prices in active markets for identical assets and liabilities Level 1 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Foreign exchange contracts [Member] | Significant other observable inputs Level 2 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	996		537	[2]
Derivatives designated as hedging instruments : Liabilities	751		133	[2]
Derivatives not designated as hedging instruments : Assets	29		25	[2]
Derivatives not designated as hedging instruments : Liabilities	51		29	[2]
Foreign exchange contracts [Member] | Significant unobservable inputs Level 3 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Interest Rate Swap [Member] | Quoted prices in active markets for identical assets and liabilities Level 1 [Member]
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$0
[1]	Classified as non-current other assets.
[2]	2013 assets and liabilities are all classified as Level 2 with the exception of Other investments of $333 million, which are classified as Level 1.
[3]	Includes $29 million and $169 million of non-current assets for the fiscal years ending December 28, 2014 and December 29, 2013, respectively.
[4]	Includes cross currency interest rate swaps and interest rate swaps.
[5]	Includes $8 million and $19 million of non-current liabilities for the fiscal years ending December 28, 2014 and December 29, 2013, respectively.

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details Textuals) (USD $)	12 Months Ended
	Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012	Jan. 01, 2012
Derivative [Line Items]
Maximum Length of Time Hedged in Foreign Currency Cash Flow Hedge	18 months
Fair Value Measurements (Textuals)
Deferred net gains on derivatives included in accumulated other comprehensive income	$141,000,000		$245,000,000		$8,000,000	($168,000,000)
Reclassification of foreign exchange contracts into earnings, period	next 12 months
Other income/(expense), net, related to foreign exchange contracts, non hedging	5,000,000		32,000,000
Other investments	679,000,000	[1]
Interest Rate Contract [Member]
Derivative [Line Items]
Derivative, notional amount	2,200,000,000
Non-current assets included in interest rate contracts	29,000,000		169,000,000
Non-current liabilities included in interest rate contracts	8,000,000		19,000,000
Foreign exchange contracts [Member]
Derivative [Line Items]
Derivative, notional amount	29,600,000,000
Cross currency interest rate swaps [Member]
Derivative [Line Items]
Derivative, notional amount	2,400,000,000
Fair Value, Inputs, Level 1 [Member]
Fair Value Measurements (Textuals)
Other investments	$679,000,000	[1]	$333,000,000	[1],[2]
[1]	Classified as non-current other assets.
[2]	2013 assets and liabilities are all classified as Level 2 with the exception of Other investments of $333 million, which are classified as Level 1.

Borrowings_Details

Borrowings (Details) (USD $)	Dec. 28, 2014		Dec. 29, 2013
In Millions, unless otherwise specified
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	$15,122		$13,328
Debt Instrument, Interest Rate, Effective Percentage	4.08%	[1]	4.00%	[1]
3 month LIBOR0.09% FRN due 2014
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	0		750
Debt Instrument, Interest Rate, Effective Percentage	0.00%		0.33%
1.20% Notes due 2014
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	0		999
Debt Instrument, Interest Rate, Effective Percentage	0.00%		1.24%
2.15% Notes due 2016
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	898		898
Debt Instrument, Interest Rate, Effective Percentage	2.22%		2.22%
3 month LIBOR0.07% FRN due 2016
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	800		800
Debt Instrument, Interest Rate, Effective Percentage	0.31%		0.31%
0.70% Notes due 2016
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	398		397
Debt Instrument, Interest Rate, Effective Percentage	0.74%		0.74%
5.55% Debentures due 2017
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	1,000		1,000
Debt Instrument, Interest Rate, Effective Percentage	5.55%		5.55%
1.125% Notes due 2017
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	697		0
Debt Instrument, Interest Rate, Effective Percentage	1.15%		0.00%
5.15% Debentures due 2018
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	898		898
Debt Instrument, Interest Rate, Effective Percentage	5.15%		5.15%
1.65% Notes due 2018
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	597		589
Debt Instrument, Interest Rate, Effective Percentage	1.70%		1.70%
4.75% Notes due 2019 (1B Euro 1.2199)(2)/ (1B Euro 1.3683)(3)
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	1,216	[2]	1,363	[3]
Debt Instrument, Interest Rate, Effective Percentage	5.83%		5.83%
1.875% Notes due 2019
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	497		0
Debt Instrument, Interest Rate, Effective Percentage	1.93%		0.00%
3% Zero Coupon Convertible Subordinated Debentures due 2020
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	158		179
Debt Instrument, Interest Rate, Effective Percentage	3.00%		3.00%
2.95% Debentures due 2020
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	543		542
Debt Instrument, Interest Rate, Effective Percentage	3.15%		3.15%
3.55% Notes due 2021
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	446		446
Debt Instrument, Interest Rate, Effective Percentage	3.67%		3.67%
2.45% Notes due 2021
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	349		0
Debt Instrument, Interest Rate, Effective Percentage	2.48%		0.00%
6.73% Debentures due 2023
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	250		250
Debt Instrument, Interest Rate, Effective Percentage	6.73%		6.73%
3.375% Notes due 2023
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	812	[4]	550
Debt Instrument, Interest Rate, Effective Percentage	3.17%		3.38%
5.50% Notes due 2024 (500MM GBP 1.5542)(2)/(500MM GBP 1.6414)(3)
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	772	[2]	816	[3]
Debt Instrument, Interest Rate, Effective Percentage	6.75%		6.75%
6.95% Notes due 2029
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	297		296
Debt Instrument, Interest Rate, Effective Percentage	7.14%		7.14%
4.95% Debentures due 2033
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	500		500
Debt Instrument, Interest Rate, Effective Percentage	4.95%		4.95%
4.375% Notes due 2033
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	865	[4]	646
Debt Instrument, Interest Rate, Effective Percentage	4.23%		4.42%
5.95% Notes due 2037
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	995		995
Debt Instrument, Interest Rate, Effective Percentage	5.99%		5.99%
5.85% Debentures due 2038
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	700		700
Debt Instrument, Interest Rate, Effective Percentage	5.86%		5.86%
4.50% Debentures due 2040
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	539		539
Debt Instrument, Interest Rate, Effective Percentage	4.63%		4.63%
4.85% Notes due 2041
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	298		298
Debt Instrument, Interest Rate, Effective Percentage	4.89%		4.89%
4.50% Notes due 2043
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	499		499
Debt Instrument, Interest Rate, Effective Percentage	4.52%		4.52%
Other
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	105		147
Debt Instrument, Interest Rate, Effective Percentage	0.00%		0.00%
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	15,122		13,328
Long-term Debt, Current Maturities	7		1,769
Long-term Debt	$15,129	[5]	$15,097	[5]
[1]	Weighted average effective rate.
[2]	Translation rate at December 28, 2014.
[3]	Translation rate at December 29, 2013.
[4]	Includes the reopening of these issues.
[5]	The excess of the fair value over the carrying value of debt was $2.2 billion in 2014 and $1.4 billion in 2013.

Borrowings_Details_1

Borrowings (Details 1) (USD $)	Dec. 28, 2014
In Millions, unless otherwise specified
Aggregate maturities of long-term obligations
2015	$7
2016	2,152
2017	1,722
2018	1,496
2019	1,713
After 2019	$8,039

Borrowings_Details_Textual

Borrowings (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Dec. 28, 2014	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Borrowings (Textual) [Abstract]
Excess of fair value over carrying value of debt		$2,200,000,000	$1,400,000,000
Initiation date of credit facility		18-Sep-14
Borrowing capacity under credit facility	10,000,000,000	10,000,000,000
Expiration date of credit facility		17-Sep-15
Short-term borrowings and the current portion of long-term debt	3,600,000,000	3,600,000,000
Borrowed under the commercial paper program	3,100,000,000	3,100,000,000
Proceeds from Issuance of Long-term Debt	$2,000,000,000	$2,098,000,000	$3,607,000,000	$45,000,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Currently payable:
U.S. taxes	$2,625	$594	$2,023
International taxes	1,174	1,653	1,277
Total currently payable	3,799	2,247	3,300
Deferred:
U.S. taxes	-258	-251	-120
International taxes	699	-356	81
Total deferred	441	-607	-39
Provision for taxes on income	$4,240	$1,640	$3,261

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	3 Months Ended																12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014		Sep. 28, 2014		Jun. 29, 2014		Mar. 30, 2014		Dec. 29, 2013		Sep. 29, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012
Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract
U.S.																	$8,001		$4,261		$4,664
International																	12,562		11,210		9,111
Earnings before provision for taxes on income	$2,703	[1]	$6,810	[2]	$5,626	[3]	$5,424	[4]	$2,750	[5]	$3,667	[6]	$4,793	[7]	$4,261	[8]	$20,563	[9]	$15,471	[10]	$13,775	[11]
Tax Rates:
U.S. statutory rate																	35.00%		35.00%		35.00%
International operations excluding Ireland																	-7.00%		-10.60%		-9.80%
Ireland and Puerto Rico operations																	-6.90%		-9.00%		-3.90%
Research and orphan drug tax credits																	-0.30%		-0.80%		0.00%
U.S. state and local																	1.00%		0.40%		1.30%
U.S. manufacturing deduction																	-0.60%		-0.80%		-0.90%
U.S. tax on international income																	1.40%		1.70%		1.10%
U.S. tax benefit on asset/business disposals																	-1.90%		-5.10%		0.00%
All other																	-0.10%		-0.20%		0.90%
Effective tax rate																	20.60%		10.60%		23.70%
[1]	The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
[2]	The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
[3]	The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
[4]	The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.
[5]	The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASRâ„¢ Hip program and a $707 million tax benefit associated with Scios Inc.
[6]	The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.
[7]	The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).
[8]	The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).
[9]	Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. Includes an additional year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.
[10]	Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
[11]	Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments, respectively. The Medical Devices segment also includes $110 million expense for the cost associated with the DePuy ASRâ„¢ Hip program.

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 28, 2014		Dec. 29, 2013
In Millions, unless otherwise specified
Components of Deferred Tax Assets and Liabilities [Abstract]
Deferred Tax Assets, Employee related obligations	$3,426		$1,908
Deferred Tax Assets, Stock based compensation	799		1,121
Deferred Tax Assets, International R&D capitalized for tax	1,433		1,656
Deferred Tax Assets, Reserves & liabilities	1,497		1,587
Deferred Tax Assets, Income reported for tax purposes	1,067		1,043
Deferred Tax Assets, Net operating loss carryforward international	949		1,090
Deferred Tax Assets, Miscellaneous international	1,128	[1]	1,508	[1]
Deferred Tax Assets, Valuation Allowance	172		187
Deferred Tax Assets, Total deferred income taxes	11,295		10,840
Deferred Tax Liabilities, Depreciation	-564		-772
Deferred Tax Liabilities, Non-deductible intangibles	-6,671		-6,250
Deferred Tax Liabilities, Miscellaneous international	-305		-361
Deferred Tax Assets Other Domestic	996		927
Deferred Tax Liabilities, Total deferred income taxes	($7,540)		($7,383)
[1]	The $1,128 million in 2014 was net of a valuation allowance related to Belgium of $172 million. The $1,508 million in 2013 was net of a valuation allowance related to Belgium of $187 million.

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Summary of unrecognized tax benefits
Beginning of year	$2,729	$3,054	$2,699
Increases related to current year tax positions	281	643	538
Increases related to prior period tax positions	295	80	57
Decreases related to prior period tax positions	-288	-574	-41
Settlements	-477	-418	-120
Lapse of statute of limitations	-75	-56	-79
End of year	$2,465	$2,729	$3,054

Income_Taxes_Details_Textuals

Income Taxes (Details Textuals) (USD $)	3 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Mar. 30, 2014	Dec. 29, 2013		Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012	Jan. 01, 2012
Tax Credit Carryforward [Line Items]
U.S. statutory rate				35.00%		35.00%		35.00%
Other Tax Benefit	($398)	($707)		($400)
Deferred Tax Assets, Other		1,508	[1]	1,128	[1]	1,508	[1]
Deferred Tax Assets, Valuation Allowance		187		172		187
Unrecognized tax benefits		2,729		2,465		2,729		3,054	2,699
Unrecognized Tax Benefits, Interest on Income Taxes Expense				12		40		41
Unrecognized Tax Benefits, Interest on Income Taxes Accrued		$412		$298		$412
OCD [Member]
Tax Credit Carryforward [Line Items]
U.S. statutory rate				44.00%
[1]	The $1,128 million in 2014 was net of a valuation allowance related to Belgium of $172 million. The $1,508 million in 2013 was net of a valuation allowance related to Belgium of $187 million.

Employee_Related_Obligations_D

Employee Related Obligations (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Employee-related Liabilities [Abstract]
Pension benefits	$4,547	$2,950
Postretirement benefits	3,161	2,655
Postemployment benefits	2,062	1,872
Deferred compensation	599	693
Total employee obligations	10,369	8,170
Less current benefits payable	397	386
Employee related obligations — non-current	$9,972	$7,784

Employee_Related_Obligations_D1

Employee Related Obligations (Details Textual) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Employee Related Obligations (Textual) [Abstract]
Prepaid employee related obligation	$233	$2,363

Pensions_and_Other_Postretirem1

Pensions and Other Postretirement Benefits (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Retirement Plans [Member]
Components of net periodic benefit cost
Service cost	$882	$906	$722
Interest cost	1,018	908	878
Expected return on plan assets	-1,607	-1,447	-1,236
Amortization of prior service cost (credit)	6	6	6
Amortization of net transition obligation	1	1	1
Recognized actuarial losses	460	681	494
Curtailments and settlements	-17	0	0
Net periodic benefit cost	743	1,055	865
Other Benefit Plans [Member]
Components of net periodic benefit cost
Service cost	211	196	175
Interest cost	197	151	165
Expected return on plan assets	-7	-6	-4
Amortization of prior service cost (credit)	-34	-2	-3
Amortization of net transition obligation	0	0	0
Recognized actuarial losses	136	111	76
Curtailments and settlements	0	2	0
Net periodic benefit cost	$503	$452	$409

Pensions_and_Other_Benefit_Pla1

Pensions and Other Benefit Plans (Details 1) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014
Pension and Other Postretirement Benefit Plans, Amounts that Will be Amortized from Accumulated Other Comprehensive Income (Loss) in Next Fiscal Year [Abstract]
Amortization of net transition obligation	$0
Amortization of net actuarial losses	944
Amortization of prior service credit	$33

Pensions_and_Other_Benefit_Pla2

Pensions and Other Benefit Plans (Details 2)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Retirement Plans [Member]
Rates used to develop the actuarial present value of projected benefit obligation
Discount rate	3.78%	4.78%	4.25%
Expected long-term rate of return on plan assets	8.53%	8.46%	8.45%
Rate of increase in compensation levels	4.05%	4.08%	4.08%
Other Benefit Plans [Member]
Rates used to develop the actuarial present value of projected benefit obligation
Discount rate	4.31%	5.25%	4.55%
Rate of increase in compensation levels	4.11%	4.29%	4.28%

Pensions_and_Other_Benefit_Pla3

Pensions and Other Benefit Plans (Details 3)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013
Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]
Health care cost trend rate assumed for next year	6.00%	6.50%
Rate to which the cost trend rate is assumed to decline (ultimate trend)	4.50%	4.50%
Year the rate reaches the ultimate trend rate	2032	2032

Pensions_and_Other_Benefit_Pla4

Pensions and Other Benefit Plans (Details 4) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014
Effect of one percentage point change in assumed health care cost trend rates
Effect of one percentage point increase on total interest and service cost	$45
Effect of one percentage point decrease on total interest and service cost	-34
Effect of one percentage point increase on post-retirement benefit obligation	560
Effect of one percentage point decrease on post-retirement benefit obligation	($444)

Pensions_and_Other_Benefit_Pla5

Pensions and Other Benefit Plans (Details 5) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Retirement Plans [Member]
Change in Benefit Obligation
Projected benefit obligation - beginning of year	$21,488	$21,829
Service cost	882	906	722
Interest cost	1,018	908	878
Plan participant contributions	59	54
Amendments	-60	35
Actuarial (gains) losses	5,395	-1,432
Divestitures & acquisitions	-121	8
Curtailments, settlements & restructuring	-53	-15
Benefits paid from plan	-813	-751
Effect of exchange rates	-906	-54
Projected benefit obligation - end of year	26,889	21,488	21,829
Other Benefit Plans [Member]
Change in Benefit Obligation
Projected benefit obligation - beginning of year	4,407	4,159
Service cost	211	196	175
Interest cost	197	151	165
Plan participant contributions	0	0
Amendments	-254	7
Actuarial (gains) losses	1,030	296
Divestitures & acquisitions	0	0
Curtailments, settlements & restructuring	0	-11
Benefits paid from plan	-493	-373
Effect of exchange rates	-17	-18
Projected benefit obligation - end of year	$5,081	$4,407	$4,159

Pensions_and_Other_Benefit_Pla6

Pensions and Other Benefit Plans (Details 6) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value - End of year	$22,575	$20,901
Retirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value - beginning of year	20,901	17,536
Actual return on plan assets	2,078	3,573
Company contributions	1,176	565
Plan participant contributions	59	54
Settlements	-40	-4
Divestitures & acquisitions	-109	9
Benefits paid from plan assets	-813	-751
Effect of exchange rates	-677	-81
Plan assets at fair value - End of year	22,575	20,901
Funded status — end of year	-4,314	-587
Other Benefit Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value - beginning of year	87	122
Actual return on plan assets	8	15
Company contributions	477	323
Plan participant contributions	0	0
Settlements	0	0
Divestitures & acquisitions	0	0
Benefits paid from plan assets	-493	-373
Effect of exchange rates	0	0
Plan assets at fair value - End of year	79	87
Funded status — end of year	($5,002)	($4,320)

Pensions_and_Other_Benefit_Pla7

Pensions and Other Benefit Plans (Details 7) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Defined Benefit Plan Disclosure [Line Items]
Current Liabilities	$397	$386
Non-current liabilities	-9,972	-7,784
Retirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Non-current assets	233	2,363
Current Liabilities	-74	-71
Non-current liabilities	-4,473	-2,879
Total recognized in the consolidated balance sheet - end of year	-4,314	-587
Other Benefit Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Non-current assets	0	0
Current Liabilities	-309	-302
Non-current liabilities	-4,693	-4,018
Total recognized in the consolidated balance sheet - end of year	($5,002)	($4,320)

Pensions_and_Other_Benefit_Pla8

Pensions and Other Benefit Plans (Details 8) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Retirement Plans [Member]
Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:
Net actuarial loss	$7,547	$3,344
Prior service cost (credit)	-33	26
Unrecognized net transition obligation	1	2
Total before tax effects	7,515	3,372
Accumulated Benefit Obligations - end of year	23,816	19,203
Other Benefit Plans [Member]
Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:
Net actuarial loss	2,611	1,732
Prior service cost (credit)	-225	-6
Unrecognized net transition obligation	0	0
Total before tax effects	$2,386	$1,726

Pensions_and_Other_Benefit_Pla9

Pensions and Other Benefit Plans (Details 9) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Retirement Plans [Member]
Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income
Net periodic benefit cost	$743	$1,055	$865
Net actuarial loss	4,942	-3,559
Amortization of net actuarial (loss) gain	-460	-681
Prior service cost	-60	34
Amortization of prior service (cost) credit	-6	-13
Effect of exchange rates	-273	-6
Total recognized in other comprehensive income, before tax	4,143	-4,225
Total recognized in net periodic benefit cost and other comprehensive income	4,886	-3,170
Other Benefit Plans [Member]
Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income
Net periodic benefit cost	503	452	409
Net actuarial loss	1,015	248
Amortization of net actuarial (loss) gain	-136	-111
Prior service cost	-253	8
Amortization of prior service (cost) credit	34	0
Effect of exchange rates	0	-6
Total recognized in other comprehensive income, before tax	660	139
Total recognized in net periodic benefit cost and other comprehensive income	$1,163	$591

Recovered_Sheet1

Pensions and Other Benefit Plans (Details 10) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$22,575	$20,901
Unfunded Plans [Member] | International retirement plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected benefit obligation	432	474
Accumulated benefit obligations	373	419
Projected benefit obligation	-432	-474
Accumulated benefit obligation	-373	-419
Funded Plans [Member] | International retirement plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	7,374	6,911
Projected benefit obligation	9,203	7,797
Accumulated benefit obligations	8,205	6,974
Projected benefit obligation	-1,829	-886
Accumulated benefit obligation	-831	-63
Non Qualified Plans [Member] | U.S. retirement plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected benefit obligation	1,683	1,296
Accumulated benefit obligations	1,363	1,065
Projected benefit obligation	-1,683	-1,296
Accumulated benefit obligation	-1,363	-1,065
Qualified Plans [Member] | U.S. retirement plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	15,201	13,990
Projected benefit obligation	15,571	11,921
Accumulated benefit obligations	13,875	10,745
Projected benefit obligation	-370	2,069
Accumulated benefit obligation	$1,326	$3,245

Recovered_Sheet2

Pensions and Other Benefit Plans (Details 11) (USD $)	Dec. 28, 2014
In Millions, unless otherwise specified
Other Benefit Plans [Member]
Defined Benefit Plan, Estimated Future Benefit Payments [Abstract]
Projected future benefit payments, 2014	$316
Projected future benefit payments, 2015	309
Projected future benefit payments, 2016	306
Projected future benefit payments, 2017	303
Projected future benefit payments, 2018	300
Projected future benefit payments, 2019-2023	1,475
Retirement Plans [Member]
Defined Benefit Plan, Estimated Future Benefit Payments [Abstract]
Projected future benefit payments, 2014	793
Projected future benefit payments, 2015	813
Projected future benefit payments, 2016	868
Projected future benefit payments, 2017	907
Projected future benefit payments, 2018	963
Projected future benefit payments, 2019-2023	$5,858

Recovered_Sheet3

Pensions and Other Benefit Plans (Details 12) (USD $)	Dec. 28, 2014
In Millions, unless otherwise specified
The projected future minimum contributions to the Company's U.S. and international unfunded retirement plans
Projected future contributions, 2014	$74
Projected future contributions, 2015	75
Projected future contributions, 2016	78
Projected future contributions, 2017	84
Projected future contributions, 2018	89
Projected future contributions, 2019-2023	$531

Recovered_Sheet4

Pensions and Other Benefit Plans (Details 13)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013
Defined Benefit Plan Disclosure [Line Items]
Percent of Asset allocation	100.00%	100.00%
Target Allocation Percent	100.00%
Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Percent of Asset allocation	23.00%	24.00%
Target Allocation Percent	27.00%
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Percent of Asset allocation	77.00%	76.00%
Target Allocation Percent	73.00%

Recovered_Sheet5

Pensions and Other Benefit Plans (Details 14) (USD $)	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
In Millions, unless otherwise specified
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$22,575	$20,901
Short-term investment funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	719	865
Government and agency securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1,934	1,965
Debt instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1,144	1,216
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,225	10,553
Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	7,251	5,890
Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	24	25
Other Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	278	387
Quoted prices in active markets for identical assets and liabilities Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,373	10,834
Quoted prices in active markets for identical assets and liabilities Level 1 [Member] | Short-term investment funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	168	304
Quoted prices in active markets for identical assets and liabilities Level 1 [Member] | Government and agency securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Quoted prices in active markets for identical assets and liabilities Level 1 [Member] | Debt instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Quoted prices in active markets for identical assets and liabilities Level 1 [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,204	10,526
Quoted prices in active markets for identical assets and liabilities Level 1 [Member] | Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Quoted prices in active markets for identical assets and liabilities Level 1 [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Quoted prices in active markets for identical assets and liabilities Level 1 [Member] | Other Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1	4
Significant other observable inputs Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,068	9,926
Significant other observable inputs Level 2 [Member] | Short-term investment funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	551	561
Significant other observable inputs Level 2 [Member] | Government and agency securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1,934	1,965
Significant other observable inputs Level 2 [Member] | Debt instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1,143	1,215
Significant other observable inputs Level 2 [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	21	23
Significant other observable inputs Level 2 [Member] | Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	7,205	5,846
Significant other observable inputs Level 2 [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	2
Significant other observable inputs Level 2 [Member] | Other Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	214	314
Significant unobservable inputs Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	134	141	150
Significant unobservable inputs Level 3 [Member] | Short-term investment funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Significant unobservable inputs Level 3 [Member] | Government and agency securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Significant unobservable inputs Level 3 [Member] | Debt instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	1	1	3
Significant unobservable inputs Level 3 [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	4	4
Significant unobservable inputs Level 3 [Member] | Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	46	44	50
Significant unobservable inputs Level 3 [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	24	23	24
Significant unobservable inputs Level 3 [Member] | Other Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$63	$69	$69

Recovered_Sheet6

Pensions and Other Benefit Plans (Details 15) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013
Change in Plan Asstes
Plan assets at fair value - End of year	$22,575	$20,901
Debt Securities [Member]
Change in Plan Asstes
Plan assets at fair value - End of year	1,144	1,216
Equity Securities [Member]
Change in Plan Asstes
Plan assets at fair value - End of year	11,225	10,553
Commingled Funds [Member]
Change in Plan Asstes
Plan assets at fair value - End of year	7,251	5,890
Insurance Contracts [Member]
Change in Plan Asstes
Plan assets at fair value - End of year	24	25
Other Assets [Member]
Change in Plan Asstes
Plan assets at fair value - End of year	278	387
Fair Value, Inputs, Level 3 [Member]
Change in Plan Asstes
Plan assets at fair value - beginning of year	141	150
Realized gains (losses)	-5	-5
Unrealized gains (losses)	2	-2
Purchases, sales, issuances and settlements, net	0	-2
Transfers in/out and exchange rate changes	-4
Plan assets at fair value - End of year	134	141
Fair Value, Inputs, Level 3 [Member] | Debt Securities [Member]
Change in Plan Asstes
Plan assets at fair value - beginning of year	1	3
Realized gains (losses)	0	0
Unrealized gains (losses)	0	0
Purchases, sales, issuances and settlements, net	0	-2
Transfers in/out and exchange rate changes	0
Plan assets at fair value - End of year	1	1
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member]
Change in Plan Asstes
Plan assets at fair value - beginning of year	4	4
Realized gains (losses)	0	0
Unrealized gains (losses)	0	-1
Purchases, sales, issuances and settlements, net	0	1
Transfers in/out and exchange rate changes	-4
Plan assets at fair value - End of year	0	4
Fair Value, Inputs, Level 3 [Member] | Commingled Funds [Member]
Change in Plan Asstes
Plan assets at fair value - beginning of year	44	50
Realized gains (losses)	0	0
Unrealized gains (losses)	2	0
Purchases, sales, issuances and settlements, net	-2	-6
Transfers in/out and exchange rate changes	2
Plan assets at fair value - End of year	46	44
Fair Value, Inputs, Level 3 [Member] | Insurance Contracts [Member]
Change in Plan Asstes
Plan assets at fair value - beginning of year	23	24
Realized gains (losses)	0	0
Unrealized gains (losses)	0	-1
Purchases, sales, issuances and settlements, net	3	0
Transfers in/out and exchange rate changes	-2
Plan assets at fair value - End of year	24	23
Fair Value, Inputs, Level 3 [Member] | Other Assets [Member]
Change in Plan Asstes
Plan assets at fair value - beginning of year	69	69
Realized gains (losses)	-5	-5
Unrealized gains (losses)	0	0
Purchases, sales, issuances and settlements, net	-1	5
Transfers in/out and exchange rate changes	0
Plan assets at fair value - End of year	$63	$69

Pensions_and_Other_Postretirem2

Pensions and Other Postretirement Benefit (Details Textuals) (USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$22,575,000,000	$20,901,000,000
Pensions and Other Benefit Plans (Textuals)
Percentage of corridor of greater of market value of assets	10.00%
Projected benefit obligation, unfunded plans	9,400,000,000	5,800,000,000
Accumulated benefit obligation unfunded plans	8,200,000,000	5,400,000,000
Plan Assets	5,300,000,000	3,300,000,000
Percent of Asset allocation, Equity securities	100.00%
Fair value of company's common stock directly held in plan assets	778,000,000	671,000,000
Percentage of company's common stock to plan asset	3.40%	3.20%
Defined Benefit Plan, Measurement Date	December 28, 2014	December 29, 2013
U.S. retirement plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	561,000,000
International retirement plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	615,000,000
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	22,575,000,000	20,901,000,000	17,536,000,000
Net periodic benefit cost attributable to other benefit plans	743,000,000	1,055,000,000	865,000,000
Other Benefit Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	79,000,000	87,000,000	122,000,000
Net periodic benefit cost attributable to other benefit plans	503,000,000	452,000,000	409,000,000
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	11,068,000,000	9,926,000,000
Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	7,251,000,000	5,890,000,000
Commingled Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	7,205,000,000	5,846,000,000
Commingled Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Benefit Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	79,000,000	76,000,000
Short-term investment funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	719,000,000	865,000,000
Short-term investment funds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	551,000,000	561,000,000
Short-term investment funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Benefit Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$0	$11,000,000
Minimum [Member] | Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period	3 years
Maximum [Member] | Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period	5 years

Savings_Plan_Details_Textual

Savings Plan (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Savings Plan [Abstract]
Defined Contribution Plan, Cost Recognized	$172	$164	$160

Capital_and_Treasury_Stock_Det

Capital and Treasury Stock (Details) (USD $)	12 Months Ended				3 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012		Jul. 01, 2012
Changes in treasury stock
Treasury Stock, Balance	$15,700	$18,476	$21,659
Treasury Stock, Balance, Shares	299,215	341,354	395,480
Employee compensation and stock option plans, Shares	-32,302	-48,555	-55,170
Employee compensation and stock option plans related to treasury stock	-2,933	-3,367	-3,250
Repurchase of common stock, Shares	69,707	6,416	204,784	[1]
Repurchase of common stock, Amounts	7,124	3,538	12,919	[1]
Treasury Stock, Ending Balance	19,891	15,700	18,476
Treasury Stock, Ending Balance, Shares	336,620	299,215	341,354
Treasury Stock [Member]
Changes in treasury stock
Repurchase of common stock, Amounts	7,124	591	12,919	[1]
Synthes, Inc [Member]
Changes in treasury stock
Stock Issued During Period, Value, Acquisitions	0	0	-13,335
Synthes, Inc [Member] | Treasury Stock [Member]
Changes in treasury stock
Stock Issued During Period, Value, Acquisitions			-12,852
Synthes, Inc [Member]
Changes in treasury stock
Stock Issued During Period, Shares, Acquisitions			-203,740		-203,700
Stock Issued During Period, Value, Acquisitions					($13,335)
[1]	Includes repurchase of common stock associated with the acquisition of Synthes, Inc.

Capital_and_Treasury_Stock_Det1

Capital and Treasury Stock (Details Textual) (USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Equity, Class of Treasury Stock [Line Items]
Aggregate shares of Common Stock issued	3,119,843	3,119,843	3,119,843
Cash Dividend paid per share	$2.76	$2.59	$2.40
Stock Repurchase Program, Authorized Amount	$5,000,000,000
Payments for Repurchase of Common Stock	7,124,000,000	3,538,000,000	12,919,000,000
Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Payments for Repurchase of Common Stock	$3,500,000,000

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Foreign Currency Translation
Beginning Balance	($202)	($296)	($1,526)
Net change	-4,601	94	1,230
Ending Balance	-4,803	-202	-296
Gains/(Losses) on Securities
Beginning Balance	106	195	448
Net change	151	-89	-253
Ending Balance	257	106	195
Employee Benefit Plans
Begining Balance	-3,009	-5,717	-4,386
Net change	-3,308	2,708	-1,331
Ending Balance	-6,317	-3,009	-5,717
Gains/(Losses) on Derivatives & Hedges
Beginning Balance	245	8	-168
Net change	-104	237	176
Ending Balance	141	245	8
Total Accumulated Other Comprehensive Income/(Loss)
Beginning Balance	-2,860	-5,810	-5,632
Net change	-7,862	2,950	-178
Ending Balance	($10,722)	($2,860)	($5,810)

International_Currency_Transla1

International Currency Translation (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Foreign Currency Translation [Abstract]
Compound Cumulative Rates Of Inflation In Highly Inflationary Economies Minimum	100% or more during the past three years
Foreign Currency Transaction Gain (Loss), before Tax	($156)	($186)	($58)

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended																12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 28, 2014		Sep. 28, 2014		Jun. 29, 2014		Mar. 30, 2014		Dec. 29, 2013		Sep. 29, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share attributable to parent	$0.90	[1]	$1.69	[2]	$1.53	[3]	$1.67	[4]	$1.25	[5]	$1.06	[6]	$1.36	[7]	$1.25	[8]	$5.80	$4.92	$3.94
Average shares outstanding - basic																	2,815.20	2,809.20	2,753.30
Potential shares exercisable under stock option plans																	142.6	148.5	164.6
Less: shares which could be repurchased under treasury stock method																	-96.5	-103.3	-128.2
Convertible debt shares																	2.6	3	3.6
Accelerated share repurchase program																	0	19.6	19.3
Average shares outstanding - diluted																	2,863.90	2,877	2,812.60
Diluted net earnings per share attributable to parent	$0.89	[1]	$1.66	[2]	$1.51	[3]	$1.64	[4]	$1.23	[5]	$1.04	[6]	$1.33	[7]	$1.22	[8]	$5.70	$4.81	$3.86
[1]	The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
[2]	The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
[3]	The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
[4]	The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.
[5]	The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASRâ„¢ Hip program and a $707 million tax benefit associated with Scios Inc.
[6]	The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.
[7]	The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).
[8]	The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).

Earnings_Per_Share_Details_Tex

Earnings Per Share (Details Textuals) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Earnings Per Share (Textuals) [Abstract]
Interest on Convertible Debt, Net of Tax	$3	$4	$4
Antidilutive shares excluded from computation of earnings per share	0	0	200,000
Accelerated share repurchase program	0	19,600,000	19,300,000

Rental_Expense_and_Lease_Commi2

Rental Expense and Lease Commitments (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Minimum rental payments under operating leases
2015	$200
2016	157
2017	111
2018	80
2019	66
After 2019	77
Total	691
Rental Expense and Lease Commitments (Textual) [Abstract]
Rentals under operating leases	$341	$363	$375

Common_Stock_Stock_Option_Plan2

Common Stock, Stock Option Plans and Stock Compensation Agreements (Details)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Weighted average assumptions of fair value of options
Risk-free rate	1.87%	1.01%	1.06%
Expected volatility	14.60%	14.04%	18.38%
Expected life	6 years	6 years	6 years
Dividend yield	3.10%	3.40%	3.60%

Common_Stock_Stock_Option_Plan3

Common Stock, Stock Option Plans and Stock Compensation Agreements (Details 1) (USD $)	12 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Summary of option activity under the Plan
Weighted Average Exercise Price, Beginning of Period	$64.70	$61.58	$60.10
Outstanding Shares, Number, Beginning of Period	119,556	134,351	179,459
Options granted under stock-based compensation plans	24,356	29,010	8,661
Options granted, Weighted Average Exercise Price	$90.44	$72.54	$65.36
Options exercised, Outstanding Shares	-25,319	-41,357	-49,388
Options exercised, , Weighted Average Exercise Price	$62.31	$59.99	$56.73
Options canceled/forfeited	-2,881	-2,448	-4,381
Options canceled/forfeited, Weighted Average Exercise Price	$75.48	$65.89	$62.97
Outstanding Shares, Number, End of Period	115,712	119,556	134,351
Weighted Average Exercise Price, End of Period	$70.37	$64.70	$61.58
Aggrerate Intrinsic Value, End of Period	$4,014	$3,306	$1,061	$1,004

Common_Stock_Stock_Option_Plan4

Common Stock, Stock Option Plans and Stock Compensation Agreements (Details 2) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012
Stock options outstanding and exercisable
Outstanding number of Options	115,712		119,556		134,351
Outstanding, Average Life	5 years 8 months 12 days	[1]	5 years 1 month 6 days	[1]	4 years 3 months 18 days	[1]
Outstanding Average Exercise Price	$70.37
Exercisable number of Options	57,846
Exercisable, Average Exercise Price	$61.94
$52.13-$58.33
Stock options outstanding and exercisable
Price Range, Minimum	$52.13
Price Range, Maximum	$58.33
Outstanding number of Options	10,182
Outstanding, Average Life	4 years 1 month 6 days	[1]
Outstanding Average Exercise Price	$58.32
Exercisable number of Options	10,182
Exercisable, Average Exercise Price	$58.32
$58.34-$62.20
Stock options outstanding and exercisable
Price Range, Minimum	$58.34
Price Range, Maximum	$62.20
Outstanding number of Options	24,179
Outstanding, Average Life	3 years 1 month 6 days	[1]
Outstanding Average Exercise Price	$60.68
Exercisable number of Options	23,653
Exercisable, Average Exercise Price	$60.64
$62.62-$65.62
Stock options outstanding and exercisable
Price Range, Minimum	$62.62
Price Range, Maximum	$65.62
Outstanding number of Options	25,630
Outstanding, Average Life	4 years 4 months 24 days	[1]
Outstanding Average Exercise Price	$64.60
Exercisable number of Options	18,346
Exercisable, Average Exercise Price	$64.30
$65.80-$72.54
Stock options outstanding and exercisable
Price Range, Minimum	$65.80
Price Range, Maximum	$72.54
Outstanding number of Options	32,252
Outstanding, Average Life	6 years 7 months 6 days	[1]
Outstanding Average Exercise Price	$71.43
Exercisable number of Options	5,661
Exercisable, Average Exercise Price	$66.20
$90.44-$100.48
Stock options outstanding and exercisable
Price Range, Minimum	$90.44
Price Range, Maximum	$100.48
Outstanding number of Options	23,469
Outstanding, Average Life	9 years 1 month 6 days	[1]
Outstanding Average Exercise Price	$90.44
Exercisable number of Options	4
Exercisable, Average Exercise Price	$90.44
[1]	Average contractual life remaining in years.

Common_Stock_Stock_Option_Plan5

Common Stock, Stock Option Plans and Stock Compensation Agreements (Details 3)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option units vesting period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Shares, Beginning balance	1,535	285
Shares, granted	1,113	1,290	327
Shares, issued	-19	0	0
Shares, canceled/forfieted	-98	-40	-42
Shares, Ending balance	2,531	1,535	285
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Shares, Beginning balance	30,617	31,834	31,026
Shares, granted	8,487	10,582	12,197
Shares, issued	-9,685	-10,078	-9,278
Shares, canceled/forfieted	-1,726	-1,721	-2,111
Shares, Ending balance	27,693	30,617	31,834
Minimum [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option units vesting period	6 months
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option units vesting period	6 months
Maximum [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option units vesting period	3 years
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option units vesting period	3 years

Common_Stock_Stock_Option_Plan6

Common Stock, Stock Option Plans and Stock Compensation Agreements (Details Textual) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012
	StockBasedCompensationPlans
Restricted Share Units (Textual)
Number of stock-based compensation plan	3
Number of shares authorized for issuance under long-term incentive plan	650,000,000
Shares available for future grants under long-term incentive plan	530,000,000
Compensation cost charged for Long term incentive plan	$792		$728		$662
Total income tax benefit recognized	259		243		220
Total compensation cost not yet recognized for option	722		636		565
Weighted average period for total compensation cost not yet recognized	1 year 2 months 5 days		1 year 3 months 4 days		1 year 7 days
Stock options expiration date	10 years
Average fair value of option granted	$8.42		$4.88		$6.39
Total intrinsic value of options exercised	954		941		547
Stock Options Outstanding	115,712,000		119,556,000		134,351,000
Stock Option Average life	5 years 8 months 12 days	[1]	5 years 1 month 6 days	[1]	4 years 3 months 18 days	[1]
Stock options exercisable			75,210,000		104,860,000
Stock options average price			$62.01		$61.15
Restricted Stock Units (RSUs) [Member]
Restricted Share Units (Textual)
Average fair value of RSU's and PSU's granted	$83.01		$65.90		$58.93
Fair Value of restricted share units settled	541		569.2		483.2
Performance Shares [Member]
Restricted Share Units (Textual)
Award vesting period	3 years
Average fair value of RSU's and PSU's granted	$85.94		$73.42		$55.01
Fair Value of restricted share units settled	$1.40
Minimum [Member] | Employee Stock Option [Member]
Restricted Share Units (Textual)
Award vesting period	6 months
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Restricted Share Units (Textual)
Award vesting period	6 months
Minimum [Member] | Performance Shares [Member]
Restricted Share Units (Textual)
Award vesting period	6 months
Maximum [Member] | Employee Stock Option [Member]
Restricted Share Units (Textual)
Award vesting period	4 years
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Restricted Share Units (Textual)
Award vesting period	3 years
Maximum [Member] | Performance Shares [Member]
Restricted Share Units (Textual)
Award vesting period	3 years
[1]	Average contractual life remaining in years.

Segments_of_Business_and_Geogr2

Segments of Business and Geographic Areas (Details) (USD $)

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Sales by segment of business

Total

$18,254

[1]

$18,467

[2]

$19,495

[3]

$18,115

[4]

$18,355

[5]

$17,575

[6]

$17,877

[7]

$17,505

[8]

$74,331

$71,312

$67,224

United States [Member]

Sales by segment of business

Total

34,782

31,910

29,830

Consumer [Member]

Sales by segment of business

Total

14,496

14,697

14,447

Total

3,606

[1]

3,589

[2]

3,744

[3]

3,557

[4]

3,753

[5]

3,611

[6]

3,658

[7]

3,675

[8]

Consumer [Member] | United States [Member]

Sales by segment of business

Total

5,096

5,162

5,046

Consumer [Member] | International [Member]

Sales by segment of business

Total

9,400

9,535

9,401

Pharmaceutical [Member]

Sales by segment of business

Total

32,313

28,125

25,351

Total

7,999

[1]

8,307

[2]

8,509

[3]

7,498

[4]

7,296

[5]

7,036

[6]

7,025

[7]

6,768

[8]

Pharmaceutical [Member] | United States [Member]

Sales by segment of business

Total

17,432

13,948

12,421

Pharmaceutical [Member] | International [Member]

Sales by segment of business

Total

14,881

14,177

12,930

Medical Devices [Member]

Sales by segment of business

Total

27,522

28,490

27,426

Total

6,649

[1]

6,571

[2]

7,242

[3]

7,060

[4]

7,306

[5]

6,928

[6]

7,194

[7]

7,062

[8]

Medical Devices [Member] | United States [Member]

Sales by segment of business

Total

12,254

12,800

12,363

Medical Devices [Member] | International [Member]

Sales by segment of business

Total

$15,268

$15,690

$15,063

[1]

The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.

[2]

The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.

[3]

The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).

[4]

The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.

[5]

The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASRâ„¢ Hip program and a $707 million tax benefit associated with Scios Inc.

[6]

The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.

[7]

The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).

[8]

The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).

Segments_of_Business_and_Geogr3

Segments of Business and Geographic Areas (Details 1) (USD $)

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Segment Reporting Information [Line Items]

Total Segment Operating Income

$21,590

[1]

$16,412

[2]

$14,955

[3]

Less: Expense not allocated to segments

1,027

[1],[4]

941

[2],[4]

1,180

[3],[4]

Earnings before provision for taxes on income

2,703

[5]

6,810

[6]

5,626

[7]

5,424

[8]

2,750

[9]

3,667

[10]

4,793

[11]

4,261

[12]

20,563

[1]

15,471

[2]

13,775

[3]

Consumer [Member]

Segment Reporting Information [Line Items]

Total Segment Operating Income

1,941

[1]

1,973

[2]

1,693

[3]

Pharmaceutical [Member]

Segment Reporting Information [Line Items]

Total Segment Operating Income

11,696

[1]

9,178

[2]

6,075

[3]

Medical Devices [Member]

Segment Reporting Information [Line Items]

Total Segment Operating Income

$7,953

[1]

$5,261

[2]

$7,187

[3]

[1]

Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. Includes an additional year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.

[2]

Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.

[3]

Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments, respectively. The Medical Devices segment also includes $110 million expense for the cost associated with the DePuy ASRâ„¢ Hip program.

[4]

Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes currency related expense of $0.2 billion associated with the acquisition of Synthes, Inc. in 2012.

[5]

The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.

[6]

The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.

[7]

The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).

[8]

The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.

[9]

The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASRâ„¢ Hip program and a $707 million tax benefit associated with Scios Inc.

[10]

The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.

[11]

The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).

[12]

The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).

Segments_of_Business_and_Geogr4

Segments of Business and Geographic Areas (Details 2) (USD $)	Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012
In Millions, unless otherwise specified
Segment Reporting Information [Line Items]
Identifiable Assets	$131,119	[1]	$132,683	[1]	$121,347	[1]
Consumer [Member]
Segment Reporting Information [Line Items]
Identifiable Assets	21,813		23,711		24,131
Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Identifiable Assets	25,803		23,783		23,219
Medical Devices [Member]
Segment Reporting Information [Line Items]
Identifiable Assets	41,445		44,585		42,926
Operating Segments [Member]
Segment Reporting Information [Line Items]
Identifiable Assets	89,061		92,079		90,276
General Corporate [Member]
Segment Reporting Information [Line Items]
Identifiable Assets	$42,058	[2]	$40,604	[2]	$31,071	[2]
[1]	Long-lived assets include property, plant and equipment, net for 2014, 2013 and 2012 of $16,126, $16,710 and $16,097, respectively, and intangible assets and goodwill, net for 2014, 2013 and 2012 of $49,054, $50,745 and $51,176, respectively.
[2]	General corporate includes cash, cash equivalents and marketable securities.

Segments_of_Business_and_Geogr5

Segments of Business and Geographic Areas (Details 3) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Additions	$3,714	$3,595	$2,934
Consumer [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Additions	581	533	468
Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Additions	977	856	737
Medical Devices [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Additions	1,807	1,724	1,230
Operating Segments [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Additions	3,365	3,113	2,435
General Corporate [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Additions	$349	$482	$499

Segments_of_Business_and_Geogr6

Segments of Business and Geographic Areas (Details 4) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Segment Reporting Information [Line Items]
Depreciation and Amortization by Segment	$3,895	$4,104	$3,666
Consumer [Member]
Segment Reporting Information [Line Items]
Depreciation and Amortization by Segment	577	539	575
Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Depreciation and Amortization by Segment	1,053	1,075	1,010
Medical Devices [Member]
Segment Reporting Information [Line Items]
Depreciation and Amortization by Segment	1,974	2,224	1,857
Operating Segments [Member]
Segment Reporting Information [Line Items]
Depreciation and Amortization by Segment	3,604	3,838	3,442
General Corporate [Member]
Segment Reporting Information [Line Items]
Depreciation and Amortization by Segment	$291	$266	$224

Segments_of_Business_and_Geogr7

Segments of Business and Geographic Areas (Details 5) (USD $)

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Sales by geographic area

Total

$18,254

[1]

$18,467

[2]

$19,495

[3]

$18,115

[4]

$18,355

[5]

$17,575

[6]

$17,877

[7]

$17,505

[8]

$74,331

$71,312

$67,224

UNITED STATES

Sales by geographic area

Total

34,782

31,910

29,830

Europe [Member]

Sales by geographic area

Total

18,947

18,599

16,945

Western Hemisphere, excluding U.S. [Member]

Sales by geographic area

Total

7,160

7,421

7,207

Asia-Pacific, Africa [Member]

Sales by geographic area

Total

13,442

13,382

13,242

Operating Segments [Member]

Sales by geographic area

Total

$74,331

$71,312

$67,224

[1]

The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.

[2]

The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.

[3]

The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).

[4]

The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.

[5]

The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASRâ„¢ Hip program and a $707 million tax benefit associated with Scios Inc.

[6]

The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.

[7]

The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).

[8]

The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).

Segments_of_Business_and_Geogr8

Segments of Business and Geographic Areas (Details 6) (USD $)

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Revenues from External Customers and Long-Lived Assets [Line Items]

Long-Lived Assets

$64,042

[1]

$66,463

[1]

$64,042

[1]

$66,463

[1]

$66,374

[1]

Other non long-lived assets

65,939

[1]

65,228

[1]

65,939

[1]

65,228

[1]

54,074

[1]

Worldwide total

131,119

[1]

132,683

[1]

131,119

[1]

132,683

[1]

121,347

[1]

Sales Revenue, Goods, Net

18,254

[2]

18,467

[3]

19,495

[4]

18,115

[5]

18,355

[6]

17,575

[7]

17,877

[8]

17,505

[9]

74,331

71,312

67,224

UNITED STATES

Revenues from External Customers and Long-Lived Assets [Line Items]

Long-Lived Assets

36,835

[1]

35,880

[1]

36,835

[1]

35,880

[1]

35,115

[1]

Sales Revenue, Goods, Net

34,782

31,910

29,830

Europe [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Long-Lived Assets

21,559

[1]

24,868

[1]

21,559

[1]

24,868

[1]

25,261

[1]

Sales Revenue, Goods, Net

18,947

18,599

16,945

Western Hemisphere, excluding U.S. [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Long-Lived Assets

3,210

[1]

3,281

[1]

3,210

[1]

3,281

[1]

3,636

[1]

Sales Revenue, Goods, Net

7,160

7,421

7,207

Asia-Pacific, Africa [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Long-Lived Assets

2,438

[1]

2,434

[1]

2,438

[1]

2,434

[1]

2,362

[1]

Sales Revenue, Goods, Net

13,442

13,382

13,242

Operating Segments [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Sales Revenue, Goods, Net

74,331

71,312

67,224

General Corporate [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Long-Lived Assets

$1,138

[1]

$992

[1]

$1,138

[1]

$992

[1]

$899

[1]

[1]

Long-lived assets include property, plant and equipment, net for 2014, 2013 and 2012 of $16,126, $16,710 and $16,097, respectively, and intangible assets and goodwill, net for 2014, 2013 and 2012 of $49,054, $50,745 and $51,176, respectively.

[2]

The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.

[3]

The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.

[4]

The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).

[5]

The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.

[6]

The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASRâ„¢ Hip program and a $707 million tax benefit associated with Scios Inc.

[7]

The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.

[8]

The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).

[9]

The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).

Segments_of_Business_and_Geogr9

Segments of Business and Geographic Areas (Details Textuals) (USD $)	3 Months Ended										12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014		Sep. 28, 2014	Jun. 29, 2014	Mar. 30, 2014	Dec. 29, 2013		Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012
Segment Reporting Information [Line Items]
Concentration Risk, Percentage											11.00%		10.00%
Segment of Business and Geographic Areas (Textuals) [Abstract]
Acquisition integration, transaction costs and currency related	$325		$167	$144	$118	$181		$122	$122	$258
Gain (Loss) on Sale of Assets and Asset Impairment Charges			1,900								2,383		113		908
Litigation Settlement, Expense	692		285	276		506		872	375	529	1,253		2,276		1,218
Other Asset Impairment Charges															909
Research and Development in process impairment charge	156					338		178			178		580		1,163
Recall Program			126			134
Other Selling and Marketing Expense			220
other adjustments													98
Long-Lived Assets	64,042	[1]				66,463	[1]				64,042	[1]	66,463	[1]	66,374	[1]
Corporate and Other [Member]
Segment of Business and Geographic Areas (Textuals) [Abstract]
Acquisition integration, transaction costs and currency related															200
Consumer [Member]
Segment of Business and Geographic Areas (Textuals) [Abstract]
Litigation Settlement, Expense											87
Other Asset Impairment Charges															264
Gain (Loss) on Disposition of Other Assets													55
Pharmaceutical [Member]
Segment of Business and Geographic Areas (Textuals) [Abstract]
Litigation Settlement, Expense											259		301		658
Other Asset Impairment Charges															499
Research and Development in process impairment charge											147		514		1,111
Other Selling and Marketing Expense											220
other adjustments													43
Medical Devices [Member]
Segment of Business and Geographic Areas (Textuals) [Abstract]
Acquisition integration, transaction costs and currency related											754		683		795
Gain (Loss) on Sale of Assets and Asset Impairment Charges											1,899
Litigation Settlement, Expense											907		1,975		560
Other Asset Impairment Charges															146
Research and Development in process impairment charge											31		66		52
Recall Program											126		251		110
Property, Plant and Equipment [Member]
Segment of Business and Geographic Areas (Textuals) [Abstract]
Long-Lived Assets	16,126					16,710					16,126		16,710		16,097
Other Intangible Assets [Member]
Segment of Business and Geographic Areas (Textuals) [Abstract]
Long-Lived Assets	$49,054					$50,745					$49,054		$50,745		$51,176
[1]	Long-lived assets include property, plant and equipment, net for 2014, 2013 and 2012 of $16,126, $16,710 and $16,097, respectively, and intangible assets and goodwill, net for 2014, 2013 and 2012 of $49,054, $50,745 and $51,176, respectively.

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended																12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 28, 2014		Sep. 28, 2014		Jun. 29, 2014		Mar. 30, 2014		Dec. 29, 2013		Sep. 29, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	$18,254	[1]	$18,467	[2]	$19,495	[3]	$18,115	[4]	$18,355	[5]	$17,575	[6]	$17,877	[7]	$17,505	[8]	$74,331		$71,312		$67,224
Gross profit	12,401	[1]	13,068	[2]	13,456	[3]	12,660	[4]	12,400	[5]	12,231	[6]	12,388	[7]	11,951	[8]	51,585		48,970		45,566
Earnings before provision for taxes on income	2,703	[1]	6,810	[2]	5,626	[3]	5,424	[4]	2,750	[5]	3,667	[6]	4,793	[7]	4,261	[8]	20,563	[9]	15,471	[10]	13,775	[11]
Net earnings	2,521	[1]	4,749	[2]	4,326	[3]	4,727	[4]	3,519	[5]	2,982	[6]	3,833	[7]	3,497	[8]	16,323		13,831		10,853
Basic	$0.90	[1]	$1.69	[2]	$1.53	[3]	$1.67	[4]	$1.25	[5]	$1.06	[6]	$1.36	[7]	$1.25	[8]	$5.80		$4.92		$3.94
Diluted	$0.89	[1]	$1.66	[2]	$1.51	[3]	$1.64	[4]	$1.23	[5]	$1.04	[6]	$1.33	[7]	$1.22	[8]	$5.70		$4.81		$3.86
Consumer [Member]
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	3,606	[1]	3,589	[2]	3,744	[3]	3,557	[4]	3,753	[5]	3,611	[6]	3,658	[7]	3,675	[8]
Pharmaceutical [Member]
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	7,999	[1]	8,307	[2]	8,509	[3]	7,498	[4]	7,296	[5]	7,036	[6]	7,025	[7]	6,768	[8]
Medical Devices [Member]
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	$6,649	[1]	$6,571	[2]	$7,242	[3]	$7,060	[4]	$7,306	[5]	$6,928	[6]	$7,194	[7]	$7,062	[8]
[1]	The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
[2]	The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
[3]	The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
[4]	The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.
[5]	The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASRâ„¢ Hip program and a $707 million tax benefit associated with Scios Inc.
[6]	The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.
[7]	The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).
[8]	The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).
[9]	Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. Includes an additional year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.
[10]	Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
[11]	Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments, respectively. The Medical Devices segment also includes $110 million expense for the cost associated with the DePuy ASRâ„¢ Hip program.

Selected_Quarterly_Financial_D3

Selected Quarterly Financial Data (Unaudited) (Details Textual) (USD $)	3 Months Ended								12 Months Ended
	Dec. 28, 2014	Sep. 28, 2014	Jun. 29, 2014	Mar. 30, 2014	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Selected Quarterly Financial Information [Abstract]
Integration costs after tax	$237,000,000	$130,000,000	$104,000,000	$84,000,000	$110,000,000	$103,000,000	$87,000,000	$183,000,000
Selected Quarterly Financial Data Unaudited (Textual) [Abstract]
Litigation income expense net after-tax	652,000,000	231,000,000	342,000,000		227,000,000	720,000,000	308,000,000	391,000,000
Litigation Settlement, Expense	692,000,000	285,000,000	276,000,000		506,000,000	872,000,000	375,000,000	529,000,000	1,253,000,000	2,276,000,000	1,218,000,000
Cost associated with the DePuy ASR Hip recall program, after tax		111,000,000			118,000,000
Litigation And Recall Expense		126,000,000			134,000,000
Gain on sale of assets after tax		1,100,000,000
Gain (Loss) on Sale of Assets and Asset Impairment Charges		1,900,000,000							2,383,000,000	113,000,000	908,000,000
Other Tax Benefit				-398,000,000	-707,000,000				-400,000,000
Acquisition integration, transaction costs and currency related	325,000,000	167,000,000	144,000,000	118,000,000	181,000,000	122,000,000	122,000,000	258,000,000
research and development after tax	115,000,000				294,000,000	126,000,000
Other Selling and Marketing Expense		220,000,000
In-process research and development	156,000,000				338,000,000	178,000,000			178,000,000	580,000,000	1,163,000,000
Asset Impairment Charges									$410,000,000	$739,000,000	$2,131,000,000

Business_Combinations_and_Dive2

Business Combinations and Divestitures (Details)

3 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

Dec. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Jun. 14, 2012

Dec. 28, 2014

Dec. 28, 2014

Dec. 29, 2013

Dec. 29, 2013

Jun. 14, 2012

Jul. 01, 2012

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Sep. 29, 2013

Jun. 14, 2012

Dec. 29, 2013

Dec. 30, 2012

Dec. 28, 2014

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Dec. 28, 2014

Dec. 28, 2014

Dec. 29, 2013

Dec. 29, 2013

Dec. 30, 2012

Dec. 30, 2012

Dec. 29, 2013

Dec. 29, 2013

Dec. 29, 2013

Dec. 29, 2013

Dec. 28, 2014

Jun. 30, 2015

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Alios Biopharma [Member]

Covagen AG [Member]

Aragon Pharmaceuticals, Inc [Member]

Flexible Stenting Solutions, Inc [Member]

Synthes, Inc [Member]

Synthes, Inc [Member]

Synthes, Inc [Member]

Synthes, Inc [Member]

Synthes, Inc [Member]

Synthes, Inc [Member]

Synthes, Inc [Member]

Corlmmun [Member]

Corlmmun [Member]

OCD [Member]

Purchased In-Process Research And Development [Member]

Purchased In-Process Research And Development [Member]

Purchased In-Process Research And Development [Member]

Purchased In-Process Research And Development [Member]

Purchased In-Process Research And Development [Member]

Purchased In-Process Research And Development [Member]

Purchased In-Process Research And Development [Member]

Purchased In-Process Research And Development [Member]

Purchased In-Process Research And Development [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Patents And Trademarks [Member]

Subsequent Event [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

CHF

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Alios Biopharma [Member]

Covagen AG [Member]

Aragon Pharmaceuticals, Inc [Member]

Flexible Stenting Solutions, Inc [Member]

Synthes, Inc [Member]

Corlmmun [Member]

Aragon Pharmaceuticals, Inc [Member]

Flexible Stenting Solutions, Inc [Member]

Aragon Pharmaceuticals, Inc [Member]

Flexible Stenting Solutions, Inc [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Business Acquisition [Line Items]

Cash & Cash equivalents

$2,749,000,000

Cost in CHF for each share

55.65

Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)

2,129,000,000

835,000,000

17,821,000,000

Business Acquisition, Cost of Acquired Entity, Cash Paid

6,902,000,000

Aquirees Common Stock Outstanding

118,700,000

Exchange rate used for acquisition

0.95674

Share exchanged for acquirees stock

1.717

Business Acquisition, Initial Consideration Transferred

19,700,000,000

Business Acquisition, Pro Forma Information [Abstract]

Net Sales

68,894,000,000

Net Earnings

11,564,000,000

Diluted Net Earnings per Common Share

$4.11

Business Combinations and Divestitures (Textuals) [Abstract]

Acquisition transaction and integration costs

325,000,000

167,000,000

144,000,000

118,000,000

181,000,000

122,000,000

122,000,000

258,000,000

754,000,000

683,000,000

1,028,000,000

Gain (Loss) on Disposition of Assets

2,400,000,000

100,000,000

900,000,000

1,900,000,000

Assets Held-for-sale, Current

41,000,000

41,000,000

Assets Held-for-sale, Other, Noncurrent

117,000,000

117,000,000

Proceeds from Sales of Business, Affiliate and Productive Assets

4,000,000,000

1,100,000,000

Business Combination, Consideration Transferred

20,200,000,000

Discount Rate Used in Probability of Success in Research and Development

11.40%

12.50%

15.50%

14.00%

25.00%

16.50%

17.50%

Probability Of Success

60.00%

26.00%

100.00%

100.00%

38.00%

37.00%

52.00%

Issuance of common stock associated with the acquisition of Synthes, Inc.

13,335,000,000

Stock Issued During Period, Shares, Acquisitions

203,700,000

203,740,000

Accelerated Share Repurchases, Settlement Payment or Receipt

12,900,000,000

2,900,000,000

Finite-Lived Intangible Assets, Useful Life, Minimum

17 years

Total

18,254,000,000

[1]

18,467,000,000

[2]

19,495,000,000

[3]

18,115,000,000

[4]

18,355,000,000

[5]

17,575,000,000

[6]

17,877,000,000

[7]

17,505,000,000

[8]

74,331,000,000

71,312,000,000

67,224,000,000

2,159,000,000

Synthes Net earnings

16,323,000,000

13,831,000,000

10,514,000,000

324,000,000

Noncash or Part Noncash Acquisition, Value of Liabilities Assumed

38,000,000

193,000,000

1,204,000,000

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

350,000,000

Acquired indefinite lived asset, amounts

2,069,000,000

941,000,000

2,069,000,000

941,000,000

15,785,000,000

Payments to Acquire Businesses, Net of Cash Acquired

2,129,000,000

835,000,000

4,486,000,000

17,500,000,000

Indefinite-Lived Intangible Assets (Excluding Goodwill)

10,105,000,000

8,774,000,000

10,105,000,000

8,774,000,000

2,842,000,000

1,155,000,000

Common Stock Share Price

$65.45

Research and Development in process impairment charge

156,000,000

338,000,000

178,000,000

178,000,000

580,000,000

1,163,000,000

200,000,000

purchased in process research and development

1,913,000,000

831,000,000

208,000,000

1,688,000,000

225,000,000

810,000,000

21,000,000

63,000,000

145,000,000

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

$20,237,000,000

[1]

The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.

[2]

The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.

[3]

The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).

[4]

The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.

[5]

The fourth quarter of 2013 includes net litigation expense of $227 million after-tax ($506 million before-tax), Synthes integration/transaction costs $110 million after-tax ($181 million before-tax), $294 million after-tax ($338 million before-tax) from impairment of in-process research and development and $118 million after-tax ($134 million before-tax) for costs associated with the DePuy ASRâ„¢ Hip program and a $707 million tax benefit associated with Scios Inc.

[6]

The third quarter of 2013 includes net litigation expense of $720 million after-tax ($872 million before-tax), Synthes integration/transaction costs of $103 million after-tax ($122 million before-tax) and $126 million after-tax ($178 million before-tax) from impairment of in-process research and development.

[7]

The second quarter of 2013 includes net litigation expense of $308 million after-tax ($375 million before-tax) and Synthes integration/transaction costs of $87 million after-tax ($122 million before-tax).

[8]

The first quarter of 2013 includes Synthes integration/transaction costs of $183 million after-tax ($258 million before-tax) and net litigation expense of $391 million after-tax ($529 million before-tax).

Legal_Proceedings_Details

Legal Proceedings (Details) (USD $)	3 Months Ended							12 Months Ended			3 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Sep. 28, 2014	Jun. 29, 2014	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Mar. 31, 2015
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Expense	$692	$285	$276	$506	$872	$375	$529	$1,253	$2,276	$1,218
Pharmaceutical [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Expense								259	301	658
ASR [Member]
Legal Proceeding (Textuals) [Abstract]
Product Liability Contingency Number Of Claimants	11,200							11,200
Pinnacle Acetabular Cup System [Member]
Legal Proceeding (Textuals) [Abstract]
Product Liability Contingency Number Of Claimants	7,300							7,300
Risperdal [Member]
Legal Proceeding (Textuals) [Abstract]
Product Liability Contingency Number Of Claimants	1,200							1,200
Pelvic Meshes [Member]
Legal Proceeding (Textuals) [Abstract]
Product Liability Contingency Number Of Claimants	36,600							36,600
Pending Litigation [Member] | Restitution [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								45
Pending Litigation [Member] | Civil penalties [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								6.5
Pending Litigation [Member] | Risperdal [Member] | Civil penalties [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								327.1
settled litigation [Member] | Subsequent Event [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount											-600
Investigative Demands [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Expense								4
DePuy ASR U.S. [Member] | settled litigation [Member]
Legal Proceeding (Textuals) [Abstract]
Number of patients in settlement	8,000							8,000
DePuy ASR U.S.Second Agreement [Member] | Pending Litigation [Member]
Legal Proceeding (Textuals) [Abstract]
Number of patients in settlement	1,400							1,400
Tyco [Member] | Pending Litigation [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								176
Risperdal [Member] | Pending Litigation [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								1,200
Risperdal [Member] | Pending Litigation [Member] | Legal professional fees [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								181
alleged consumer fraud [Member] | Pending Litigation [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								4.5
medicare fraud [Member] | Pending Litigation [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								257.7
medicare fraud [Member] | Pending Litigation [Member] | Legal professional fees [Member]
Legal Proceeding (Textuals) [Abstract]
Litigation Settlement, Amount								$73